Methods and compositions relating to anti-ccr7 antigen binding proteins

ABSTRACT

The present invention provides compositions and methods relating to antigen binding proteins against CCR7, including antibodies, nucleic acids, vectors, methods of making the antigen binding proteins, and methods of using the antigen binding proteins.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Application Ser.No. 61/962,296, filed Mar. 15, 2013. The above-identified application isincorporated herein by reference.

REFERENCE TO THE SEQUENCE LISTING

The present application is being filed along with a Sequence Listing inelectronic format via EFS-Web. The Sequence Listing is provided as atext file entitled A-1814-WO-PCT_ST25.txt, created Mar. 11, 2014, whichis 242,848 bytes in size. The information in the electronic format ofthe Sequence Listing is incorporated herein by reference in itsentirety.

BACKGROUND

CCR7 and its ligands CCL19 and CCL21 play non-redundant roles inregulating the migration, organization, and activation of dendriticcells and naïve T and B cells in secondary and tertiary(disease-associated) lymphoid structures.

CCR7 activity has been implicated in a diverse variety of diseasestates, including chronic inflammatory conditions (Moschovakis et al.,2012, Eur J Immunol. 42:1949-55), atherosclerosis (Luchtefeld et al.,2010, Circulation 122:1621-28), HIV infection (Evans et al., 2012,Cytokine Growth Factor Rev. 23:151-57), and cancer (Ben-Baruch, 2009,Cell Adhesion Migration 3:328-33).

SUMMARY OF THE INVENTION

In one aspect, the present invention provides an isolated anti-CCR7antigen binding protein, wherein said antigen binding protein compriseseither: the light chain variable domain sequence of antibody 6B4.1,6B5.1, 6E1.2, 6B4.1 LC desS, 6E1.2 LC H36Q, MAB22_KLC-V1, MAB22_KLC_V2,MAB22_KLC_V3, MAB22_KLC_V4, MAB22_KLC_V5, MAB22_KLC_V6, MAB22_KLC_V7, orMAB22_KLC_V8; or the heavy chain variable domain sequence of 6B4.1,6B5.1, 6E1.2, 6E1.2 HC G2V, 6E1.2 HC F80Y, 6E1.2 HC G2V F80Y orMAB22_HC_V1; or the heavy chain variable domain and the light chainvariable domain of antibody 6B4.1, 6B5.1, or 6E1.2; or a light chainvariable domain sequence that is at least 90%, 95%, 97%, or 99%identical to the light chain variable domain sequence of 6B4.1, 6B5.1,6E1.2, 6B4.1 LC desS, or 6E1.2 LC H36Q; or a heavy chain variable domainsequence that is at least 90%, 95%, 97%, or 99% identical to the heavychain variable domain sequence of 6B4.1, 6B5.1, or 6E1.2; or a lightchain variable domain sequence and a heavy chain variable domainsequence that each is at least 90%, 95%, 97%, or 99% identical to thelight chain variable domain sequence and the heavy chain variable domainsequence, respectively, of antibody 6B4.1, 6B5.1, or 6E1.2; or a lightchain variable domain sequence that differs at no more than 15, 12, 10,8, 5, or 3 amino acid positions from the light chain variable domainsequence of 6B4.1, 6B5.1, 6E1.2, 6B4.1 LC desS, or 6E1.2 LC H36Q; or aheavy chain variable domain sequence that differs at no more than 15,12, 10, 8, 5, or 3 amino acid positions from the heavy chain variabledomain sequence of 6B4.1, 6B5.1, or 6E1.2; or a light chain variabledomain sequence and a heavy chain variable domain sequence that eachdiffers at no more than 15, 12, 10, 8, 5, or 3 amino acid positions fromthe light chain variable domain sequence and the heavy chain variabledomain sequence, respectively, of 6B4.1, 6B5.1, or 6E1.2; or a lightchain variable domain sequence that is encoded by a nucleic acidsequence that is at least 90%, 95%, 97%, or 99% identical to the nucleicacid sequence encoding the light chain variable domain sequence of6B4.1, 6B5.1, 6E1.2, 6B4.1 LC desS, 6E1.2 LC H36Q, MAB22_KLC-V1,MAB22_KLC_V2, MAB22_KLC_V3, MAB22_KLC_V4, MAB22_KLC_V5, MAB22_KLC_V6,MAB22_KLC_V7, or MAB22_KLC_V8 as provided in FIG. 1; or a heavy chainvariable domain sequence that is encoded by a nucleic acid sequence thatis at least 90%, 95%, 97%, or 99% identical to the nucleic acid sequenceencoding the heavy chain variable domain sequence of 6B4.1, 6B5.1,6E1.2, 6E1.2 HC G2V, 6E1.2 HC F80Y, 6E1.2 HC G2V F80Y or MAB22_HC_V1, asprovided in FIG. 1; or a light chain variable domain sequence that isencoded by a nucleic acid sequence that is at least 90%, 95%, 97%, or99% identical to the nucleic acid sequence encoding the light chainvariable domain sequence of 6B4.1, 6B5.1, 6E1.2, 6B4.1 LC desS, 6E1.2 LCH36Q, MAB22_KLC-V1, MAB22_KLC_V2, MAB22_KLC_V3, MAB22_KLC_V4,MAB22_KLC_V5, MAB22_KLC_V6, MAB22_KLC_V7, or MAB22_KLC_V8 as provided inFIG. 1, and a heavy chain variable domain sequence that is encoded by anucleic acid sequence that is at least 90%, 95%, 97%, or 99% identicalto the nucleic acid sequence encoding the heavy chain variable domainsequence of 6B4.1, 6B5.1, 6E1.2, 6E1.2 HC G2V, 6E1.2 HC F80Y, 6E1.2 HCG2V F80Y or MAB22_HC_V1, as provided in FIG. 1; or a light chainvariable domain sequence that is encoded by a nucleic acid sequence thathybridizes under moderately stringent, stringent, or highly stringentconditions to the nucleic acid sequence encoding the light chainvariable domain sequence of 6B4.1, 6B5.1, 6E1.2, 6B4.1 LC desS, 6E1.2 LCH36Q, MAB22_KLC-V1, MAB22_KLC_V2, MAB22_KLC_V3, MAB22_KLC_V4,MAB22_KLC_V5, MAB22_KLC_V6, MAB22_KLC_V7, or MAB22_KLC_V8 as provided inFIG. 1; or a heavy chain variable domain sequence that is encoded by anucleic acid sequence that hybridizes under moderately stringent,stringent, or highly stringent conditions to the nucleic acid sequenceencoding the heavy chain variable domain sequence of 6B4.1, 6B5.1,6E1.2, 6E1.2 HC G2V, 6E1.2 HC F80Y, 6E1.2 HC G2V F80Y or MAB22_HC_V1, asprovided in FIG. 1; or a light chain variable domain sequence that isencoded by a nucleic acid sequence that hybridizes under moderatelystringent, stringent, or highly stringent conditions to the nucleic acidsequence encoding the light chain variable domain sequence of 6B4.1,6B5.1, 6E1.2, 6B4.1 LC desS, 6E1.2 LC H36Q, MAB22_KLC-V1, MAB22_KLC_V2,MAB22_KLC_V3, MAB22_KLC_V4, MAB22_KLC_V5, MAB22_KLC_V6, MAB22_KLC_V7, orMAB22_KLC_V8 as provided in FIG. 1, and a heavy chain variable domainsequence that is encoded by a nucleic acid sequence that hybridizesunder moderately stringent, stringent, or highly stringent conditions tothe nucleic acid sequence encoding the heavy chain variable domainsequence of the same antibody 6B4.1, 6B5.1, 6E1.2, 6E1.2 HC G2V, 6E1.2HC F80Y, 6E1.2 HC G2V F80Y or MAB22_HC_V1; or CDR1, CDR2, and CDR3 ofthe light chain variable domain sequence of 6B4.1, 6B5.1, 6E1.2, 6B4.1LC desS, 6E1.2 LC H36Q; or CDR1, CDR2, and CDR3 of the heavy chainvariable domain sequence of 6B4.1, 6B5.1, 6E1.2, 6E1.2 HC G2V, 6E1.2 HCF80Y, or 6E1.2 HC G2V F80Y; or CDR1, CDR2, and CDR3 of the light chainvariable domain sequence, and CDR1, CDR2, and CDR3 of the heavy chainvariable domain sequence, of 6B4.1, 6B5.1, or 6E1.2; or light chainvariable domain CDR1, CDR2, and CDR3 sequences that each differs at nomore than 3, 2, or 1 amino acid positions from the light chain variabledomain CDR1, CDR2, and CDR3 sequences, respectively, of the light chainvariable domain sequence of 6B4.1, 6B5.1, 6E1.2, 6B4.1 LC desS, 6E1.2 LCH36Q; or heavy chain variable domain CDR1, CDR2, and CDR3 sequences thateach differs at no more than 3, 2, or 1 amino acid positions from theheavy chain variable domain CDR1, CDR2, and CDR3 sequences,respectively, of the heavy chain variable domain sequence of 6B4.1,6B5.1, 6E1.2, 6E1.2 HC G2V, 6E1.2 HC F80Y, or 6E1.2 HC G2V F80Y; orlight chain variable domain CDR1, CDR2, and CDR3 sequences that eachdiffers at no more than 3, 2, or 1 amino acid positions from the lightchain variable domain CDR1, CDR2, and CDR3 sequences, respectively, ofthe light chain variable domain sequence of antibody 6B4.1, 6B5.1, or6E1.2, and heavy chain variable domain CDR1, CDR2, and CDR3 sequencesthat each differs at no more than 3, 2, or 1 amino acid positions fromthe heavy chain variable domain CDR1, CDR2, and CDR3 sequences,respectively, of the heavy chain variable domain sequence of the sameantibody 6B4.1, 6B5.1, or 6E1.2.

In one embodiment, the anti-CCR7 antigen binding protein comprises: thelight chain sequence of 6B4.1 LC or of 6B4.1 LC desS and the heavy chainsequence of 6B4.1 HC, as shown in FIG. 1; or the light chain sequence of6B5.1 LC and the heavy chain sequence of 6B5.1 HC, as shown in FIG. 1;or the light chain sequence of 6E1.2 LC or of 6E1.2 LC H36Q and theheavy chain sequence of 6E1.2, 6E1.2 HC G2V, 6E1.2 HC F80Y, or 6E1.2 HCG2V F80Y, as shown in FIG. 1; or the light chain sequence ofMAB22_KLC-V1, MAB22_KLC_V2, MAB22_KLC_V3, MAB22_KLC_V4, MAB22_KLC_V5,MAB22_KLC_V6, MAB22_KLC_V7, or MAB22_KLC_V8 and the heavy chain sequenceof MAB22_HC_V1.

In another embodiment, the isolated anti-CCR7 antigen binding proteincompetes for binding to a human CCR7 with antibody 6B4.1, 6B5.1, or6E1.2.

In another embodiment, the antigen binding protein comprises either: alight chain variable domain that differs from the light chain variabledomain of antibody 6B4.1, 6B5.1, or 6E1.2 only in that one or morenon-germline amino acid residues are replaced with the correspondinggermline residues; a heavy chain variable domain that differs from theheavy chain variable domain of antibody 6B4.1, 6B5.1, or 6E1.2 only inthat one or more non-germline amino acid residues are replaced with thecorresponding germline residues; or a light chain variable domain thatdiffers from the light chain variable domain of antibody 6B4.1, 6B5.1,or 6E1.2 only in that one or more non-germline amino acid residues arereplaced with the corresponding germline residues, and a heavy chainvariable domain that differs from the heavy chain variable domain of thesame antibody 6B4.1, 6B5.1, or 6E1.2 only in that one or morenon-germline amino acid residues are replaced with the correspondinggermline residues.

In another embodiment, the isolated CCR7 antigen binding proteincomprises: a human antibody; a humanized antibody; a chimeric antibody;a monoclonal antibody; a polyclonal antibody; a recombinant antibody; anantigen-binding antibody fragment; a single chain antibody; a diabody; atriabody; a tetrabody; a Fab fragment; a F(ab′)2 fragment; a domainantibody; an IgD antibody; an IgE antibody; an IgM antibody; an IgG1antibody; an IgG2 antibody; an IgG3 antibody; an IgG4 antibody; or anIgG4 antibody having at least one mutation in a hinge region thatalleviates a tendency to form intra-H chain disulfide bond.

In another embodiment, the isolated anti-CCR7 antigen binding proteininhibits binding of CCL19 or CCL21 to CCR7.

In another aspect, the present invention provides an isolatedpolynucleotide comprising a sequence that encodes the light chain, theheavy chain, or both of an isolated anti-CCR7 antigen binding protein.

In one embodiment, the isolated polynucleotide comprises a light chainvariable domain nucleic acid sequence and/or a heavy chain variabledomain nucleic acid sequence of FIG. 1.

In another aspect, the present invention provides a plasmid comprisingthe isolated polynucleotide.

In one embodiment, the plasmid is an expression vector.

In another aspect, the present invention provides an isolated cellcomprising the isolated polynucleotide.

In another embodiment, a chromosome of the cell comprises thepolynucleotide.

In another embodiment, the cell is a hybridoma.

In another embodiment, an expression vector comprises saidpolynucleotide.

In another embodiment, the cell is a CHO cell.

In another embodiment, the cell is a bacterial cell.

In another embodiment, the cell is an E. coli cell.

In another embodiment, the cell is a yeast cell.

In another embodiment, the cell is an animal cell.

In another embodiment, the cell is a human cell.

In another aspect, the present invention provides a method of making ananti-CCR7 antigen binding protein, comprising incubating the isolatedcell under conditions that allow it to express the antigen bindingprotein.

In another aspect, the present invention provides a pharmaceuticalcomposition comprising the anti-CCR7 antigen binding protein.

BRIEF DESCRIPTION OF THE FIGURE

FIG. 1A-AR provides nucleic acid and amino acid sequences of theantibodies and other polypeptides disclosed herein. Variable domainsequences of light and heavy chain antibody sequences are underlined.

FIG. 2 provides the results of a hybridoma supernatant screen.

FIG. 3 provides graphs for determining the IC50 of antibodies mAb197,6B4.1, 6B5.1, and 6E1.2 for inhibition of CCR7 activity induced by CCL19or by CCL21.

FIG. 4 provides IC50 determinations for antibodies mAB197, 6B5.1, 6B4.1,6E1.2, 6E1.2 G2V, and 6E1.2 F90Y.

FIG. 5 provides epitope mapping data for antibodies mAb197, 6B4.1, and6B5.1.

FIG. 6 provides epitope mapping data for antibodies mAb197, 6B4.1, and6B5.1.

FIG. 7 provides epitope mapping data for antibodies mAb197, 6B4.1, and6B5.1.

FIG. 8 provides epitope mapping data for antibodies mAb197, 6B4.1, and6B5.1.

DETAILED DESCRIPTION

The section headings used herein are for organizational purposes onlyand are not to be construed as limiting the subject matter described.

Unless otherwise defined herein, scientific and technical terms used inconnection with the present application shall have the meanings that arecommonly understood by those of ordinary skill in the art. Further,unless otherwise required by context, singular terms shall includepluralities and plural terms shall include the singular.

Generally, the terminology and techniques of cell and tissue culture,molecular biology, immunology, microbiology, genetics, protein andnucleic acid chemistry, manufacturing, formulation, pharmacology, andmedicine described herein are those well known and commonly used in theart. The methods and techniques of the present application are generallyperformed according to conventional methods well known in the art and asdescribed in various general and more specific references that are citedand discussed throughout the present specification unless otherwiseindicated. See, e.g., Sambrook et al., Molecular Cloning: A LaboratoryManual, 3rd ed., Cold Spring Harbor Laboratory Press, Cold SpringHarbor, N.Y. (2001), Ausubel et al., Current Protocols in MolecularBiology, Greene Publishing Associates (1992), and Harlow and LaneAntibodies: A Laboratory Manual Cold Spring Harbor Laboratory Press,Cold Spring Harbor, N.Y. (1990), which are incorporated herein byreference. Enzymatic reactions and purification techniques are performedaccording to manufacturer's specifications, as commonly accomplished inthe art, or as described herein. The terminology used in connectionwith, and the laboratory procedures and techniques of, analyticalchemistry, synthetic organic chemistry, and medicinal and pharmaceuticalchemistry described herein are those well known and commonly used in theart. Standard techniques can be used for chemical syntheses, chemicalanalyses, pharmaceutical preparation, formulation, and delivery, andtreatment of patients.

This invention is not limited to the particular methodology, protocols,reagents, etc., described herein. The terminology used herein is for thepurpose of describing particular embodiments only, and is not intendedto limit the scope of the present invention as defined by the claims.

Other than in the operating examples, or where otherwise indicated, allnumbers expressing quantities of ingredients or reaction conditions usedherein should be understood as modified in all instances by the term“about” as that term would be interpreted by the person skilled in therelevant art.

DEFINITIONS

The term “polynucleotide” or “nucleic acid” includes nucleotide polymersof any length. They can be, for example, single-stranded,double-stranded, or triple-stranded, or a combination of single- and/ordouble- and/or triple-stranded. Where a nucleotide polymer comprisesmore than one strand, each strand is itself understood to be apolynucleotide or nucleic acid. Where a nucleotide polymer isdouble-stranded, typically each of the strands is complementary to theother, although their complementarity need not be perfect and in someinstances is sufficient to allow the stable association or hybridizationof the two strands only under certain hybridization conditions. Thenucleotides comprising the polynucleotide can be naturally-occurring orartificial nucleotide analogs, such as, for example, ribonucleotides,deoxyribonucleotides, or modified forms of either type of nucleotide, ora combination of different types of nucleotides and/or nucleotideanalogs. Said modifications include, for example, base modifications,such as bromouridine and inosine derivatives, ribose modifications, suchas 2′,3′-dideoxyribose, and internucleotide linkage modifications, suchas phosphorothioate, phosphorodithioate, phosphoroselenoate,phosphorodiselenoate, phosphoroanilothioate, phoshoraniladate andphosphoroamidate. The terms “polynucleotide” and “nucleic acid” includenucleotide polymers that have been covalently or non-covalently modifiedby the addition of one or more non-polynucleotide chemical entities,such as, for example, labels, (e.g., radiolabels), fluorescent labels,haptens or antigenic labels as well as nucleotide polymers that havebeen covalently or non-covalently bound to a solid object or surface,such as a hybridization membrane (e.g., a nitrocellulose hybridizationmembrane), a bead, a vessel wall, or the like.

The term “oligonucleotide” refers generally to shorter polynucleotide ornucleic acid sequences. The length of a particular oligonucleotide willdepend on how it is made and/or its intended use. Typically, it refersto a polynucleotide comprising 200 or fewer nucleotides. In someembodiments, oligonucleotides are 10 to 60 bases in length. In otherembodiments, oligonucleotides are 12, 13, 14, 15, 16, 17, 18, 19, or 20to 40 nucleotides in length. Oligonucleotides may be, for example,single-, double-, or triple-stranded. Single stranded oligonucleotidesmay be sense or antisense oligonucleotides. Oligonucleotides have manyuses, including, for example, as PCR primers, cloning primers, adaptersfor joining two or more polynucleotides, and hybridization probes.

An “isolated nucleic acid molecule” means a DNA or RNA of genomic, mRNA,cDNA, or synthetic origin, or some combination thereof, which is atleast partially removed from its natural environment. Examples ofisolated nucleic acid molecules include nucleic acids that havesequences found in nature but that are produced synthetically,naturally-occurring nucleic acids that are not associated with all or aportion of a polynucleotide in which the isolated polynucleotide isfound in nature, naturally-occurring nucleic acids that are linked to apolynucleotide to which they are not linked in nature, andnaturally-occurring nucleic acids that have been at least partiallyremoved from their natural cellular environment. For purposes of thisdisclosure, it should be understood that “a nucleic acid moleculecomprising” a particular nucleotide sequence does not encompass intactnaturally-occurring chromosomes. Isolated nucleic acid molecules“comprising” specified nucleic acid sequences may include othersequences as well, such as, for example, one or more other codingsequences, operably linked regulatory sequences that control or affectexpression of the coding region of the recited nucleic acid sequences,vector or plasmid sequences, sequences controlling or affectingreplication of the nucleic acid, restriction sites, primer bindingsites, and the like.

Unless specified otherwise, the left-hand end of any single-strandedpolynucleotide sequence provided herein is the 5′ end; the left-handdirection of double-stranded polynucleotide sequences is referred to asthe 5′ direction. The direction of 5′ to 3′ addition of nascent RNAtranscripts is referred to as the transcription direction; sequenceregions on the DNA strand having the same sequence as the RNA transcriptthat are 5′ to the 5′ end of the RNA transcript are referred to as“upstream sequences;” sequence regions on the DNA strand having the samesequence as the RNA transcript that are 3′ to the 3′ end of the RNAtranscript are referred to as “downstream sequences.”

The term “control sequence” refers to a polynucleotide sequence that canaffect the expression and/or processing of a coding sequence to which itis ligated. The nature of such control sequences may depend upon thehost organism. In particular embodiments, control sequences forprokaryotes may include a promoter, a ribosomal binding site, and atranscription termination sequence. Examples of control sequences foreukaryotes include promoters comprising one or a plurality ofrecognition sites for transcription factors, transcription enhancersequences, and transcription termination sequences. The term “controlsequences” can refer to leader sequences and/or fusion partner sequencesas well.

The term “vector” means any molecule or entity (e.g., nucleic acid,plasmid, bacteriophage or virus) used to transfer protein codinginformation into a host cell.

The terms “expression vector,” “expression plasmid,” and “expressionconstruct” each refers to a vector that is suitable for transformationof a host cell and contains nucleic acid sequences that allows (inconjunction with the host cell) expression of one or more heterologouscoding regions operatively linked thereto. An expression construct mayinclude, but is not limited to, sequences that affect or controltranscription, translation, and, if introns are present, affect RNAsplicing of a coding region operably linked thereto.

As used herein, “operably linked” means that the components to which theterm is applied are in a relationship that allows them to carry outtheir inherent or desired functions under suitable conditions. Anexample of a control sequence that is “operably linked” to a proteincoding sequence in a vector is an enhancer region that is ligated(either directly or via intermediary sequences) to the protein codingsequence such that expression of the protein coding sequence is achievedunder conditions compatible with the transcriptional activity of theenhancer region.

The term “host cell” means a cell capable of expressing, under thecorrect conditions, a coding sequence of interest. The term includes theprogeny of the parent cell, whether or not the progeny is identical inmorphology or in genetic make-up to the original parent cell, so long asthe coding sequence of interest is present. A “host cell” can be a cellthat has been transformed, or is capable of being transformed, with anucleic acid sequence and thereby express a coding sequence of interest.

The term “transduction” means the transfer of genes from one bacteriumto another, usually by bacteriophage. “Transduction” also refers to theacquisition and transfer of eukaryotic cellular sequences by replicationdefective retroviruses.

The term “transfection” means the uptake of foreign or exogenous DNA bya cell, and a cell has been “transfected” when the exogenous DNA hasbeen introduced into the cell. A number of transfection techniques arewell known in the art and are disclosed herein. See, e.g., Graham etal., 1973, Virology 52:456; Sambrook et al., 2001, Molecular Cloning: ALaboratory Manual, supra; Davis et al., 1986, Basic Methods in MolecularBiology, Elsevier; Chu et al., 1981, Gene 13:197. Such techniques can beused to introduce one or more exogenous DNA moieties into suitable hostcells. Depending on the technique used to make the transfected cell andthe desired use of the transfected cell, a cell can be transfectedeither stably or transiently.

The term “transformation” refers to a change in a cell's geneticcharacteristics, and a cell has been transformed when it has beenmodified to contain new DNA or RNA. For example, a cell is transformedwhere it is genetically modified from its native state by introducingnew genetic material via, for example, transfection or transduction, orvia another technique, such as a chemical, ballistic, or electroporationtechnique. Following transformation, the transforming DNA may recombinewith that of the cell by physically integrating into a chromosome of thecell, or may be maintained transiently as an episomal element withoutbeing replicated and/or stably propagated during cellular division, orit may replicate independently as a plasmid. A cell is considered tohave been “stably transformed” when the transforming DNA is replicatedas part of the host cell's cycle of cell division.

The terms “polypeptide” or “protein” are used interchangeably herein torefer to a polymer of amino acid residues. The terms also apply to aminoacid polymers in which one or more amino acid residues is an analog,derivative, or mimetic of a naturally occurring amino acid, as well asto naturally occurring amino acid polymers. The terms also encompassamino acid polymers that have been modified. Such modifications includeany naturally-occurring or artificial modification of a polypeptide.Some such modifications will alter the sequence of the polypeptide, butothers will not. Examples of such modifications include the addition ofcarbohydrate residues and phosphorylation. Polypeptides and proteins canbe produced and/or modified by a naturally-occurring and non-recombinantcell or they can be produced by a genetically-engineered or recombinantcell. “Polypeptides” and “proteins” comprise molecules having the aminoacid sequence of a native protein, or molecules having deletions from,additions to, and/or substitutions of one or more amino acids of, thenative sequence. The terms “polypeptide” and “protein” specificallyencompass CCR7 antigen-binding proteins, antibodies, or sequences thathave deletions from, additions to, and/or substitutions of one or moreamino acids of an antigen-binding protein. The term “polypeptidefragment” refers to a polypeptide that has an amino-terminal deletion, acarboxyl-terminal deletion, and/or an internal deletion as compared withthe full-length protein. Such fragments may also contain modified aminoacids as compared with the full-length protein. In certain embodiments,fragments are about five to 500 amino acids long. For example, fragmentsmay be at least 5, 6, 8, 10, 14, 20, 50, 70, 100, 110, 150, 200, 250,300, 350, 400, or 450 amino acids long. Useful polypeptide fragmentsinclude immunologically functional fragments of antibodies, includingbinding domains. In the case of a CCR7-binding antibody, usefulfragments include but are not limited to a CDR region, a variable domainof a heavy or light chain, a portion of an antibody chain or just itsvariable region including two CDRs, and the like.

An “isolated protein” (1) is free of at least some other proteins orcellular components with which it would normally be found, (2) isessentially free of other proteins from the same source, e.g., from thesame species, (3) is expressed by a cell from a different species, (4)has been separated from at least about 50 percent of polynucleotides,lipids, carbohydrates, or other materials with which it is associated innature, (5) is operably associated (by covalent or noncovalent bonds)with a polypeptide with which it is not associated in nature, or (6)does not occur in nature. An “isolated protein” can constitute at leastabout 5%, at least about 10%, at least about 25%, or at least about 50%of a given sample. Genomic DNA, cDNA, mRNA or other RNA, of syntheticorigin, or any combination thereof may encode such an isolated protein.In some embodiments, the isolated protein is substantially free fromproteins or polypeptides or other contaminants that are found in itsnatural environment that would interfere with its therapeutic,diagnostic, prophylactic, research or other use.

A “variant” of a polypeptide (e.g., of an antigen binding protein or ofan antibody) comprises an amino acid sequence wherein one or more aminoacid residues are inserted into, deleted from and/or substituted intothe amino acid sequence relative to another polypeptide sequence. Afusion protein comprising all or part of a polypeptide is one example ofa variant of the polypeptide.

A “derivative” of a polypeptide is a polypeptide (e.g., an antigenbinding protein, or an antibody) that has been chemically modified insome manner distinct from the insertion, deletion, and/or substitutionof amino acids, e.g., via conjugation to another chemical moiety. Anantigen binding protein that contains all or most of either the light-or heavy-chain variable domain of an antibody, but lacks most or all ofthe other variable domain of the antibody, is an example of a derivativeof the antibody.

The term “naturally occurring” as used throughout the specification inconnection with biological materials such as polypeptides, nucleicacids, host cells, and the like, refers to materials which are found innature.

An “antigen binding protein” as used herein means a protein thatspecifically binds a specified target antigen, such as CCR7 or humanCCR7.

An antigen binding protein, such as an antibody or antibody fragment,variant, or derivative, is said to “specifically bind” its targetantigen when it binds immunospecifically to its target antigen. In someembodiments, a specifically binding antigen binding protein has adissociation constant (K_(D)) of 1 to 10×10⁻⁸ M. The antibodyspecifically binds antigen with “high affinity” when the K_(D) is 1 to10×10⁻⁹ M, and with “very high affinity” when the K_(D) is 1 to 10×10⁻¹⁰M. In one embodiment, the antibody has a K_(D) of 1 to 10×10⁻⁹ M and anoff-rate of about 1×10⁻⁴/sec. In one embodiment, the off-rate is about1×10⁻⁵/sec. In other embodiments, the antibodies will bind to CCR7, orhuman CCR7, with a K_(D) of between about 10⁻⁸ M and 10⁻¹⁰ M, and in yetanother embodiment it will bind with a K_(D) of 1 to 2×10⁻¹⁰.

“Antigen binding region” means the portion of an antibody or otherantigen binding protein, or a fragment, derivative, or variant thereof,that specifically binds a specified antigen. An antigen binding regioncan include one or more “complementarity determining regions” (“CDRs”).Certain antigen binding regions also include one or more “framework”regions. Residues within the framework regions of some antibodies andother antigen binding proteins can contribute directly to the specificbinding of the antibody or antigen binding protein to its antigen, buttypically framework regions aid in maintaining a conformation of theCDRs that allows binding between the antigen binding region and theantigen.

In certain aspects, recombinant antigen binding proteins that bind CCR7,or human CCR7, are provided. In this context, a “recombinant protein” isa protein made using recombinant techniques, e.g., through theexpression of a recombinant nucleic acid. Methods and techniques for theproduction of recombinant proteins are well known in the art.

The term “antibody” refers to an intact antigen-binding immunoglobulinof any kind, or a fragment thereof that itself specifically binds to theantibody's target antigen, and includes, for example, chimeric,humanized, fully human, and bispecific antibodies. An “antibody” is atype of an antigen binding protein. In some embodiments, an intactantibody comprises two full-length heavy chains and two full-lengthlight chains. In other embodiments, an intact antibody includes fewerchains such as antibodies naturally occurring in camelids, which maycomprise only heavy chains. In other embodiments, a fragment orderivative of an antibody is made that lacks part or all of theantibody's light chains or light chain variable regions. In otherembodiments, a fragment or derivative of an antibody is made that lackssome or all of the antibody's heavy chains. Such derivatives orfragments typically will comprise one or more linker or other amino acidsequences to join the light chains or light chain fragments and/or allowthem to adopt a conformation that allows for binding of the fragment orderivative to its antigen.

The amino acid sequences of an antibody may be derived solely from asingle source, or may be “chimeric”; that is, different portions of theantibody may be derived from two different antibodies as describedfurther below. The antigen binding proteins, antibodies, or bindingfragments may be produced in hybridomas, by recombinant DNA techniques,or by enzymatic or chemical cleavage of intact antibodies. Unlessotherwise indicated, the term “antibody” includes, in addition toantibodies comprising two full-length heavy chains and two full-lengthlight chains, derivatives, variants, fragments, and mutations thereof.

The term “light chain” includes full-length light chain as well asfragments, derivatives, and variants thereof having a variable regionsequence that is sufficient, in combination, as needed, with a suitableheavy chain or heavy chain fragment, derivative, or variant, to conferspecific binding to an antigen. A full-length light chain includes avariable region domain, V_(L), and a constant region domain, C_(L).Examples of light chains include kappa light chains and lambda lightchains.

The term “heavy chain” includes a full-length heavy chain as well asfragments, derivatives, and variants thereof having a variable regionsequence that is sufficient, in combination, as needed, with a suitablelight chain or light chain fragment, derivative, or variant, to conferspecific binding to an antigen. A full-length heavy chain includes avariable region domain, V_(H), and three constant region domains,C_(H1), C_(H2), and C_(H3). Heavy chains may be of any isotype,including IgG (including IgG1, IgG2, IgG3 and IgG4 subtypes), IgA(including IgA1 and IgA2 subtypes), IgM and IgE, as well as derivativesand variants thereof.

The term “immunologically functional fragment” of an antibody orimmunoglobulin chain (heavy or light chain), as used herein, is anantigen binding protein comprising a portion (regardless of how thatportion is obtained or synthesized) of an antibody that lacks at leastsome of the amino acids present in a full-length chain but which iscapable of specifically binding to an antigen. Such fragments arebiologically active in that they bind specifically to the targetantigen. In some embodiment, such a fragment will retain at least oneCDR present in the full-length light or heavy chain, and in someembodiments will comprise a single heavy chain and/or light chain orportion thereof. These biologically active fragments may be produced by,for example, recombinant DNA techniques or by enzymatic or chemicalcleavage of antigen binding proteins, including of intact antibodies.Immunologically functional immunoglobulin fragments include, but are notlimited to, Fab, Fab′, F(ab′)₂, Fv, domain antibodies and single-chainantibodies, and may be derived from any mammalian source, including butnot limited to human, mouse, rat, camelid or rabbit. It is contemplatedfurther that a functional portion of the antigen binding proteinsdisclosed herein, for example, one or more CDRs, could be covalentlybound to a second protein or to a small molecule to create a therapeuticagent directed to a particular target in the body, possessingbifunctional therapeutic properties, or having a prolonged serumhalf-life.

“Single-chain antibodies” are Fv molecules in which the heavy and lightchain variable regions have been connected by a flexible linker to forma single polypeptide chain, which forms an antigen-binding region.Single chain antibodies are discussed in detail in International PatentApplication Publication No. WO 88/01649 and U.S. Pat. No. 4,946,778 andU.S. Pat. No. 5,260,203, the disclosures of which are incorporated byreference.

A “domain antibody” is an immunologically functional immunoglobulinfragment containing only the variable region of a heavy chain or thevariable region of a light chain. In some instances, two or more V_(H)regions are covalently joined with a peptide linker to create a bivalentdomain antibody. The two V_(H) regions of a bivalent domain antibody maytarget the same or different antigens.

A “bivalent antigen binding protein” or “bivalent antibody” comprisestwo antigen binding sites. In some embodiments, the two binding siteshave the same antigen specificities. In other embodiments, the bivalentantigen binding proteins and bivalent antibodies are bispecific.

A multispecific antigen binding protein” or “multispecific antibody” isone that specifically binds more than one antigen or epitope.

A “bispecific,” “dual-specific” or “bifunctional” antigen bindingprotein or antibody is a hybrid antigen binding protein or antibody,respectively, having two antigen binding sites that each specificallybinds to a different epitope. The two epitopes can be present on thesame molecule (e.g., on the CCR7 protein) or on different molecules(e.g., on the CCR7 protein and on CCL19 OR CCL21). Bispecific antigenbinding proteins and antibodies are a species of multispecific antigenbinding protein or multispecific antibody and may be produced by avariety of methods including, but not limited to, fusion of hybridomasor linking of Fab′ fragments. See, e.g., Songsivilai and Lachmann, 1990,Clin. Exp. Immunol 79:315-321; Kostelny et al., 1992, J. Immunol148:1547-1553.

The terms “inhibitory antigen binding protein,” “inhibitory antibody,”“antagonistic antigen binding protein,” “antagonistic antibody,”“neutralizing antigen binding protein” and “neutralizing antibody”refers to an antigen binding protein or antibody, respectively, thatspecifically binds to its target and thereby reduces or prevents abiological activity of the target, such as, for example, its ability tobind with a ligand, receptor, binding partner, regulatory molecule, orsubstrate, catalyze a reaction, send or propagate a signal, orphosphorylate or de-phosphorylate itself or another protein.

The term “compete” when used in the context of antigen binding proteins(e.g., neutralizing antigen binding proteins or neutralizing antibodies)that bind to the same target means competition between antigen bindingproteins is determined by an assay in which the antigen binding protein(e.g., antibody or immunologically functional fragment thereof) undertest prevents, reduces or inhibits specific binding of a referenceantigen binding protein (e.g., a ligand, or a reference antibody) to acommon antigen (e.g., CCR7 or a fragment thereof). Numerous types ofcompetitive binding assays can be used, for example: solid phase director indirect radioimmunoassay (RIA), solid phase direct or indirectenzyme immunoassay (EIA), sandwich competition assay (see, e.g., Stahliet al., 1983, Methods in Enzymology 9:242-253); solid phase directbiotin-avidin EIA (see, e.g., Kirkland et al., 1986, J. Immunol.137:3614-3619) solid phase direct labeled assay, solid phase directlabeled sandwich assay (see, e.g., Harlow and Lane, 1988, Antibodies, ALaboratory Manual, Cold Spring Harbor Press); solid phase direct labelRIA using 1-125 label (see, e.g., Morel et al., 1988, Molec. Immunol25:7-15); solid phase direct biotin-avidin EIA (see, e.g., Cheung, etal., 1990, Virology 176:546-552); and direct labeled RIA (Moldenhauer etal., 1990, Scand. J. Immunol. 32:77-82). Typically, such an assayinvolves the use of purified antigen bound to a solid surface or cellsbearing either of these, an unlabelled test antigen binding protein anda labeled reference antigen binding protein. Competitive inhibition ismeasured by determining the amount of label bound to the solid surfaceor cells in the presence of the test antigen binding protein. Usuallythe test antigen binding protein is present in excess. Antigen bindingproteins identified by competition assay (competing antigen bindingproteins) include antigen binding proteins binding to the same epitopeas the reference antigen binding proteins, an epitope that overlaps theepitope as the reference antigen binding proteins, and epitopes that donot overlap but that allow for steric hindrance to occur between thetest and reference antigen binding proteins. A specific method fordetermining competitive binding is provided in the examples herein.Usually, when a competing antigen binding protein is present in excess,it will inhibit specific binding of a reference antigen binding proteinto a common antigen by at least 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%,60%, 65%, 70% or 75%. In some instance, binding is inhibited by at least80%, 85%, 90%, 95%, or 97% or more.

The term “antigen” refers to a molecule or a portion of a moleculecapable of being bound by a selective binding agent, such as an antigenbinding protein (including, e.g., an antibody or immunologicalfunctional fragment thereof), and additionally capable of being used inan animal to produce antibodies capable of binding to that antigen. Anantigen may possess one or more epitopes that are capable of interactingwith different antigen binding proteins, e.g., antibodies.

The term “epitope” is the portion of a molecule that is bound by anantigen binding protein (for example, an antibody). The term includesany determinant capable of specifically binding to an antigen bindingprotein, such as an antibody or to a T-cell receptor. An epitope can becontiguous or non-contiguous (e.g., in a polypeptide, amino acidresidues that are not contiguous to one another in the polypeptidesequence but that within in context of the molecule are bound by theantigen binding protein). In certain embodiments, epitopes may bemimetic in that they comprise a three dimensional structure that issimilar to an epitope used to generate the antigen binding protein, yetcomprise none or only some of the amino acid residues found in thatepitope used to generate the antigen binding protein. Most often,epitopes reside on proteins, but in some instances may reside on otherkinds of molecules, such as nucleic acids. Epitope determinants mayinclude chemically active surface groupings of molecules such as aminoacids, sugar side chains, phosphoryl or sulfonyl groups, and may havespecific three dimensional structural characteristics, and/or specificcharge characteristics. Generally, antibodies specific for a particulartarget antigen will preferentially recognize an epitope on the targetantigen in a complex mixture of proteins and/or macromolecules.

The term “identity” refers to a relationship between the sequences oftwo or more polypeptide molecules or two or more nucleic acid molecules,as determined by aligning and comparing the sequences. “Percentidentity” means the percent of identical residues between the aminoacids or nucleotides in the compared molecules and is calculated basedon the size of the smallest of the molecules being compared. For thesecalculations, gaps in alignments (if any) must be addressed by aparticular mathematical model or computer program (i.e., an“algorithm”). Methods that can be used to calculate the identity of thealigned nucleic acids or polypeptides include those described inComputational Molecular Biology, (Lesk, A. M., ed.), 1988, New York:Oxford University Press; Biocomputing Informatics and Genome Projects,(Smith, D. W., ed.), 1993, New York: Academic Press; Computer Analysisof Sequence Data, Part I, (Griffin, A. M., and Griffin, H. G., eds.),1994, New Jersey: Humana Press; von Heinje, G., 1987, Sequence Analysisin Molecular Biology, New York: Academic Press; Sequence AnalysisPrimer, (Gribskov, M. and Devereux, J., eds.), 1991, New York: M.Stockton Press; and Carillo et al., 1988, SIAM J. Applied Math. 48:1073.

In calculating percent identity, the sequences being compared arealigned in a way that gives the largest match between the sequences. Thecomputer program used to determine percent identity is the GCG programpackage, which includes GAP (Devereux et al., 1984, Nucl. Acid Res.12:387; Genetics Computer Group, University of Wisconsin, Madison,Wis.). The computer algorithm GAP is used to align the two polypeptidesor polynucleotides for which the percent sequence identity is to bedetermined. The sequences are aligned for optimal matching of theirrespective amino acid or nucleotide (the “matched span”, as determinedby the algorithm). A gap opening penalty (which is calculated as 3× theaverage diagonal, wherein the “average diagonal” is the average of thediagonal of the comparison matrix being used; the “diagonal” is thescore or number assigned to each perfect amino acid match by theparticular comparison matrix) and a gap extension penalty (which isusually 1/10 times the gap opening penalty), as well as a comparisonmatrix such as PAM 250 or BLOSUM 62 are used in conjunction with thealgorithm. In certain embodiments, a standard comparison matrix (see,Dayhoff et al., 1978, Atlas of Protein Sequence and Structure 5:345-352for the PAM 250 comparison matrix; Henikoff et al., 1992, Proc. Natl.Acad. Sci. USA. 89:10915-10919 for the BLOSUM 62 comparison matrix) isalso used by the algorithm.

Parameters for determining percent identity for polypeptides ornucleotide sequences using the GAP program are the following:

Algorithm: Needleman et al., 1970, J. Mol. Biol. 48:443-453;

Comparison matrix: BLOSUM 62 from Henikoff et al., 1992, supra;

Gap Penalty: 12 (but with no penalty for end gaps)

Gap Length Penalty: 4

Threshold of Similarity: 0

Certain alignment schemes for aligning two amino acid sequences mayresult in matching of only a short region of the two sequences, and thissmall aligned region may have very high sequence identity even thoughthere is no significant relationship between the two full-lengthsequences. Accordingly, the selected alignment method (GAP program) canbe adjusted if so desired to result in an alignment that spans at least50 contiguous amino acids of the target polypeptide.

As used herein, “substantially pure” means that the described species ofmolecule is the predominant species present, that is, on a molar basisit is more abundant than any other individual species in the samemixture. In certain embodiments, a substantially pure molecule is acomposition wherein the object species comprises at least 50% (on amolar basis) of all macromolecular species present. In otherembodiments, a substantially pure composition will comprise at least80%, 85%, 90%, 95%, or 99% of all macromolecular species present in thecomposition. In other embodiments, the object species is purified toessential homogeneity wherein contaminating species cannot be detectedin the composition by conventional detection methods and thus thecomposition consists of a single detectable macromolecular species.

The term “treating” refers to any indicia of success in the prevention,prophylaxis, treatment or amelioration of an injury, pathology, diseaseor condition, including any objective or subjective parameter such asabatement; remission; diminishing of symptoms or making the injury,pathology or condition more tolerable to the patient; slowing in therate of degeneration or decline; making the final point of degenerationless debilitating; improving a patient's physical or mental well-being.The treatment or amelioration of symptoms can be based on objective orsubjective parameters; including the results of a physical examination,neuropsychiatric exams, and/or a psychiatric evaluation. For example,certain methods presented herein successfully treat inflammatoryconditions by decreasing the incidence of inflammation, causingremission of inflammation and/or ameliorating a symptom associated withinflammation.

An “effective amount” of a therapeutic treatment is generally an amountsufficient to reduce the severity and/or frequency of symptoms,eliminate the symptoms and/or underlying cause, prevent the occurrenceof symptoms and/or their underlying cause, and/or improve or remediatethe damage that results from or is associated with symptoms or theirunderlying cause. In some embodiments, the effective amount is atherapeutically effective amount or a prophylactically effective amount.A “therapeutically effective amount” is an amount sufficient to remedy adisease state (e.g. inflammation) or symptoms, particularly a state orsymptoms associated with the disease state, or otherwise prevent,hinder, retard or reverse the progression of the disease state or anyother undesirable symptom associated with the disease in any waywhatsoever. A “prophylactically effective amount” is an amount of apharmaceutical composition that, when administered to a subject, willhave the intended prophylactic effect, e.g., preventing or delaying theonset (or reoccurrence) of inflammation, or reducing the likelihood ofthe onset (or reoccurrence) of inflammation or inflammation symptoms.The full therapeutic or prophylactic effect does not necessarily occurby administration of one dose, and may occur only after administrationof a series of doses. Thus, a therapeutically or prophylacticallyeffective amount may be administered in one or more administrations.

“Amino acid” includes its normal meaning in the art. The twentynaturally-occurring amino acids and their abbreviations followconventional usage. See, Immunology—A Synthesis, 2nd Edition, (E. S.Golub and D. R. Green, eds.), Sinauer Associates: Sunderland, Mass.(1991), incorporated herein by reference for any purpose. Stereoisomers(e.g., D-amino acids) of the twenty conventional amino acids, unnaturalamino acids such as [alpha]-, [alpha]-disubstituted amino acids, N-alkylamino acids, and other unconventional amino acids may also be suitablecomponents for polypeptides and are included in the phrase “amino acid.”Examples of unconventional amino acids include: 4-hydroxyproline,[gamma]-carboxyglutamate, [epsilon]-N,N,N-trimethyllysine,[epsilon]-N-acetyllysine, O-phosphoserine, N-acetylserine,N-formylmethionine, 3-methylhistidine, 5-hydroxylysine,[sigma]-N-methylarginine, and other similar amino acids and imino acids(e.g., 4-hydroxyproline). In the polypeptide notation used herein, theleft-hand direction is the amino terminal direction and the right-handdirection is the carboxyl-terminal direction, in accordance withstandard usage and convention.

The term “CCR7 mediated disease” includes, but is not limited to,inflammatory, infectious, and autoimmune diseases. An “autoimmunedisease” as used herein refers to disease states and conditions whereina patient's immune response is directed toward the patient's ownconstituents. For example, CCR7 mediated diseases include, but are notlimited to, Acquired Immune Deficiency Syndrome (AIDS), rheumatoidarthritis including juvenile rheumatoid arthritis, inflammatory boweldiseases including ulcerative colitis and Crohn's disease, multiplesclerosis, Addison's disease, diabetes (type I), diabetes (type 2),insulin resistance, metabolic syndrome, heart disease, coronary arterydisease, epididymitis, glomerulonephritis, Graves' disease,Guillain-Barre syndrome, Hashimoto's disease, hemolytic anemia, systemiclupus erythematosus (SLE), lupus nephritis, myasthenia gravis,pemphigus, psoriasis, psoriatic arthritis, atherosclerosis,erythropoietin resistance, graft versus host disease, transplantrejection, autoimmune hepatitis-induced hepatic injury, biliarycirrhosis, alcohol-induced liver injury including alcoholic cirrhosis,rheumatic fever, sarcoidosis, scleroderma, Sjogren's syndrome,spondyloarthropathies including ankylosing spondylitis, thyroiditis,vasculitis, atherosclerosis, coronary artery disease, and heart disease.The term “CCR7 mediated disease” also encompasses any medical conditionassociated with increased levels of CCL19 or CCL21 or CCR7 or increasedsensitivity to CCL19 OR CCL21.

Antigen Binding Proteins

In one aspect, the present invention provides antigen binding proteins(e.g., antibodies, antibody fragments, antibody derivatives, antibodymuteins, and antibody variants), that bind to CCR7, e.g., human CCR7.

Antigen binding proteins in accordance with the present inventioninclude antigen binding proteins that inhibit a biological activity ofCCR7. Examples of such biological activities include binding a signalingmolecule (e.g., CCL19 or CCL21), and transducing a signal in response tobinding a signaling molecule.

Different antigen binding proteins may bind to different domains orepitopes of CCR7 or act by different mechanisms of action. Examplesinclude but are not limited to antigen binding proteins that interferewith binding of CCL19 or CCL21 to CCR7 or that inhibit signaltransduction. The site of action may be, for example, intracellular(e.g., by interfering with an intracellular signaling cascade) orextracellular. An antigen binding protein need not completely inhibit aCCL19 or CCL21 induced activity to find use in the present invention;rather, antigen binding proteins that reduce a particular activity ofCCL19 or CCL21 are contemplated for use as well. (Discussions herein ofparticular mechanisms of action for CCR7-binding antigen bindingproteins in treating particular diseases are illustrative only, and themethods presented herein are not bound thereby.)

In another aspect, the present invention provides CCR7 antigen bindingproteins that comprise a light chain variable region and/or a heavychain variable region selected from the sequences provided herein, orthat comprise one or more CDR sequences selected from the sequencesprovided herein. Examples of antigen binding proteins of the presentinvention include antigen binding proteins, antibodies, and antibodyderivatives and fragments comprising all or part of the sequences of6B4.1, 6B5.1, 6E1.2, 6B4.1 LC desS, 6E1.2 HC G2V, 6E1.2 HC F80Y, 6E1.2HC G2V F80Y, 6E1.2 LC H36Q, MAB22_KLC-V1, MAB22_KLC_V2, MAB22_KLC_V3,MAB22_KLC_V4, MAB22_KLC_V5, MAB22_KLC_V6, MAB22_KLC_V7, MAB22_KLC_V8,and/or MAB22_HC_V1, as disclosed herein. Specific examples of suchantigen binding proteins include antibody 6B4.1 [SEQ ID NO:2 and 42],antibody 6B5.1 [SEQ ID NO:18 and 50], antibody 6E1.2 [SEQ ID NO:26 and58], and antibody mAb 22 [SEQ ID NO:92 and 108]. Specific fragments ofthese antibodies that are found in various embodiments of the inventioninclude their signal sequences, variable domains, CDRs, frameworkregions, and constant regions. In one such embodiment, the antigenbinding protein comprises the heavy chain variable domain of 6B4.1 HC,6B5.1 HC, 6E1.2 HC, 6E1.2 HC G2V, 6E1.2 HC F80Y, 6E1.2 HC G2V F80Y orMAB22_HC_V1. In another such embodiment, the antigen binding proteincomprises the light chain variable domain of 6B4.1 LC, 6B5.1 LC, 6E1.2LC, 6B4.1 LC desS, 6E1.2 LC H36Q, MAB22_KLC-V1, MAB22_KLC_V2,MAB22_KLC_V3, MAB22_KLC_V4, MAB22_KLC_V5, MAB22_KLC_V6, MAB22_KLC_V7, orMAB22_KLC_V8. In another such embodiment, the antigen binding proteincomprises the light chain variable domain and the heavy chain variabledomain of antibody 6B4.1, 6B5.1, 6E1.2, or the heavy chain variabledomain of 6B4.1 and the light chain variable domain of 6B4.1 LC desS, orthe light chain variable domain of 6E1.2 LC and the heavy chain variabledomain of 6E1.2 HC G2V, 6E1.2 HC F80Y, or 6E1.2 HC G2V F80Y, or theheavy chain variable domain of 6E1.2 HC and the light chain variabledomain of 6E1.2 LC H36Q. In another such embodiment, the antigen bindingprotein comprises the heavy chain CDR sequences of antibody 6B4.1 HC,6B5.1 HC, or 6E1.2 HC. In another such embodiment, the antigen bindingprotein comprises the light chain CDR sequences of antibody 6B4.1,6B5.1, or 6E1.2. In another such embodiment, the antigen binding proteincomprises the heavy chain CDR sequences and the light chain CDRsequences of antibody 6B4.1 LC, 6B5.1 LC, or 6E1.2 LC. In some suchembodiments, the antigen binding protein is an antibody or anantigen-binding fragment of an antibody.

In another embodiment, the present invention provides a CCR7 antigenbinding protein comprising a light chain variable domain comprising asequence of amino acids that differs from the sequence of a light chainvariable domain disclosed herein only at 15, 14, 13, 12, 11, 10, 9, 8,7, 6, 5, 4, 3, 2, or 1 residues, wherein each such sequence differenceis independently either a deletion, insertion, or substitution of oneamino acid residue. In another embodiment, the light-chain variabledomain comprises a sequence of amino acids that is at least 70%, 75%,80%, 85%, 90%, 95%, 97%, or 99% identical to the sequence of a lightchain variable domain selected from the light chain variable domainsequences disclosed herein. In another embodiment, the light chainvariable domain comprises a sequence of amino acids that is encoded by anucleotide sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 97%,or 99% identical to a nucleotide sequence disclosed herein. In anotherembodiment, the light chain variable domain comprises a sequence ofamino acids that is encoded by a polynucleotide that hybridizes undermoderately stringent conditions to the complement of a polynucleotidedisclosed herein. In another embodiment, the light chain variable domaincomprises a sequence of amino acids that is encoded by a polynucleotidethat hybridizes under moderately stringent conditions to the complementof a polynucleotide disclosed herein. In another embodiment, the lightchain variable domain comprises a sequence of amino acids that isencoded by a polynucleotide that hybridizes under moderately stringentconditions to a complement of a light chain polynucleotide disclosedherein.

In another embodiment, the present invention provides a CCR7 antigenbinding protein comprising a heavy chain variable domain comprising asequence of amino acids that differs from the sequence of a heavy chainvariable domain selected disclosed herein only at 15, 14, 13, 12, 11,10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 residue(s), wherein each such sequencedifference is independently either a deletion, insertion, orsubstitution of one amino acid residue. In another embodiment, the heavychain variable domain comprises a sequence of amino acids that is atleast 70%, 75%, 80%, 85%, 90%, 95%, 97%, or 99% identical to thesequence of a heavy chain variable domain sequence disclosed herein. Inanother embodiment, the heavy chain variable domain comprises a sequenceof amino acids that is encoded by a nucleotide sequence that is at least70%, 75%, 80%, 85%, 90%, 95%, 97%, or 99% identical to a nucleotidesequence disclosed herein. In another embodiment, the heavy chainvariable domain comprises a sequence of amino acids that is encoded by apolynucleotide that hybridizes under moderately stringent conditions tothe complement of a polynucleotide disclosed herein. In anotherembodiment, the heavy chain variable domain comprises a sequence ofamino acids that is encoded by a polynucleotide that hybridizes undermoderately stringent conditions to the complement of a polynucleotidedisclosed herein. In another embodiment, the heavy chain variable domaincomprises a sequence of amino acids that is encoded by a polynucleotidethat hybridizes under moderately stringent conditions to a complement ofa heavy chain polynucleotide disclosed herein.

Particular embodiments of antigen binding proteins of the presentinvention comprise one or more amino acid sequences that are identicalto the amino acid sequences of one or more of the CDRs and/or FRsdisclosed herein. In one embodiment, the antigen binding proteincomprises a light chain CDR1 sequence disclosed herein. In anotherembodiment, the antigen binding protein comprises a light chain CDR2sequence disclosed herein. In another embodiment, the antigen bindingprotein comprises a light chain CDR3 sequence disclosed herein. Inanother embodiment, the antigen binding protein comprises a heavy chainCDR1 sequence disclosed herein. In another embodiment, the antigenbinding protein comprises a heavy chain CDR2 sequence disclosed herein.In another embodiment, the antigen binding protein comprises a heavychain CDR3 sequence disclosed herein. In another embodiment, the antigenbinding protein comprises a light chain FR1 sequence disclosed herein.In another embodiment, the antigen binding protein comprises a lightchain FR2 sequence disclosed herein. In another embodiment, the antigenbinding protein comprises a light chain FR3 sequence disclosed herein.In another embodiment, the antigen binding protein comprises a lightchain FR4 sequence disclosed herein. In another embodiment, the antigenbinding protein comprises a heavy chain FR1 sequence disclosed herein.In another embodiment, the antigen binding protein comprises a heavychain FR2 sequence disclosed herein. In another embodiment, the antigenbinding protein comprises a heavy chain FR3 sequence disclosed herein.In another embodiment, the antigen binding protein comprises a heavychain FR4 sequence disclosed herein.

In one embodiment, the present invention provides an antigen bindingprotein that comprises one or more CDR sequences that each differs froma CDR sequence disclosed herein by no more than 5, 4, 3, 2, or 1 aminoacid residues.

In another embodiment, the present invention provides antibodies thatcross-compete with one or more of the antibodies described herein forbinding to the extracellular domain of human CCR7, wherein twoantibodies “cross-compete” if each antibody reduces the binding of theother by at least 80%.

The nucleotide sequences or amino acid sequences disclosed herein can bealtered, for example, by random mutagenesis or by site-directedmutagenesis (e.g., oligonucleotide-directed site-specific mutagenesis)to create an altered polynucleotide comprising one or more particularnucleotide substitutions, deletions, or insertions as compared to thenon-mutated polynucleotide. Examples of techniques for making suchalterations are described in Walder et al., 1986, Gene 42:133; Bauer etal. 1985, Gene 37:73; Craik, BioTechniques, January 1985, 12-19; Smithet al., 1981, Genetic Engineering: Principles and Methods, Plenum Press;and U.S. Pat. Nos. 4,518,584 and 4,737,462. These and other methods canbe used to make, for example, derivatives of anti-CCR7 antibodies thathave a desired property, for example, increased affinity, avidity, orspecificity for CCR7, increased activity or stability in vivo or invitro, or reduced in vivo side-effects as compared to the underivatizedantibody.

Other derivatives of anti-CCR7 antibodies within the scope of thisinvention include covalent or aggregative conjugates of anti-CCR7antibodies, or fragments thereof, with other proteins or polypeptides,such as by expression of recombinant fusion proteins comprisingheterologous polypeptides fused to the N-terminus or C-terminus of ananti-CCR7 antibody polypeptide. For example, the conjugated peptide maybe a heterologous signal (or leader) polypeptide, e.g., the yeastalpha-factor leader, or a peptide such as an epitope tag. Antigenbinding protein-containing fusion proteins can comprise peptides addedto facilitate purification or identification of antigen binding protein(e.g., polyHis). An antigen binding protein also can be linked to theFLAG peptide Asp-Tyr-Lys-Asp-Asp-Asp-Asp-Lys (DYKDDDDK) as described inHopp et al., Bio/Technology 6:1204, 1988, and U.S. Pat. No. 5,011,912.The FLAG peptide is highly antigenic and provides an epitope reversiblybound by a specific monoclonal antibody (mAb), enabling rapid assay andfacile purification of expressed recombinant protein. Reagents usefulfor preparing fusion proteins in which the FLAG peptide is fused to agiven polypeptide are commercially available (Sigma, St. Louis, Mo.).

Oligomers that contain one or more antigen binding proteins may beemployed as CCR7 antagonists. Oligomers may be in the form ofcovalently-linked or non-covalently-linked dimers, trimers, or higheroligomers. Oligomers comprising two or more antigen binding protein arecontemplated for use, with one example being a homodimer. Otheroligomers include heterodimers, homotrimers, heterotrimers,homotetramers, heterotetramers, etc.

One embodiment is directed to oligomers comprising multiple antigenbinding proteins joined via covalent or non-covalent interactionsbetween peptide moieties fused to theantigen binding proteins. Suchpeptides may be peptide linkers (spacers), or peptides that have theproperty of promoting oligomerization. Leucine zippers and certainpolypeptides derived from antibodies are among the peptides that canpromote oligomerization of antigen binding proteins attached thereto, asdescribed in more detail below.

In particular embodiments, the oligomers comprise from two to fourantigen binding proteins. The antigen binding proteins of the oligomermay be in any form, such as any of the forms described above, e.g.,variants or fragments. Preferably, the oligomers comprise antigenbinding proteins that have CCR7 binding activity.

In one embodiment, an oligomer is prepared using polypeptides derivedfrom immunoglobulins. Preparation of fusion proteins comprising certainheterologous polypeptides fused to various portions of antibody-derivedpolypeptides (including the Fc domain) has been described, e.g., byAshkenazi et al., 1991, PNAS USA 88:10535; Byrn et al., 1990, Nature344:677; and Hollenbaugh et al., 1992 “Construction of ImmunoglobulinFusion Proteins”, in Current Protocols in Immunology, Suppl. 4, pages10.19.1-10.19.11.

One embodiment of the present invention is directed to a dimercomprising two fusion proteins created by fusing a CCR7 binding fragmentof an anti-CCR7 antibody to the Fc region of an antibody. The dimer canbe made by, for example, inserting a gene fusion encoding the fusionprotein into an appropriate expression vector, expressing the genefusion in host cells transformed with the recombinant expression vector,and allowing the expressed fusion protein to assemble much like antibodymolecules, whereupon interchain disulfide bonds form between the Fcmoieties to yield the dimer

The term “Fc polypeptide” as used herein includes native and muteinforms of polypeptides derived from the Fc region of an antibody.Truncated forms of such polypeptides containing the hinge region thatpromotes dimerization also are included. Fusion proteins comprising Fcmoieties (and oligomers formed therefrom) offer the advantage of facilepurification by affinity chromatography over Protein A or Protein Gcolumns.

One suitable Fc polypeptide, described in PCT application WO 93/10151(hereby incorporated by reference), is a single chain polypeptideextending from the N-terminal hinge region to the native C-terminus ofthe Fc region of a human IgG1 antibody. Another useful Fc polypeptide isthe Fc mutein described in U.S. Pat. No. 5,457,035 and in Baum et al.,1994, EMBO J. 13:3992-4001. The amino acid sequence of this mutein isidentical to that of the native Fc sequence presented in WO 93/10151,except that amino acid 19 has been changed from Leu to Ala, amino acid20 has been changed from Leu to Glu, and amino acid 22 has been changedfrom Gly to Ala. The mutein exhibits reduced affinity for Fc receptors.

In other embodiments, the variable portion of the heavy and/or lightchains of an anti-CCR7 antibody may be substituted for the variableportion of an antibody heavy and/or light chain.

Alternatively, the oligomer is a fusion protein comprising multipleantigen binding proteins, with or without peptide linkers (spacerpeptides). Among the suitable peptide linkers are those described inU.S. Pat. Nos. 4,751,180 and 4,935,233.

Another method for preparing oligomeric antigen binding proteinsinvolves use of a leucine zipper. Leucine zipper domains are peptidesthat promote oligomerization of the proteins in which they are found.Leucine zippers were originally identified in several DNA-bindingproteins (Landschulz et al., 1988, Science 240:1759), and have sincebeen found in a variety of different proteins. Among the known leucinezippers are naturally occurring peptides and derivatives thereof thatdimerize or trimerize. Examples of leucine zipper domains suitable forproducing soluble oligomeric proteins are described in PCT applicationWO 94/10308, and the leucine zipper derived from lung surfactant proteinD (SPD) described in Hoppe et al., 1994, FEBS Letters 344:191, herebyincorporated by reference. The use of a modified leucine zipper thatallows for stable trimerization of a heterologous protein fused theretois described in Fanslow et al., 1994, Semin. Immunol. 6:267-78. In oneapproach, recombinant fusion proteins comprising an anti-CCR7 antibodyfragment or derivative fused to a leucine zipper peptide are expressedin suitable host cells, and the soluble oligomeric anti-CCR7 antibodyfragments or derivatives that form are recovered from the culturesupernatant.

In another aspect, the present invention provides an antigen bindingprotein that binds to the ligand binding domain of human CCR7. Antigenbinding proteins that bind to the ligand binding domain can be madeusing any technique known in the art. For example, such antigen bindingproteins can be isolated using the full-length CCR7 polypeptide (e.g.,in a membrane-bound preparation), a soluble extracellular domainfragment of CCR7, or a smaller fragment of the CCR7 extracellular domaincomprising or consisting of the ligand binding domain. Antigen bindingproteins so isolated can be screened to determine their bindingspecificity using any method known in the art. Examples of suitableassays are assays that test the antigen binding proteins for the abilityto inhibit binding of CCL19 or CCL21 to cells expressing CCR7, or thattest antigen binding proteins for the ability to reduce a biological orcellular response that results from the binding of CCL19 or CCL21 tocell surface CCR7 receptors.

In another aspect, the present invention provides an antigen bindingprotein that binds to the same epitope as a reference antibody disclosedherein, for example, 6B4.1, 6B5.1, or 6E1.2. In one embodiment, theantigen binding protein competes for binding to human CCR7 with thereference antibody. In another embodiment, the antigen binding proteinand the reference antibody cross-compete for binding to human CCR7. Inanother embodiment, the epitope of the reference antibody and of theantigen binding protein is determined by solving the X-ray crystalstructure of the antibody or antigen binding protein bound to humanCCR7, for example, to a soluble fragment of human CCR7. In one suchembodiment, the epitope is defined as those residues on the surface ofhuman CCR7 that show at least a 10% reduction in solvent accessibilitywhen the reference antibody or the antigen binding protein is bound toit as compared to when it is bound to neither. In one embodiment, theepitope substantially overlaps the CCL19 or CCL21 binding domain ofhuman CCR7.

In another aspect, the present invention provides an antigen bindingprotein that demonstrates species selectivity. In one embodiment, theantigen binding protein binds to one or more mammalia CCR7s, forexample, to human CCR7 and to one or more of mouse, rat, guinea pig,hamster, gerbil, cat, rabbit, dog, goat, sheep, cow, horse, camel, andnon-human primate CCR7. In another embodiment, the antigen bindingprotein binds to one or more primate CCR7s, for example, to human CCR7and to one or more of cynomologous, marmoset, rhesus, and chimpanzeeCCR7s. In another embodiment, the antigen binding protein bindsspecifically to human, cynomologous, marmoset, rhesus, or chimpanzeeCCR7. In another embodiment, the antigen binding protein does not bindto one or more of mouse, rat, guinea pig, hamster, gerbil, cat, rabbit,dog, goat, sheep, cow, horse, camel, and non-human primate CCR7. Inanother embodiment, the antigen binding protein does not bind to a NewWorld monkey species such as a marmoset. In another embodiment, theantigen binding protein does not exhibit specific binding to anynaturally occurring protein other tha CCR7. In another embodiment, theantigen binding protein does not exhibit specific binding to anynaturally occurring protein other than mammalia CCR7. In anotherembodiment, the antigen binding protein does not exhibit specificbinding to any naturally occurring protein other than primate CCR7. Inanother embodiment, the antigen binding protein does not exhibitspecific binding to any naturally occurring protein other than humanCCR7. In another embodiment, the antigen binding protein specificallybinds to mouse, rat, cynomolgus monkey, and human CCR7. In anotherembodiment, the antigen binding protein specifically binds to mouse,rat, cynomolgus monkey, and human CCR7 with a similar binding affinity.In another embodiment, the antigen binding protein blocks binding ofhuman CCL19 or CCL21 with mouse, rat, cynomolgus monkey, and human CCR7.In another embodiment, the antigen binding protein blocks binding ofhuman CCL19 OR CCL21 with mouse, rat, cynomolgus monkey, and human CCR7with similar K_(i).

One may determine the selectivity of an antigen binding protein for aCCR7 using methods well known in the art and following the teachings ofthe specification. For example, one may determine the selectivity usingWestern blot, FACS, ELISA or RIA.

Antigen-binding fragments of antigen binding proteins of the inventionmay be produced by conventional techniques. Examples of such fragmentsinclude, but are not limited to, Fab and F(ab′)2 fragments. Antibodyfragments and derivatives produced by genetic engineering techniquesalso are contemplated.

Additional embodiments include chimeric antibodies, e.g., humanizedversions of non-human (e.g., murine) monoclonal antibodies. Suchhumanized antibodies may be prepared by known techniques, and offer theadvantage of reduced immunogenicity when the antibodies are administeredto humans. In one embodiment, a humanized monoclonal antibody comprisesthe variable domain of a murine antibody (or all or part of the antigenbinding site thereof) and a constant domain derived from a humanantibody. Alternatively, a humanized antibody fragment may comprise theantigen binding site of a murine monoclonal antibody and a variabledomain fragment (lacking the antigen-binding site) derived from a humanantibody. Procedures for the production of chimeric and furtherengineered monoclonal antibodies include those described in Riechmann etal., 1988, Nature 332:323, Liu et al., 1987, Proc. Nat. Acad. Sci. USA84:3439, Larrick et al., 1989, Bio/Technology 7:934, and Winter et al.,1993, TIPS 14:139. In one embodiment, the chimeric antibody is a CDRgrafted antibody. Techniques for humanizing antibodies are discussed in,e.g., U.S. patent application Ser. No. 10/194,975 (published Feb. 27,2003), U.S. Pat. Nos. 5,869,619, 5,225,539, 5,821,337, 5,859,205, Padlanet al., 1995, FASEB J. 9:133-39, and Tamura et al., 2000, J. Immunol.164:1432-41.

Procedures have been developed for generating human or partially humanantibodies in non-human animals. For example, mice in which one or moreendogenous immunoglobulin genes have been inactivated by various meanshave been prepared. Human immunoglobulin genes have been introduced intothe mice to replace the inactivated mouse genes. Antibodies produced inthe animal incorporate human immunoglobulin polypeptide chains encodedby the human genetic material introduced into the animal. In oneembodiment, a non-human animal, such as a transgenic mouse, is immunizedwith a CCR7 polypeptide, such that antibodies directed against the CCR7polypeptide are generated in the animal. One example of a suitableimmunogen is a soluble human CCR7, such as a polypeptide comprising itsextracellular domain or other immunogenic fragment. Examples oftechniques for production and use of transgenic animals for theproduction of human or partially human antibodies are described in U.S.Pat. Nos. 5,814,318, 5,569,825, and 5,545,806, Davis et al., 2003,Production of human antibodies from transgenic mice in Lo, ed. AntibodyEngineering: Methods and Protocols, Humana Press, NJ:191-200, Kellermannet al., 2002, Curr Opin Biotechnol. 13:593-97, Russel et al., 2000,Infect Immun. 68:1820-26, Gallo et al., 2000, Eur J Immun 30:534-40,Davis et al., 1999, Cancer Metastasis Rev. 18:421-25, Green, 1999, JImmunol Methods. 231:11-23, Jakobovits, 1998, Advanced Drug DeliveryReviews 31:33-42, Green et al., 1998, J Exp Med. 188:483-95, JakobovitsA, 1998, Exp. Opin. Invest. Drugs. 7:607-14, Tsuda et al., 1997,Genomics. 42:413-21, Mendez et al., 1997, Nat Genet. 15:146-56,Jakobovits, 1994, Curr Biol. 4:761-63, Arbones et al., 1994, Immunity.1:247-60, Green et al., 1994, Nat Genet. 7:13-21, Jakobovits et al.,1993, Nature. 362:255-58, Jakobovits et al., 1993, Proc Natl Acad SciUSA. 90:2551-55. Chen, J., M. Trounstine, F. W. Alt, F. Young, C.Kurahara, J. Loring, D. Huszar. “Immunoglobulin gene rearrangement in Bcell deficient mice generated by targeted deletion of the JH locus.”International Immunology 5 (1993): 647-656, Choi et al., 1993, NatureGenetics 4: 117-23, Fishwild et al., 1996, Nature Biotechnology 14:845-51, Harding et al., 1995, Annals of the New York Academy ofSciences, Lonberg et al., 1994, Nature 368: 856-59, Lonberg, 1994,Transgenic Approaches to Human Monoclonal Antibodies in Handbook ofExperimental Pharmacology 113: 49-101, Lonberg et al., 1995, InternalReview of Immunology 13: 65-93, Neuberger, 1996, Nature Biotechnology14: 826, Taylor et al., 1992, Nucleic Acids Research 20: 6287-95, Tayloret al., 1994, International Immunology 6: 579-91, Tomizuka et al., 1997,Nature Genetics 16: 133-43, Tomizuka et al., 2000, Proceedings of theNational Academy of Sciences USA 97: 722-27, Tuaillon et al., 1993,Proceedings of the National Academy of Sciences USA 90: 3720-24, andTuaillon et al., 1994, Journal of Immunology 152: 2912-20.

In another aspect, the present invention provides monoclonal antibodiesthat bind to CCR7. Monoclonal antibodies may be produced using anytechnique known in the art, e.g., by immortalizing spleen cellsharvested from the transgenic animal after completion of theimmunization schedule. The spleen cells can be immortalized using anytechnique known in the art, e.g., by fusing them with myeloma cells toproduce hybridomas. Myeloma cells for use in hybridoma-producing fusionprocedures preferably are non-antibody-producing, have high fusionefficiency, and enzyme deficiencies that render them incapable ofgrowing in certain selective media which support the growth of only thedesired fused cells (hybridomas). Examples of suitable cell lines foruse in mouse fusions include Sp-20, P3-X63/Ag8, P3-X63-Ag8.653, NS1/1.Ag4 1, Sp210-Ag14, FO, NSO/U, MPC-11, MPC11-X45-GTG 1.7 and S194/5XX0 Bul;examples of cell lines used in rat fusions include R210.RCY3, Y3-Ag1.2.3, IR983F and 4B210. Other cell lines useful for cell fusions areU-266, GM1500-GRG2, LICR-LON-HMy2 and UC729-6.

In one embodiment, a hybridoma cell line is produced by immunizing ananimal (e.g., a transgenic animal having human immunoglobulin sequences)with a CCR7 immunogen; harvesting spleen cells from the immunizedanimal; fusing the harvested spleen cells to a myeloma cell line,thereby generating hybridoma cells; establishing hybridoma cell linesfrom the hybridoma cells, and identifying a hybridoma cell line thatproduces an antibody that binds a CCR7 polypeptide. Such hybridoma celllines, and anti-CCR7 monoclonal antibodies produced by them, areencompassed by the present invention.

Monoclonal antibodies secreted by a hybridoma cell line can be purifiedusing any technique known in the art. Hybridomas or mAbs may be furtherscreened to identify mAbs with particular properties, such as theability to block an CCL19 or CCL21 induced activity. Examples of suchscreens are provided in the examples below.

Molecular evolution of the complementarity determining regions (CDRs) inthe center of the antibody binding site also has been used to isolateantibodies with increased affinity, for example, antibodies havingincreased affinity for c-erbB-2, as described by Schier et al., 1996, J.Mol. Biol. 263:551. Accordingly, such techniques are useful in preparingantibodies to CCR7.

Antigen binding proteins directed against a CCR7 can be used, forexample, in assays to detect the presence of CCR7 polypeptides, eitherin vitro or in vivo. The antigen binding proteins also may be employedin purifying CCR7 proteins by immunoaffinity chromatography. Thoseantigen binding proteins that additionally can block binding of CCL19 orCCL21 to CCR7 may be used to inhibit a biological activity that resultsfrom such binding. Blocking antigen binding proteins can be used in themethods of the present invention. Such antigen binding proteins thatfunction as CCL19 or CCL21 antagonists may be employed in treating anyCCL19- or CCL21-induced condition, including but not limited to lupus,SLE, and arthritis. In one embodiment, a human anti-CCR7 monoclonalantibody generated by procedures involving immunization of transgenicmice is employed in treating such conditions.

Antigen binding proteins may be employed in an in vitro procedure, oradministered in vivo to inhibit an CCL19 or CCL21-induced biologicalactivity. Disorders caused or exacerbated (directly or indirectly) bythe interaction of CCL19 or CCL21 with cell surface CCR7, examples ofwhich are provided herein, thus may be treated. In one embodiment, thepresent invention provides a therapeutic method comprising in vivoadministration of an CCL19 or CCL21 blocking antigen binding protein toa mammal in need thereof in an amount effective for reducing an CCL19 orCCL21-induced biological activity.

Antigen binding proteins of the invention include partially human andfully human monoclonal antibodies that inhibit a biological activity ofCCL19 or CCL21. One embodiment is directed to a human monoclonalantibody that at least partially blocks binding of CCL19 or CCL21 to acell that expresses human CCR7. In one embodiment, the antibodies aregenerated by immunizing a transgenic mouse with a CCR7 immunogen. Inanother embodiment, the immunogen is a human CCR7 polypeptide (e.g., asoluble fragment comprising all or part of the CCR7 extracellulardomain). Hybridoma cell lines derived from such immunized mice, whereinthe hybridoma secretes a monoclonal antibody that binds CCR7, also areprovided herein.

Although human, partially human, or humanized antibodies will besuitable for many applications, particularly those involvingadministration of the antibody to a human subject, other types ofantigen binding proteins will be suitable for certain applications. Thenon-human antibodies of the invention can be, for example, derived fromany antibody-producing animal, such as mouse, rat, rabbit, goat, donkey,or non-human primate (such as monkey (e.g., cynomologous or rhesusmonkey) or ape (e.g., chimpanzee)). Non-human antibodies of theinvention can be used, for example, in in vitro and cell-culture basedapplications, or any other application where an immune response to theantibody of the invention does not occur, is insignificant, can beprevented, is not a concern, or is desired. In one embodiment, anon-human antibody of the invention is administered to a non-humansubject. In another embodiment, the non-human antibody does not elicitan immune response in the non-human subject. In another embodiment, thenon-human antibody is from the same species as the non-human subject,e.g., a mouse antibody of the invention is administered to a mouse. Anantibody from a particular species can be made by, for example,immunizing an animal of that species with the desired immunogen (e.g., asoluble CCR7 polypeptide) or using an artificial system for generatingantibodies of that species (e.g., a bacterial or phage display-basedsystem for generating antibodies of a particular species), or byconverting an antibody from one species into an antibody from anotherspecies by replacing, e.g., the constant region of the antibody with aconstant region from the other species, or by replacing one or moreamino acid residues of the antibody so that it more closely resemblesthe sequence of an antibody from the other species. In one embodiment,the antibody is a chimeric antibody comprising amino acid sequencesderived from antibodies from two or more different species.

Antigen binding proteins may be prepared by any of a number ofconventional techniques. For example, they may be purified from cellsthat naturally express them (e.g., an antibody can be purified from ahybridoma that produces it), or produced in recombinant expressionsystems, using any technique known in the art. See, for example,Monoclonal Antibodies, Hybridomas: A New Dimension in BiologicalAnalyses, Kennet et al. (eds.), Plenum Press, New York (1980); andAntibodies: A Laboratory Manual, Harlow and Land (eds.), Cold SpringHarbor Laboratory Press, Cold Spring Harbor, N.Y., (1988).

Any expression system known in the art can be used to make therecombinant polypeptides of the invention. In general, host cells aretransformed with a recombinant expression vector that comprises DNAencoding a desired polypeptide. Among the host cells that may beemployed are prokaryotes, yeast or higher eukaryotic cells. Prokaryotesinclude gram negative or gram positive organisms, for example E. coli orbacilli. Higher eukaryotic cells include insect cells and establishedcell lines of mammalian origin. Examples of suitable mammalian host celllines include the COS-7 line of monkey kidney cells (ATCC CRL 1651)(Gluzman et al., 1981, Cell 23:175), L cells, 293 cells, C127 cells, 3T3cells (ATCC CCL 163), Chinese hamster ovary (CHO) cells, HeLa cells, BHK(ATCC CRL 10) cell lines, and the CVI/EBNA cell line derived from theAfrican green monkey kidney cell line CVI (ATCC CCL 70) as described byMcMahan et al., 1991, EMBO J. 10: 2821. Appropriate cloning andexpression vectors for use with bacterial, fungal, yeast, and mammaliancellular hosts are described by Pouwels et al. (Cloning Vectors: ALaboratory Manual, Elsevier, New York, 1985).

The transformed cells can be cultured under conditions that promoteexpression of the polypeptide, and the polypeptide recovered byconventional protein purification procedures. One such purificationprocedure includes the use of affinity chromatography, e.g., over amatrix having all or a portion (e.g., the extracellular domain) of CCR7bound thereto. Polypeptides contemplated for use herein includesubstantially homogeneous recombinant mammalian anti-CCR7 antibodypolypeptides substantially free of contaminating endogenous materials.

Antigen binding proteins may be prepared, and screened for desiredproperties, by any of a number of known techniques. Certain of thetechniques involve isolating a nucleic acid encoding a polypeptide chain(or portion thereof) of an antigen binding protein of interest (e.g., ananti-CCR7 antibody), and manipulating the nucleic acid throughrecombinant DNA technology. The nucleic acid may be fused to anothernucleic acid of interest, or altered (e.g., by mutagenesis or otherconventional techniques) to add, delete, or substitute one or more aminoacid residues, for example.

In one aspect, the present invention provides antigen-binding fragmentsof an anti-CCR7 antibody of the invention. Such fragments can consistentirely of antibody-derived sequences or can comprise additionalsequences. Examples of antigen-binding fragments include Fab, F(ab′)2,single chain antibodies, diabodies, triabodies, tetrabodies, and domainantibodies. Other examples are provided in Lunde et al., 2002, Biochem.Soc. Trans. 30:500-06.

Single chain antibodies may be formed by linking heavy and light chainvariable domain (Fv region) fragments via an amino acid bridge (shortpeptide linker), resulting in a single polypeptide chain. Suchsingle-chain Fvs (scFvs) have been prepared by fusing DNA encoding apeptide linker between DNAs encoding the two variable domainpolypeptides (VL and VH). The resulting polypeptides can fold back onthemselves to form antigen-binding monomers, or they can form multimers(e.g., dimers, trimers, or tetramers), depending on the length of aflexible linker between the two variable domains (Kortt et al., 1997,Prot. Eng. 10:423; Kortt et al., 2001, Biomol. Eng. 18:95-108). Bycombining different VL and VH-comprising polypeptides, one can formmultimeric scFvs that bind to different epitopes (Kriangkum et al.,2001, Biomol. Eng. 18:31-40). Techniques developed for the production ofsingle chain antibodies include those described in U.S. Pat. No.4,946,778; Bird, 1988, Science 242:423; Huston et al., 1988, Proc. Natl.Acad. Sci. USA 85:5879; Ward et al., 1989, Nature 334:544, de Graaf etal., 2002, Methods Mol Biol. 178:379-87. Single chain antibodies derivedfrom antibodies provided herein include, but are not limited to, scFvscomprising one or more variable domain sequences, or one or more CDRsequences from one or more variable domain sequences, disclosed herein.

In some embodiments, antigen binding proteins (e.g., antibodies,antibody fragments, and antibody derivatives) of the invention comprisea light chain and/or a heavy chain antibody constant region. Anyantibody constant regions known in the art can be used. The light chainconstant region can be, for example, a kappa- or lambda-type light chainconstant region, e.g., a human kappa- or lambda-type light chainconstant region. The heavy chain constant region can be, for example, analpha-, delta-, epsilon-, gamma-, or mu-type heavy chain constantregions, e.g., a human alpha-, delta-, epsilon-, gamma-, or mu-typeheavy chain constant region. In one embodiment, the light or heavy chainconstant region is a fragment, derivative, variant, or mutein of anaturally occurring constant region.

Techniques are known for deriving an antibody of a different subclass orisotype from an antibody of interest, i.e., subclass switching. Thus,IgG antibodies may be derived from an IgM antibody, for example, andvice versa. Such techniques allow the preparation of new antibodies thatpossess the antigen-binding properties of a given antibody (the parentantibody), but also exhibit biological properties associated with anantibody isotype or subclass different from that of the parent antibody.Recombinant DNA techniques may be employed. Cloned DNA encodingparticular antibody polypeptides may be employed in such procedures,e.g., DNA encoding the constant domain of an antibody of the desiredisotype. See also Lantto et al., 2002, Methods Mol. Biol. 178:303-16.

Accordingly, the antigen binding proteins of the present inventioninclude those comprising, for example, one or more of the variabledomain sequences disclosed herein and having a desired isotype (forexample, IgA, IgG1, IgG2, IgG3, IgG4, IgM, IgE, and IgD), as well as Fabor F(ab′)2 fragments thereof. Moreover, if an IgG4 is desired, it mayalso be desired to introduce a point mutation (CPSCP->CPPCP) in thehinge region as described in Bloom et al., 1997, Protein Science 6:407,incorporated by reference herein) to alleviate a tendency to formintra-H chain disulfide bonds that can lead to heterogeneity in the IgG4antibodies.

Techniques for deriving antigen binding proteins having differentproperties (i.e., varying affinities for the antigen to which they bind)are also known. One such technique, referred to as chain shuffling,involves displaying immunoglobulin variable domain gene repertoires onthe surface of filamentous bacteriophage, often referred to as phagedisplay. Chain shuffling has been used to prepare high affinityantibodies to the hapten 2-phenyloxazol-5-one, as described by Marks etal., 1992, BioTechnology, 10:779.

In another embodiment, the present invention provides an antigen bindingprotein that has a low dissociation rate from CCR7. In one embodiment,the antigen binding protein has a K_(off) of 1×10⁻⁴ s⁻¹ or lower. Inanother embodiment, the K_(off) is 5×10⁻⁵ s⁻¹ or lower. In anotherembodiment, the K_(off) is substantially the same as an antibodydisclosed herein. In another embodiment, the antigen binding proteinbinds to CCR7 with substantially the same K_(off) as an antibodydisclosed herein. In another embodiment, the antigen binding proteinbinds to CCR7 with substantially the same K_(off) as an antibody thatcomprises one or more CDRs from an antibody disclosed herein.

In another aspect, the present invention provides an antigen bindingprotein having a half-life of at least one day in vitro or in vivo(e.g., when administered to a human subject). In one embodiment, theantigen binding protein has a half-life of at least three days. Inanother embodiment, the antigen binding protein has a half-life of fourdays or longer. In another embodiment, the antigen binding protein has ahalf-life of eight days or longer. In another embodiment, the antigenbinding protein is derivatized or modified such that it has a longerhalf-life as compared to the underivatized or unmodified antigen bindingprotein. In another embodiment, the antigen binding protein contains oneor more point mutations to increase serum half life, such as describedin WO 00/09560, published Feb. 24, 2000, incorporated by reference.

The present invention further provides multi-specific antigen bindingproteins, for example, bispecific antigen binding protein, e.g., antigenbinding protein that bind to two different epitopes of CCR7, or to anepitope of CCR7 and an epitope of another molecule, via two differentantigen binding sites or regions. Moreover, bispecific antigen bindingprotein as disclosed herein can comprise a CCR7 binding site from one ofthe herein-described antibodies and a second CCR7 binding region fromanother of the herein-described antibodies, including those describedherein by reference to other publications. Alternatively, a bispecificantigen binding protein may comprise an antigen binding site from one ofthe herein described antibodies and a second antigen binding site fromanother CCR7 antibody that is known in the art, or from an antibody thatis prepared by known methods or the methods described herein.

Numerous methods of preparing bispecific antibodies are known in theart, and discussed in U.S. patent application Ser. No. 09/839,632, filedApr. 20, 2001 (incorporated by reference herein). Such methods includethe use of hybrid-hybridomas as described by Milstein et al., 1983,Nature 305:537, and others (U.S. Pat. No. 4,474,893, U.S. Pat. No.6,106,833), and chemical coupling of antibody fragments (Brennan et al.,1985, Science 229:81; Glennie et al., 1987, J. Immunol. 139:2367; U.S.Pat. No. 6,010,902). Moreover, bispecific antibodies can be produced viarecombinant means, for example by using leucine zipper moieties (i.e.,from the Fos and Jun proteins, which preferentially form heterodimers;Kostelny et al., 1992, J. Immnol. 148:1547) or other lock and keyinteractive domain structures as described in U.S. Pat. No. 5,582,996.Additional useful techniques include those described in Kortt et al.,1997, supra; U.S. Pat. No. 5,959,083; and U.S. Pat. No. 5,807,706.

In another aspect, the antigen binding protein of the present inventioncomprises a derivative of an antibody. The derivatized antibody cancomprise any molecule or substance that imparts a desired property tothe antibody, such as increased half-life in a particular use. Thederivatized antibody can comprise, for example, a detectable (orlabeling) moiety (e.g., a radioactive, colorimetric, antigenic orenzymatic molecule, a detecable bead (such as a magnetic or electrodense(e.g., gold) bead), or a molecule that binds to another molecule (e.g.,biotin or streptavidin)), a therapeutic or diagnostic moiety (e.g., aradioactive, cytotoxic, or pharmaceutically active moiety), or amolecule that increases the suitability of the antibody for a particularuse (e.g., administration to a subject, such as a human subject, orother in vivo or in vitro uses). Examples of molecules that can be usedto derivatize an antibody include albumin (e.g., human serum albumin)and polyethylene glycol (PEG). Albumin-linked and PEGylated derivativesof antibodies can be prepared using techniques well known in the art. Inone embodiment, the antibody is conjugated or otherwise linked totransthyretin (TTR) or a TTR variant. The TTR or TTR variant can bechemically modified with, for example, a chemical selected from thegroup consisting of dextran, poly(n-vinyl pyurrolidone), polyethyleneglycols, propropylene glycol homopolymers, polypropylene oxide/ethyleneoxide co-polymers, polyoxyethylated polyols and polyvinyl alcohols. USPat. App. No. 20030195154.

In another aspect, the present invention provides methods of screeningfor a molecule that binds to CCR7 using the antigen binding proteins ofthe present invention. Any suitable screening technique can be used. Inone embodiment, a CCR7 molecule, or a fragment thereof to which anantigen binding protein of the present invention binds, is contactedwith the antigen binding protein of the invention and with anothermolecule, wherein the other molecule binds to CCR7 if it reduces thebinding of the antigen binding protein to CCR7. Binding of the antigenbinding protein can be detected using any suitable method, e.g., anELISA. Detection of binding of the antigen binding protein to CCR7 canbe simplified by detectably labeling the antigen binding protein, asdiscussed above. In another embodiment, the CCR7-binding molecule isfurther analyzed to determine whether it inhibits CCR7-mediatedsignaling.

Nucleic Acids

In one aspect, the present invention provides isolated nucleic acidmolecules. The nucleic acids comprise, for example, polynucleotides thatencode all or part of an antigen binding protein, for example, one orboth chains of an antibody of the invention, or a fragment, derivative,mutein, or variant thereof, polynucleotides sufficient for use ashybridization probes, PCR primers or sequencing primers for identifying,analyzing, mutating or amplifying a polynucleotide encoding apolypeptide, anti-sense nucleic acids for inhibiting expression of apolynucleotide, and complementary sequences of the foregoing. Thenucleic acids can be any length. They can be, for example, 5, 10, 15,20, 25, 30, 35, 40, 45, 50, 75, 100, 125, 150, 175, 200, 250, 300, 350,400, 450, 500, 750, 1,000, 1,500, 3,000, 5,000 or more nucleotides inlength, and/or can comprise one or more additional sequences, forexample, regulatory sequences, and/or be part of a larger nucleic acid,for example, a vector. The nucleic acids can be single-stranded ordouble-stranded and can comprise RNA and/or DNA nucleotides, andartificial variants thereof (e.g., peptide nucleic acids).

Nucleic acids encoding antibody polypeptides (e.g., heavy or lightchain, variable domain only, or full length) may be isolated fromB-cells of mice that have been immunized with CCR7. The nucleic acid maybe isolated by conventional procedures such as polymerase chain reaction(PCR).

Representative nucleic acid sequences encoding some of the antibodies ofthe invention are disclosed herein. Particular nucleic acid sequencesencoding the variable domains of 6B4.1, 6B5.1, 6E1.2, 6B4.1 LC desS,6E1.2 HC G2V, 6E1.2 HC F80Y, 6E1.2 HC G2V F80Y, 6E1.2 LC H36Q,MAB22_KLC-V1, MAB22_KLC_V2, MAB22_KLC_V3, MAB22_KLC_V4, MAB22_KLC_V5,MAB22_KLC_V6, MAB22_KLC_V7, MAB22_KLC_V8, and MAB22_HC_V1, are disclosedherein. The skilled artisan will appreciate that, due to the degeneracyof the genetic code, each of the polypeptide sequences disclosed hereinis encoded by a large number of nucleic acid sequences. The presentinvention provides each degenerate nucleotide sequence encoding eachantigen binding protein or other polypeptide of the invention.

The invention further provides nucleic acids that hybridize to othernucleic acids (e.g., nucleic acids comprising a nucleotide sequencedisclosed herein) under particular hybridization conditions. Methods forhybridizing nucleic acids are well-known in the art. See, e.g., CurrentProtocols in Molecular Biology, John Wiley & Sons, N.Y. (1989),6.3.1-6.3.6. As defined herein, a moderately stringent hybridizationcondition uses a prewashing solution containing 5× sodiumchloride/sodium citrate (SSC), 0.5% SDS, 1.0 mM EDTA (pH 8.0),hybridization buffer of about 50% formamide, 6×SSC, and a hybridizationtemperature of 55° C. (or other similar hybridization solutions, such asone containing about 50% formamide, with a hybridization temperature of42° C.), and washing conditions of 60° C., in 0.5×SSC, 0.1% SDS. Astringent hybridization condition hybridizes in 6×SSC at 45° C.,followed by one or more washes in 0.1×SSC, 0.2% SDS at 68° C.Furthermore, one of skill in the art can manipulate the hybridizationand/or washing conditions to increase or decrease the stringency ofhybridization such that nucleic acids comprising nucleotide sequencesthat are at least 65, 70, 75, 80, 85, 90, 95, 98 or 99% identical toeach other typically remain hybridized to each other. The basicparameters affecting the choice of hybridization conditions and guidancefor devising suitable conditions are set forth by, for example,Sambrook, Fritsch, and Maniatis (1989, Molecular Cloning: A LaboratoryManual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.,chapters 9 and 11; and Current Protocols in Molecular Biology, 1995,Ausubel et al., eds., John Wiley & Sons, Inc., sections 2.10 and6.3-6.4), and can be readily determined by those having ordinary skillin the art based on, for example, the length and/or base composition ofthe DNA.

Changes can be introduced by mutation into a nucleic acid, therebyleading to changes in the amino acid sequence of a polypeptide (e.g., anantigen binding protein) that it encodes. Mutations can be introducedusing any technique known in the art. In one embodiment, one or moreparticular amino acid residues are changed using, for example, asite-directed mutagenesis protocol. In another embodiment, one or morerandomly selected residues is changed using, for example, a randommutagenesis protocol. However it is made, a mutant polypeptide can beexpressed and screened for a desired property (e.g., binding to CCR7 orblocking the binding of CCL19 or CCL21 to CCR7).

Mutations can be introduced into a nucleic acid without significantlyaltering the biological activity of a polypeptide that it encodes. Forexample, one can make nucleotide substitutions leading to amino acidsubstitutions at non-essential amino acid residues. In one embodiment, anucleotide sequence provided herein, or a desired fragment, variant, orderivative thereof, is mutated such that it encodes an amino acidsequence comprising one or more deletions, substitutions, or additionsof amino acid residues. In another embodiment, one or more mutations areintroduced into a nucleic acid that selectively change the biologicalactivity (e.g., binding of CCR7, inhibiting CCL19 or CCL21 binding,etc.) of a polypeptide that it encodes. For example, the mutation canquantitatively or qualitatively change the biological activity. Examplesof quantitative changes include increasing, reducing or eliminating theactivity. Examples of qualitative changes include changing the antigenspecificity of an antigen binding protein.

In another aspect, the present invention provides nucleic acid moleculesthat are suitable for use as primers or hybridization probes for thedetection of nucleic acid sequences of the invention. A nucleic acidmolecule of the invention can comprise only a portion of a nucleic acidsequence encoding a full-length polypeptide of the invention, forexample, a fragment that can be used as a probe or primer or a fragmentencoding an active portion (e.g., a CCR7 binding portion) of apolypeptide of the invention.

Probes based on the sequence of a nucleic acid of the invention can beused to detect the nucleic acid or similar nucleic acids, for example,transcripts encoding a polypeptide of the invention. The probe cancomprise a label group, e.g., a radioisotope, a fluorescent compound, anenzyme, or an enzyme co-factor. Such probes can be used to identify acell that expresses the polypeptide.

In another aspect, the present invention provides vectors comprising anucleic acid encoding a polypeptide of the invention or a portionthereof. Examples of vectors include, but are not limited to, plasmids,viral vectors, non-episomal mammalian vectors and expression vectors,for example, recombinant expression vectors.

The recombinant expression vectors of the invention can comprise anucleic acid of the invention in a form suitable for expression of thenucleic acid in a host cell. The recombinant expression vectors includeone or more regulatory sequences, selected on the basis of the hostcells to be used for expression, which is operably linked to the nucleicacid sequence to be expressed. Regulatory sequences include those thatdirect constitutive expression of a nucleotide sequence in many types ofhost cells (e.g., SV40 early gene enhancer, Rous sarcoma virus promoterand cytomegalovirus promoter), those that direct expression of thenucleotide sequence only in certain host cells (e.g., tissue-specificregulatory sequences, see Voss et al., 1986, Trends Biochem. Sci.11:287, Maniatis et al., 1987, Science 236:1237, incorporated byreference herein in their entireties), and those that direct inducibleexpression of a nucleotide sequence in response to particular treatmentor condition (e.g., the metallothionin promoter in mammalian cells andthe tet-responsive and/or streptomycin responsive promoter in bothprokaryotic and eukaryotic systems (see id.). It will be appreciated bythose skilled in the art that the design of the expression vector candepend on such factors as the choice of the host cell to be transformed,the level of expression of protein desired, etc. The expression vectorsof the invention can be introduced into host cells to thereby produceproteins or peptides, including fusion proteins or peptides, encoded bynucleic acids as described herein.

In another aspect, the present invention provides host cells into whicha recombinant expression vector of the invention has been introduced. Ahost cell can be any prokaryotic cell (for example, E. coli) oreukaryotic cell (for example, yeast, insect, or mammalian cells (e.g.,CHO cells)). Vector DNA can be introduced into prokaryotic or eukaryoticcells via conventional transformation or transfection techniques. Forstable transfection of mammalian cells, it is known that, depending uponthe expression vector and transfection technique used, only a smallfraction of cells may integrate the foreign DNA into their genome. Inorder to identify and select these integrants, a gene that encodes aselectable marker (e.g., for resistance to antibiotics) is generallyintroduced into the host cells along with the gene of interest.Preferred selectable markers include those which confer resistance todrugs, such as G418, hygromycin and methotrexate. Cells stablytransfected with the introduced nucleic acid can be identified by drugselection (e.g., cells that have incorporated the selectable marker genewill survive, while the other cells die), among other methods.

Methods of Making Anti-CCR7 Antigen Binding Proteins

A host cell comprising sequences that encode an anti-CCR7 antigenbinding protein of the invention can be used to make the anti-CCR7antigen binding protein. Typically, expression vectors used in a hostcell will contain sequences for plasmid maintenance and for cloning andexpression of exogenous nucleotide sequences. Such sequences,collectively referred to as “flanking sequences” in certain embodimentswill typically include one or more of the following nucleotidesequences: a promoter, one or more enhancer sequences, an origin ofreplication, a transcriptional termination sequence, a complete intronsequence containing a donor and acceptor splice site, a sequenceencoding a leader sequence for polypeptide secretion, a ribosome bindingsite, a polyadenylation sequence, a polylinker region for inserting thenucleic acid encoding the polypeptide to be expressed, and a selectablemarker element. Each of these sequences is discussed below.

Optionally, the vector may contain a “tag”-encoding sequence, i.e., anoligonucleotide molecule located at the 5′ or 3′ end of the anti-CCR7antigen binding protein coding sequence(s); the oligonucleotide sequenceencodes polyHis (such as hexaHis), or another “tag” such as FLAG, HA(hemaglutinin influenza virus), or myc, for which commercially availableantibodies exist. This tag is typically fused to the polypeptide uponexpression of the polypeptide, and can serve as a means for affinitypurification or detection of the anti-CCR7 antigen binding protein fromthe host cell. Affinity purification can be accomplished, for example,by column chromatography using antibodies against the tag as an affinitymatrix. Optionally, the tag can subsequently be removed from thepurified anti-CCR7 antigen binding protein polypeptide by various meanssuch as using certain peptidases for cleavage.

Flanking sequences may be homologous (i.e., from the same species and/orstrain as the host cell), heterologous (ie., from a species other thanthe host cell species or strain), hybrid (i.e., a combination offlanking sequences from more than one source), synthetic or native. Assuch, the source of a flanking sequence may be any prokaryotic oreukaryotic organism, any vertebrate or invertebrate organism, or anyplant, provided that the flanking sequence is functional in, and can beactivated by, the host cell machinery.

Flanking sequences useful in the vectors of this invention may beobtained by any of several methods well known in the art. Typically,flanking sequences useful herein will have been previously identified bymapping and/or by restriction endonuclease digestion and can thus beisolated from the proper tissue source using the appropriate restrictionendonucleases. In some cases, the full nucleotide sequence of a flankingsequence may be known. Here, the flanking sequence may be synthesizedusing the methods described herein for nucleic acid synthesis orcloning.

Whether all or only a portion of the flanking sequence is known, it maybe obtained using polymerase chain reaction (PCR) and/or by screening agenomic library with a suitable probe such as an oligonucleotide and/orflanking sequence fragment from the same or another species. Where theflanking sequence is not known, a fragment of DNA containing a flankingsequence may be isolated from a larger piece of DNA that may contain,for example, a coding sequence or even another gene or genes. Isolationmay be accomplished by restriction endonuclease digestion to produce theproper DNA fragment followed by isolation using agarose gelpurification, Qiagene® column chromatography (Chatsworth, Calif.), orother methods known to the skilled artisan. The selection of suitableenzymes to accomplish this purpose will be readily apparent to one ofordinary skill in the art.

An origin of replication is typically a part of those prokaryoticexpression vectors purchased commercially, and the origin aids in theamplification of the vector in a host cell. If the vector of choice doesnot contain an origin of replication site, one may be chemicallysynthesized based on a known sequence, and ligated into the vector. Forexample, the origin of replication from the plasmid pBR322 (New EnglandBiolabs, Beverly, Mass.) is suitable for most gram-negative bacteria,and various viral origins (e.g., SV40, polyoma, adenovirus, vesicularstomatitus virus (VSV), or papillomaviruses such as HPV or BPV) areuseful for cloning vectors in mammalian cells. Generally, the origin ofreplication component is not needed for mammalian expression vectors(for example, the SV40 origin is often used only because it alsocontains the virus early promoter).

A transcription termination sequence is typically located 3′ to the endof a polypeptide coding region and serves to terminate transcription.Usually, a transcription termination sequence in prokaryotic cells is aG-C rich fragment followed by a poly-T sequence. While the sequence iseasily cloned from a library or even purchased commercially as part of avector, it can also be readily synthesized using methods for nucleicacid synthesis such as those described herein.

A selectable marker gene encodes a protein necessary for the survivaland growth of a host cell grown in a selective culture medium. Typicalselection marker genes encode proteins that (a) confer resistance toantibiotics or other toxins, e.g., ampicillin, tetracycline, orkanamycin for prokaryotic host cells; (b) complement auxotrophicdeficiencies of the cell; or (c) supply critical nutrients not availablefrom complex or defined media. Preferred selectable markers are thekanamycin resistance gene, the ampicillin resistance gene, and thetetracycline resistance gene. Advantageously, a neomycin resistance genemay also be used for selection in both prokaryotic and eukaryotic hostcells.

Other selectable genes may be used to amplify the gene that will beexpressed. Amplification is the process wherein genes that are requiredfor production of a protein critical for growth or cell survival arereiterated in tandem within the chromosomes of successive generations ofrecombinant cells. Examples of suitable selectable markers for mammaliancells include dihydrofolate reductase (DHFR) and promoterless thymidinekinase genes. Mammalian cell transformants are placed under selectionpressure wherein only the transformants are uniquely adapted to surviveby virtue of the selectable gene present in the vector. Selectionpressure is imposed by culturing the transformed cells under conditionsin which the concentration of selection agent in the medium issuccessively increased, thereby leading to the amplification of both theselectable gene and the DNA that encodes another gene, such as anantibody that binds to CCR7 polypeptide. As a result, increasedquantities of a polypeptide such as an anti-CCR7 antibody aresynthesized from the amplified DNA.

A ribosome-binding site is usually necessary for translation initiationof mRNA and is characterized by a Shine-Dalgamo sequence (prokaryotes)or a Kozak sequence (eukaryotes). The element is typically located 3′ tothe promoter and 5′ to the coding sequence of the polypeptide to beexpressed.

In some cases, such as where glycosylation is desired in a eukaryotichost cell expression system, one may manipulate the various pre- orprosequences to improve glycosylation or yield. For example, one mayalter the peptidase cleavage site of a particular signal peptide, or addpro-sequences, which also may affect glycosylation. The final proteinproduct may have, in the −1 position (relative to the first amino acidof the mature protein) one or more additional amino acids incident toexpression, which may not have been totally removed. For example, thefinal protein product may have one or two amino acid residues found inthe peptidase cleavage site, attached to the amino-terminus.Alternatively, use of some enzyme cleavage sites may result in aslightly truncated form of the desired polypeptide, if the enzyme cutsat such area within the mature polypeptide.

Expression and cloning vectors of the invention will typically contain apromoter that is recognized by the host organism and operably linked tothe molecule encoding the anti-CCR7 antigen binding protein. Promotersare untranscribed sequences located upstream (i.e., 5′) to the startcodon of a structural gene (generally within about 100 to 1000 bp) thatcontrol transcription of the structural gene. Promoters areconventionally grouped into one of two classes: inducible promoters andconstitutive promoters. Inducible promoters initiate increased levels oftranscription from DNA under their control in response to some change inculture conditions, such as the presence or absence of a nutrient or achange in temperature. Constitutive promoters, on the other hand,uniformly transcribe gene to which they are operably linked, that is,with little or no control over gene expression. A large number ofpromoters, recognized by a variety of potential host cells, are wellknown. A suitable promoter is operably linked to the DNA encoding heavychain or light chain comprising an anti-CCR7 antigen binding protein ofthe invention by removing the promoter from the source DNA byrestriction enzyme digestion and inserting the desired promoter sequenceinto the vector.

Suitable promoters for use with yeast hosts are also well known in theart. Yeast enhancers are advantageously used with yeast promoters.Suitable promoters for use with mammalian host cells are well known andinclude, but are not limited to, those obtained from the genomes ofviruses such as polyoma virus, fowlpox virus, adenovirus (such asAdenovirus 2), bovine papilloma virus, avian sarcoma virus,cytomegalovirus, retroviruses, hepatitis-B virus and most preferablySimian Virus 40 (SV40). Other suitable mammalian promoters includeheterologous mammalian promoters, for example, heat-shock promoters andthe actin promoter.

Additional promoters which may be of interest include, but are notlimited to: SV40 early promoter (Benoist and Chambon, 1981, Nature290:304-10); CMV promoter (Thomsen et al., 1984, Proc. Natl. Acad. USA81:659-663); the promoter contained in the 3′ long terminal repeat ofRous sarcoma virus (Yamamoto, et al., 1980, Cell 22:787-97); herpesthymidine kinase promoter (Wagner et al., 1981, Proc. Natl. Acad. Sci.U.S.A. 78:144445); promoter and regulatory sequences from themetallothionine gene (Brinster et al., 1982, Nature 296:39-42); andprokaryotic promoters such as the beta-lactamase promoter(Villa-Kamaroff et al., 1978, Proc. Natl. Acad. Sci. U.S.A.,75:3727-31); or the tac promoter (DeBoer et al., 1983, Proc. Natl. Acad.Sci. U.S.A., 80:21-25). Also of interest are the following animaltranscriptional control regions, which exhibit tissue specificity andhave been utilized in transgenic animals: the elastase I gene controlregion that is active in pancreatic acinar cells (Swift et al., 1984,Cell 38:63946; Ornitz et al., 1986, Cold Spring Harbor Symp. Quant.Biol. 50:399409 (1986); MacDonald, 1987, Hepatology 7:425-515); theinsulin gene control region that is active in pancreatic beta cells(Hanahan, 1985, Nature 315:115-22); the immunoglobulin gene controlregion that is active in lymphoid cells (Grosschedl et al., 1984, Cell38:647-58; Adames et al., 1985, Nature 318:533-38; Alexander et al.,1987, Mol. Cell. Biol, 7:1436-44); the mouse mammary tumor virus controlregion that is active in testicular, breast, lymphoid and mast cells(Leder et al., 1986, Cell 45:485-95); the albumin gene control regionthat is active in liver (Pinkert et al., 1987, Genes and Devel.1:268-76); the alpha-feto-protein gene control region that is active inliver (Krumlauf et al., 1985, Mol. Cell. Biol., 5:1639-48; Hammer etal., 1987, Science 235:53-58); the alpha 1-antitrypsin gene controlregion that is active in liver (Kelsey et al., 1987, Genes and Devel.1:161-71); the beta-globin gene control region that is active in myeloidcells (Mogram et al., 1985, Nature 315:33840; Kollias et al., 1986, Cell46:89-94); the myelin basic protein gene control region that is activein oligodendrocyte cells in the brain (Readhead et al., 1987, Cell48:703-12); the myosin light chain-2 gene control region that is activein skeletal muscle (Sani, 1985, Nature 314:283-86); and the gonadotropicreleasing hormone gene control region that is active in the hypothalamus(Mason et al., 1986, Science 234:1372-78).

An enhancer sequence may be inserted into the vector to increasetranscription of DNA encoding light chain or heavy chain comprising ananti-CCR7 antigen binding protein of the invention by higher eukaryotes.Enhancers are cis-acting elements of DNA, usually about 10-300 bp inlength, that act on the promoter to increase transcription Enhancers arerelatively orientation and position independent, having been found atpositions both 5′ and 3′ to the transcription unit. Several enhancersequences available from mammalian genes are known (e.g., globin,elastase, albumin, alpha-feto-protein and insulin). Typically, however,an enhancer from a virus is used. The SV40 enhancer, the cytomegalovirusearly promoter enhancer, the polyorna enhancer, and adenovirus enhancersknown in the art are exemplary enhancing elements for the activation ofeukaryotic promoters. While an enhancer may be positioned in the vectoreither 5′ or 3′ to a coding sequence, it is typically located at a site5′ from the promoter.

A sequence encoding an appropriate native or heterologous signalsequence (leader sequence or signal peptide) can be incorporated into anexpression vector, to promote extracellular secretion of the antibody.The choice of signal peptide or leader depends on the type of host cellsin which the antibody is to be produced, and a heterologous signalsequence can replace the native signal sequence. Examples of signalpeptides that are functional in mammalian host cells include thefollowing: the signal sequence for interleukin-7 (IL-7) described inU.S. Pat. No. 4,965,195; the signal sequence for interleukin-2 receptordescribed in Cosman et al. (1984, Nature 312: 768); the interleukin-4receptor signal peptide described in EP Patent No. 0 367 566; the type Iinterleukin-1 receptor signal peptide described in U.S. Pat. No.4,968,607; the type II interleukin-1 receptor signal peptide describedin EP Patent No. 0 460 846; the signal sequence of human IgK; and thesignal sequence of human growth hormone.

Expression vectors of the invention may be constructed from a startingvector such as a commercially available vector. Such vectors may or maynot contain all of the desired flanking sequences. Where one or more ofthe flanking sequences described herein are not already present in thevector, they may be individually obtained and ligated into the vector.Methods used for obtaining each of the flanking sequences are well knownto one skilled in the art.

After the vector has been constructed and a nucleic acid moleculeencoding light chain, a heavy chain, or a light chain and a heavy chaincomprising an anti-CCR7 antibody has been inserted into the proper siteof the vector, the completed vector may be inserted into a suitable hostcell for amplification and/or polypeptide expression. The transformationof an expression vector for an anti-CCR7 antigen binding protein into aselected host cell may be accomplished by well known methods includingtransfection, infection, calcium phosphate co-precipitation,electroporation, microinjection, lipofection, DEAE-dextran mediatedtransfection, or other known techniques. The method selected will inpart be a function of the type of host cell to be used.

A host cell, when cultured under appropriate conditions, synthesizes ananti-CCR7 antigen binding protein that can subsequently be collectedfrom the culture medium (if the host cell secretes it into the medium)or directly from the host cell producing it (if it is not secreted). Theselection of an appropriate host cell will depend upon various factors,such as desired expression levels, polypeptide modifications that aredesirable or necessary for activity (such as glycosylation orphosphorylation) and ease of folding into a biologically activemolecule.

Mammalian cell lines available as hosts for expression are well known inthe art and include, but are not limited to, immortalized cell linesavailable from the American Type Culture Collection (ATCC), includingbut not limited to Chinese hamster ovary (CHO) cells, HeLa cells, babyhamster kidney (BHK) cells, monkey kidney cells (COS), humanhepatocellular carcinoma cells (e.g., Hep G2), and a number of othercell lines. In certain embodiments, cell lines may be selected throughdetermining which cell lines have high expression levels andconstitutively produce antibodies with CCR7 binding properties. Inanother embodiment, a cell line from the B cell lineage that does notmake its own antibody but has a capacity to make and secrete aheterologous antibody can be selected.

Formulations

In some embodiments, the invention provides pharmaceutical compositionscomprising a therapeutically effective amount of one or a plurality ofthe antibodies of the invention together with a pharmaceuticallyacceptable diluent, carrier, solubilizer, emulsifier, preservative,and/or adjuvant. Preferably, acceptable formulation materials arenontoxic to recipients at the dosages and concentrations employed. Inpreferred embodiments, pharmaceutical compositions comprising atherapeutically effective amount of anti-CCR7 antibodies are provided.

In certain embodiments, acceptable formulation materials preferably arenontoxic to recipients at the dosages and concentrations employed.

In certain embodiments, the pharmaceutical composition may containformulation materials for modifying, maintaining or preserving, forexample, the pH, osmolarity, viscosity, clarity, color, isotonicity,odor, sterility, stability, rate of dissolution or release, adsorptionor penetration of the composition. In such embodiments, suitableformulation materials include, but are not limited to, amino acids (suchas glycine, glutamine, asparagine, arginine or lysine); antimicrobials;antioxidants (such as ascorbic acid, sodium sulfite or sodiumhydrogen-sulfite); buffers (such as borate, bicarbonate, Tris-HCl,citrates, phosphates or other organic acids); bulking agents (such asmannitol or glycine); chelating agents (such as ethylenediaminetetraacetic acid (EDTA)); complexing agents (such as caffeine,polyvinylpyrrolidone, beta-cyclodextrin orhydroxypropyl-beta-cyclodextrin); fillers; monosaccharides;disaccharides; and other carbohydrates (such as glucose, mannose ordextrins); proteins (such as serum albumin, gelatin or immunoglobulins);coloring, flavoring and diluting agents; emulsifying agents; hydrophilicpolymers (such as polyvinylpyrrolidone); low molecular weightpolypeptides; salt-forming counterions (such as sodium); preservatives(such as benzalkonium chloride, benzoic acid, salicylic acid,thimerosal, phenethyl alcohol, methylparaben, propylparaben,chlorhexidine, sorbic acid or hydrogen peroxide); solvents (such asglycerin, propylene glycol or polyethylene glycol); sugar alcohols (suchas mannitol or sorbitol); suspending agents; surfactants or wettingagents (such as pluronics, PEG, sorbitan esters, polysorbates such aspolysorbate 20, polysorbate 80, triton, tromethamine, lecithin,cholesterol, tyloxapal); stability enhancing agents (such as sucrose orsorbitol); tonicity enhancing agents (such as alkali metal halides,preferably sodium or potassium chloride, mannitol sorbitol); deliveryvehicles; diluents; excipients and/or pharmaceutical adjuvants. SeeREMINGTON'S PHARMACEUTICAL SCIENCES, 18th Edition, (A. R. Gennaro, ed.),1990, Mack Publishing Company.

In certain embodiments, the optimal pharmaceutical composition will bedetermined by one skilled in the art depending upon, for example, theintended route of administration, delivery format and desired dosage.See, for example, REMINGTON'S PHARMACEUTICAL SCIENCES, supra. In certainembodiments, such compositions may influence the physical state,stability, rate of in vivo release and rate of in vivo clearance of theantibodies of the invention.

In certain embodiments, the primary vehicle or carrier in apharmaceutical composition may be either aqueous or non-aqueous innature. For example, a suitable vehicle or carrier may be water forinjection, physiological saline solution or artificial cerebrospinalfluid, possibly supplemented with other materials common in compositionsfor parenteral administration. Neutral buffered saline or saline mixedwith serum albumin are further exemplary vehicles. In preferredembodiments, pharmaceutical compositions comprise Tris buffer of aboutpH 7.0-8.5, or acetate buffer of about pH 4.0-5.5, and may furtherinclude sorbitol or a suitable substitute therefor. In certainembodiments of the invention, anti-CCR7 antigen binding proteincompositions may be prepared for storage by mixing the selectedcomposition having the desired degree of purity with optionalformulation agents (REMINGTON'S PHARMACEUTICAL SCIENCES, supra) in theform of a lyophilized cake or an aqueous solution. Further, in certainembodiments, the, anti-CCR7 antigen binding protein product may beformulated as a lyophilizate using appropriate excipients such assucrose.

The pharmaceutical compositions of the invention can be selected forparenteral delivery. Alternatively, the compositions may be selected forinhalation or for delivery through the digestive tract, such as orally.Preparation of such pharmaceutically acceptable compositions is withinthe skill of the art.

The formulation components are present preferably in concentrations thatare acceptable to the site of administration. In certain embodiments,buffers are used to maintain the composition at physiological pH or at aslightly lower pH, typically within a pH range of from about 5 to about8.

When parenteral administration is contemplated, the therapeuticcompositions for use in this invention may be provided in the form of apyrogen-free, parenterally acceptable aqueous solution comprising thedesired anti-CCR7 antigen binding protein in a pharmaceuticallyacceptable vehicle. A particularly suitable vehicle for parenteralinjection is sterile distilled water in which the, anti-CCR7 antigenbinding protein is formulated as a sterile, isotonic solution, properlypreserved. In certain embodiments, the preparation can involve theformulation of the desired molecule with an agent, such as injectablemicrospheres, bio-erodible particles, polymeric compounds (such aspolylactic acid or polyglycolic acid), beads or liposomes, that mayprovide controlled or sustained release of the product which can bedelivered via depot injection. In certain embodiments, hyaluronic acidmay also be used, having the effect of promoting sustained duration inthe circulation. In certain embodiments, implantable drug deliverydevices may be used to introduce the desired antibody molecule.

Pharmaceutical compositions of the invention can be formulated forinhalation. In these embodiments, anti-CCR7 antigen binding proteins areadvantageously formulated as a dry, inhalable powder. In preferredembodiments, anti-CCR7 antigen binding protein inhalation solutions mayalso be formulated with a propellant for aerosol delivery. In certainembodiments, solutions may be nebulized. Pulmonary administration andformulation methods therefore are further described in InternationalPatent Application No. PCT/US94/001875, which is incorporated byreference and describes pulmonary delivery of chemically modifiedproteins.

It is also contemplated that formulations can be administered orally.Anti-CCR7 antigen binding proteins that are administered in this fashioncan be formulated with or without carriers customarily used in thecompounding of solid dosage forms such as tablets and capsules. Incertain embodiments, a capsule may be designed to release the activeportion of the formulation at the point in the gastrointestinal tractwhen bioavailability is maximized and pre-systemic degradation isminimized. Additional agents can be included to facilitate absorption ofthe anti-CCR7 antigen binding protein. Diluents, flavorings, low meltingpoint waxes, vegetable oils, lubricants, suspending agents, tabletdisintegrating agents, and binders may also be employed.

A pharmaceutical composition of the invention is preferably provided tocomprise an effective quantity of one or a plurality of anti-CCR7antigen binding proteins in a mixture with non-toxic excipients that aresuitable for the manufacture of tablets. By dissolving the tablets insterile water, or another appropriate vehicle, solutions may be preparedin unit-dose form. Suitable excipients include, but are not limited to,inert diluents, such as calcium carbonate, sodium carbonate orbicarbonate, lactose, or calcium phosphate; or binding agents, such asstarch, gelatin, or acacia; or lubricating agents such as magnesiumstearate, stearic acid, or talc.

Additional pharmaceutical compositions will be evident to those skilledin the art, including formulations involving anti-CCR7 antigen bindingproteins in sustained- or controlled-delivery formulations. Techniquesfor formulating a variety of other sustained- or controlled-deliverymeans, such as liposome carriers, bio-erodible microparticles or porousbeads and depot injections, are also known to those skilled in the art.See, for example, International Patent Application No. PCT/US93/00829,which is incorporated by reference and describes controlled release ofporous polymeric microparticles for delivery of pharmaceuticalcompositions. Sustained-release preparations may include semipermeablepolymer matrices in the form of shaped articles, e.g. films, ormicrocapsules. Sustained release matrices may include polyesters,hydrogels, polylactides (as disclosed in U.S. Pat. No. 3,773,919 andEuropean Patent Application Publication No. EP 058481, each of which isincorporated by reference), copolymers of L-glutamic acid and gammaethyl-L-glutamate (Sidman et al., 1983, Biopolymers 22:547-556), poly(2-hydroxyethyl-methacrylate) (Langer et al., 1981, J. Biomed. Mater.Res. 15:167-277 and Langer, 1982, Chem. Tech. 12:98-105), ethylene vinylacetate (Langer et al., supra) or poly-D(−)-3-hydroxybutyric acid(European Patent Application Publication No. EP 133,988). Sustainedrelease compositions may also include liposomes that can be prepared byany of several methods known in the art. See e.g., Eppstein et al.,1985, Proc. Natl. Acad. Sci. USA 82:3688-3692; European PatentApplication Publication Nos. EP 036,676; EP 088,046 and EP 143,949,incorporated by reference.

Pharmaceutical compositions used for in vivo administration aretypically provided as sterile preparations. Sterilization can beaccomplished by filtration through sterile filtration membranes. Whenthe composition is lyophilized, sterilization using this method may beconducted either prior to or following lyophilization andreconstitution. Compositions for parenteral administration can be storedin lyophilized form or in a solution. Parenteral compositions generallyare placed into a container having a sterile access port, for example,an intravenous solution bag or vial having a stopper pierceable by ahypodermic injection needle.

Once the pharmaceutical composition has been formulated, it may bestored in sterile vials as a solution, suspension, gel, emulsion, solid,crystal, or as a dehydrated or lyophilized powder. Such formulations maybe stored either in a ready-to-use form or in a form (e.g., lyophilized)that is reconstituted prior to administration.

The invention also provides kits for producing a single-doseadministration unit. The kits of the invention may each contain both afirst container having a dried protein and a second container having anaqueous formulation. In certain embodiments of this invention, kitscontaining single and multi-chambered pre-filled syringes (e.g., liquidsyringes and lyosyringes) are provided.

Indications

The methods and compositions of the present invention (including, forexample, anti-CCR7 antigen binding proteins, antibodies, antibodyfragments, antibody derivatives, and other molecules of the presentinvention) can be used to treat a wide range of diseases, conditions,and indications. Examples of types of diseases that can be treatedinclude inflammatory conditions, cancerous conditions, and conditionsand complications arising from tissue or organ transplantation.

CCR7 activity is implicated in Inflammatory bowel diseases (IBDs) suchas Crohn's disease and ulcerative colitis. Crohn's disease is chronicand debilitating inflammatory bowel disease that is thought to reflect aoverly-active TH1-mediated immune response to the flora of the gut. Thelesions of Crohn's disease can appear anywhere in the bowel andoccasionally elsewhere in the gastrointestinal tract. Ulcerative colitislesions, on the other hand, usually appear in the colon. The nature ofthe lesions is also different, but the diseases are sufficiently similarthat is sometimes difficult to distinguish them clinically. See, e.g.,U.S. Pat. No. 6,558,661. The compositions and methods described hereincan be used to treat IBD patients, and/or reduce, prevent, or eliminateone or more symptoms or complications of IBD.

Inhibition of CCR7 activity has been implicated in tissue or organtransplant rejection (Lo et al., 2011, Transplantation 91:70-77; Liu etal., 2011, Eur J Immunol 41:611-23; Yuling et al., Am J Transplant8:1401-12). The compositions and methods described herein can be used totreat tissue or organ transplant recipients, for example, kidney, heart,skin, or lung transplant recipients, and/or reduce, prevent, oreliminate one or more complications of transplant surgery.

CCR7 activity has been implicated in asthma, allergic airwayinflammation, airway smooth muscle hyperplasia, and fibrotic lungdiseases (Gomperts et al., 2007, J Leukoc Biol. 82:449-56; Kawakami etal., 2012, Cell Immunol 2575:24-32; Saunders et al., 2009, Clin ExpAllergy 39:1684-92). The compositions and methods described herein canbe used to treat patients with asthma, allergic airway inflammation,airway smooth muscle hyperplasia, or fibrotic lung diseases, and/or toreduce, prevent, or eliminate one or more symptoms or complications ofthese diseases.

CCR7 activity has been implicated in rheumatoid arthritis (Moschovakiset al., 2012, Eur J Immunol. 42:1949-55). The compositions and methodsdescribed herein can be used to treat patients with rheumatoidarthritis, and/or to reduce, prevent, or eliminate one or more symptomsor complications of rheumatoid arthritis.

CCR7 activity has been implicated in multiple sclerosis (Aung et al.,2010, J Neuroimmunol. 226:158-64). The compositions and methodsdescribed herein can be used to treat patients with multiple sclerosis,and/or to reduce, prevent, or eliminate one or more symptoms orcomplications of multiple sclerosis.

CCR7 activity has been implicated in atherosclerosis (Luchtefeld et al.,2010, Circulation 122:1621-28). The compositions and methods describedherein can be used to treat patients with atherosclerosis, and/or toreduce, prevent, or eliminate one or more symptoms or complications ofatherosclerosis.

CCR7 activity has been implicated in HIV infection (Evans et al., 2012,Cytokine Growth Factor Rev. 23:151-57). The compositions and methodsdescribed herein can be used to treat patients infected with HIV,including patients having AIDS, or patients at risk of contracting HIVor of developing AIDS, and/or to reduce, prevent, or eliminate one ormore symptoms or complications of HIV or AIDS.

CCR7 activity has been implicated in certain aspects of the developmentand spread of cancer (Ben-Baruch, 2009, 3:328-33).mThe compositions andmethods described herein can be used to treat patients with cancer,and/or to reduce, prevent, or eliminate one or more symptoms orcomplications of cancer. In one particular embodiment, the compositionsand/or methods of the present invention are used to prevent, reduce,slow, or reverse the metastatic spread of cancer in a patient.

Therapeutic Methods and Administration of Antigen Binding Proteins

In one aspect, the present invention provides methods of treating asubject. The method can, for example, have a generally salubrious effecton the subject, e.g., it can increase the subject's expected longevity.Alternatively, the method can, for example, treat, prevent, cure,relieve, or ameliorate (“treat”) a disease, disorder, condition, orillness (“a condition”). Among the conditions to be treated inaccordance with the present invention are conditions characterized byinappropriate expression or activity of CCR7 and/or CCL19 and/or CCL21.In some such conditions, the expression or activity level is too high,and the treatment comprises administering a CCR7 antagonist as describedherein. In other such conditions, the expression or activity level istoo low, and the treatment comprises administering a CCR7 agonist asdescribed herein. In other such conditions, the levels of CCR7 and/orCCL19 and/or CCL21 activity are not necessarily elevated, but thesubject is more sensitive to them.

In another aspect, the present invention provides methods of identifyingsubjects who are more likely to benefit from treatment using thecompositions and/or methods of treatment of the present invention. Suchmethods can enable a caregiver to better tailor a therapeutic regimen toa particular subject's needs and reduce the likelihood of an ineffectiveor counterproductive course of treatment. In one embodiment, the presentinvention provides a method of determining whether a subject is acandidate for treatment using a composition or method as describedherein comprising determining whether a target cell type in the subjectexpresses CCR7, wherein if the target cell type expresses CCR7, then thesubject is a candidate for treatment. In another embodiment, the methodcomprises determining the approximate average number of CCR7 moleculesper target cell, wherein 10², 10³, 10⁴, 10⁵, or 10⁶ CCR7 per cellindicates that the subject is a candidate for treatment. The approximateaverage number of CCR7 molecules per target cell can be determined usingany technique known in the art, for example, by staining a samplecomprising cells of the target cell type with a CCR7 binding molecule,and detecting the amount of CCR7 binding molecule bound to the sample,where the amount of CCR7 binding molecule detected is proportional tothe average number of CCR7 molecules in the sample. In anotherembodiment, the method comprises comparing the approximate averagenumber of CCR7 molecules per target cell to a reference standard,wherein if the approximate average number of CCR7 molecules per targetcell is greater than the reference standard, then the subject is morelikely to benefit from treatment using the compositions and/or methodsof treatment of the present invention. In another aspect, the methodcomprises determining whether CCL19 or CCL21 is present at elevatedlevels in the tissue of interest, e.g., in the vicinity of immune cellsexpressing CCR7. In another aspect, the method comprises determiningwhether a molecule downstream of CCR7 is altered or activated in aCCR7-dependent fashion.

Certain methods provided herein comprise administering a CCR7 bindingantigen binding protein to a subject, thereby reducing an CCL19 orCCL21-induced biological response that plays a role in a particularcondition. In particular embodiments, methods of the invention involvecontacting endogenous CCR7 with a CCR7 binding antigen binding protein,e.g., via administration to a subject or in an ex vivo procedure.

The term “treatment” encompasses alleviation or prevention of at leastone symptom or other aspect of a disorder, or reduction of diseaseseverity, and the like. An antigen binding protein need not effect acomplete cure, or eradicate every symptom or manifestation of a disease,to constitute a viable therapeutic agent. As is recognized in thepertinent field, drugs employed as therapeutic agents may reduce theseverity of a given disease state, but need not abolish everymanifestation of the disease to be regarded as useful therapeuticagents. Similarly, a prophylactically administered treatment need not becompletely effective in preventing the onset of a condition in order toconstitute a viable prophylactic agent. Simply reducing the impact of adisease (for example, by reducing the number or severity of itssymptoms, or by increasing the effectiveness of another treatment, or byproducing another beneficial effect), or reducing the likelihood thatthe disease will occur or worsen in a subject, is sufficient. Oneembodiment of the invention is directed to a method comprisingadministering to a patient a CCR7 antagonist in an amount and for a timesufficient to induce a sustained improvement over baseline of anindicator that reflects the severity of the particular disorder.

As is understood in the pertinent field, pharmaceutical compositionscomprising the molecules of the invention are administered to a subjectin a manner appropriate to the indication. Pharmaceutical compositionsmay be administered by any suitable technique, including but not limitedto parenterally, topically, or by inhalation. If injected, thepharmaceutical composition can be administered, for example, viaintra-articular, intravenous, intramuscular, intralesional,intraperitoneal or subcutaneous routes, by bolus injection, orcontinuous infusion. Localized administration, e.g. at a site of diseaseor injury is contemplated, as are transdermal delivery and sustainedrelease from implants. Delivery by inhalation includes, for example,nasal or oral inhalation, use of a nebulizer, inhalation of theantagonist in aerosol form, and the like. Other alternatives includeeyedrops; oral preparations including pills, syrups, lozenges or chewinggum; and topical preparations such as lotions, gels, sprays, andointments.

Use of antigen binding proteins in ex vivo procedures also iscontemplated. For example, a patient's blood or other bodily fluid maybe contacted with an antigen binding protein that binds CCR7 ex vivo.The antigen binding protein may be bound to a suitable insoluble matrixor solid support material.

Advantageously, antigen binding proteins are administered in the form ofa composition comprising one or more additional components such as aphysiologically acceptable carrier, excipient or diluent. Optionally,the composition additionally comprises one or more physiologicallyactive agents, for example, a second CCR7-inhibiting substance, ananti-inflammatory substance, an anti-angiogenic substance, achemotherapeutic substance, or an analgesic substance. In variousparticular embodiments, the composition comprises one, two, three, four,five, or six physiologically active agents in addition to a CCR7 bindingantigen binding protein.

In one embodiment, the pharmaceutical composition comprise an antigenbinding protein of the invention together with one or more substancesselected from the group consisting of a buffer, an antioxidant such asascorbic acid, a low molecular weight polypeptide (such as those havingfewer than 10 amino acids), a protein, an amino acid, a carbohydratesuch as glucose, sucrose or dextrins, a chelating agent such as EDTA,glutathione, a stabilizer, and an excipient. Neutral buffered saline orsaline mixed with conspecific serum albumin are examples of appropriatediluents. In accordance with appropriate industry standards,preservatives such as benzyl alcohol may also be added. The compositionmay be formulated as a lyophilizate using appropriate excipientsolutions (e.g., sucrose) as diluents. Suitable components are nontoxicto recipients at the dosages and concentrations employed. Furtherexamples of components that may be employed in pharmaceuticalformulations are presented in Remington's Pharmaceutical Sciences, 16thEd. (1980) and 20th Ed. (2000), Mack Publishing Company, Easton, Pa.

Kits for use by medical practitioners include a CCR7-inhibitingsubstance of the invention and a label or other instructions for use intreating any of the conditions discussed herein. In one embodiment, thekit includes a sterile preparation of one or more CCR7 binding antigenbinding proteins, which may be in the form of a composition as disclosedabove, and may be in one or more vials.

Dosages and the frequency of administration may vary according to suchfactors as the route of administration, the particular antigen bindingproteins employed, the nature and severity of the disease to be treated,whether the condition is acute or chronic, and the size and generalcondition of the subject. Appropriate dosages can be determined byprocedures known in the pertinent art, e.g. in clinical trials that mayinvolve dose escalation studies.

A CCR7 inhibiting substance of the invention may be administered, forexample, once or more than once, e.g., at regular intervals over aperiod of time. In particular embodiments, an antigen binding protein isadministered over a period of at least a month or more, e.g., for one,two, or three months or even indefinitely. For treating chronicconditions, long-term treatment is generally most effective. However,for treating acute conditions, administration for shorter periods, e.g.from one to six weeks, may be sufficient. In general, the antigenbinding protein is administered until the patient manifests a medicallyrelevant degree of improvement over baseline for the chosen indicator orindicators.

Particular embodiments of the present invention involve administering toa subject an antigen binding protein at a dosage of from about 1 ng ofantigen binding protein per kg of subject's weight per day(“lng/kg/day”) to about 100 mg/kg/day, from about 500 ng/kg/day to about50 mg/kg/day, from about 5 μg/kg/day to about 20 mg/kg/day, and fromabout 5 mg/kg/day to about 20 mg/kg/day to a subject. In additionalembodiments, an antigen binding protein is administered to adults onetime per week, two times per week, three times per week, four times perweek, five times per week, six times per week, or seven or more timesper week, to treat a CCR7 mediated disease, condition or disorder, e.g.,a medical disorder disclosed herein. If injected, the effective amountof antigen binding protein per adult dose may range from, for example,1-20 mg/m², or from about 5-12 mg/m². Alternatively, a flat dose may beadministered; the amount may range from 1-300 mg/dose. One range for aflat dose is about 20-30 mg per dose. In one embodiment of theinvention, a flat dose of 25 mg/dose is repeatedly administered byinjection. If a route of administration other than injection is used,the dose is appropriately adjusted in accordance with standard medicalpractices. One example of a therapeutic regimen involves injecting adose of about 20-30 mg of antigen binding protein to one to three timesper week over a period of at least three weeks, though treatment forlonger periods may be necessary to induce the desired degree ofimprovement. For pediatric subjects (age 4-17), one exemplary suitableregimen involves the subcutaneous injection of 0.4 mg/kg, up to amaximum dose of 25 mg of antigen binding protein administered two orthree times per week.

Particular embodiments of the methods provided herein involvesubcutaneous injection of from 0.5 mg to 10 mg, preferably from 3 to 5mg, of an antigen binding protein, once or twice per week. Anotherembodiment is directed to pulmonary administration (e.g., by nebulizer)of 3 or more mg of antigen binding protein once a week.

Examples of therapeutic regimens provided herein comprise subcutaneousinjection of an antigen binding protein once a week, at a dose of 1.5 to3 mg, to treat a condition in which CCR7 signaling plays a role.Examples of such conditions are provided herein and are known in theart. Administration of antigen binding protein can be continued until adesired result is achieved, e.g., the subject's symptoms subside.Treatment may resume as needed, or, alternatively, maintenance doses maybe administered.

Other examples of therapeutic regimens provided herein comprisesubcutaneous or intravenous administration of a dose of 1, 3, 5, 6, 7,8, 9, 10, 11, 12, 15, or 20 milligrams of a CCR7 inhibitor of thepresent invention per kilogram body mass of the subject (mg/kg). Thedose can be administered once to the subject, or more than once at acertain interval, for example, once a day, three times a week, twice aweek, once a week, once every two weeks, once every three weeks, threetimes a month, twice a month, once a month, once every two months, onceevery three months, once every six months, or once a year. The durationof the treatment, and any changes to the dose and/or frequency oftreatment, can be altered or varied during the course of treatment inorder to meet the particular needs of the subject.

In another embodiment, an antigen binding protein is administered to thesubject in an amount and for a time sufficient to maintain theconcentration of the antigen binding protein at or above a desiredlevel, to maintain the amount, concentration, or other state of abiomarker at a desired level, or to induce an improvement, preferably asustained improvement, in at least one symptom or other indicator thatreflects the severity of the disorder that is being treated. Variousindicators that reflect the extent of the subject's illness, disease orcondition may be assessed for determining whether the amount and time ofthe treatment is sufficient. Such indicators include, for example,clinically recognized indicators of disease severity, symptoms, ormanifestations of the disorder in question. In one embodiment, animprovement is considered to be sustained if the subject exhibits theimprovement on at least two occasions separated by two to four weeks.The degree of improvement generally is determined by a physician, whomay make this determination based on signs, symptoms, biopsies, or othertest results, and who may also employ questionnaires that areadministered to the subject, such as quality-of-life questionnairesdeveloped for a given disease.

Combination Therapies

Treatments exist for most CCR7 mediated diseases, even though many ofthese treatments are effective only to a limited extent or for only asubset of patients, and/or have substantial toxicities that limitpatient tolerance of treatment. The CCR7 inhibitors described herein canbe combined with other existing therapies for CCR7-mediated diseases.

In one embodiment, a patient suffering from an inflammatory boweldisease (IBD), such as Crohn's disease or ulcerative colitis, can beconcurrently treated with a therapy for IBD plus an anti-CCR7 antibodyas described herein. Existing therapies for IBD include sulfasalazine,5-aminosalicylic acid and its derivatives (such as olsalazine,balsalazide, and mesalamine), anti-IFN-γ antibodies, anti-TNF antibodies(including infliximab, adalimumab, golimumab, and certolizumab pegol),corticosteroids for oral or parenteral administration (includingprednisone, methylprednisone, budesonide, or hydrocortisone),adrenocorticotropic hormone, antibiotics (including metronidazole,ciprofloxacin, or rifaximin), azathioprine, 6-mercaptopurine,methotrexate, cyclosporine, tacrolimus, and thalidomide.

In other embodiments, a patient suffering from rheumatoid arthritis canbe concurrently treated with a drug used for RA therapy plus ananti-CCR7 antibody as described herein. Therapies for rheumatoidarthritis (RA) include non-steroidal anti-inflammatory drugs (NSAIDs)(such aspirin and cyclooxygenase-2 (COX-2) inhibitors), diseasemodifying anti-inflammatory drugs (DMARDs)(such as methotrexate,leflunomide, and sulfasalazine), anti-malarials (such ashydroxychloroquine), cyclophosphamide, D-penicillamine, azathioprine,gold salts, tumor necrosis factor inhibitors (such as etanercept,infliximab, adalimumab, golimumab, and certolizumab pegol), CD20inhibitors such as rituximab, IL-1 antagonists such as anakinra, IL-6inhibitors such as tocilizumab, inhibitors of Janus kinases (JAK)(suchas tofacitinib), abatacept, and glucocorticoids, among others.

EXAMPLES Example 1 Preparation of Human Monoclonal Antibodies

Immunizations were conducted using one or more suitable forms of CCR7antigen, including: (1) CHO/AM1D cells engineered to stably expresshuCCR7, (2) murine L1.2 cells engineered to stably express full lengthhuman CCR7, and (3) 293T cells transiently transfected with human CCR7.

A suitable amount of immunogen (i.e., 3-4×10⁶ cells/mouse of stablytransfected CHO cells, transiently transfected 293T cells as mentionedabove, or other CCR7-expressing cell type was used for initialimmunization in XENOMOUSE™ (Amgen, Thousand Oaks, Calif.) according tothe methods disclosed in U.S. patent application Ser. No. 08/759,620,filed Dec. 3, 1996 and International Patent Application Nos. WO98/24893, and WO 00/76310, the disclosures of which are incorporated byreference. Following the initial immunization, subsequent boostimmunizations of immunogen (2.0×10⁶ CCR7 transfected cells/mouse) wereadministered on a schedule and for the duration necessary to induce asuitable anti-CCR7 titer in the mice. Titers were determined by asuitable method, for example, fluorescence activated cell sorting(FACS).

Animals exhibiting suitable titers were identified, and lymphocytes wereobtained from draining lymph nodes and, if necessary, pooled for eachcohort. Lymphocytes were dissociated from lymphoid tissue by grinding ina suitable medium (for example, Dulbecco's Modified Eagle Medium; DMEM;obtainable from Invitrogen, Carlsbad, Calif.) to release the cells fromthe tissues, and suspended in DMEM. B cells were selected and/orexpanded using standard methods, and fused with suitable fusion partner,for example, nonsecretory myeloma P3X63Ag8.653 cells (American TypeCulture Collection CRL 1580; Kearney et al, (1979) J. Immunol.123:1548-1550), using techniques that were known in the art.

In one suitable fusion method, lymphocytes were mixed with fusionpartner cells at a ratio of 1:4. The cell mixture was gently pelleted bycentrifugation at 400×g for 4 minutes, the supernatant decanted, and thecell mixture gently mixed. Fusion was induced with PEG/DMSO(polyethylene glycol/dimethyl sulfoxide; obtained from Sigma-Aldrich,St. Louis Mo.; 1 ml per million of lymphocytes). PEG/DMSO was slowlyadded with gentle agitation over one minute followed, by one minute ofmixing. IDMEM (DMEM without glutamine; 2 ml per million of B cells), wasthen added over 2 minutes with gentle agitation, followed by additionalIDMEM (8 ml per million B-cells) which was added over 3 minutes.

The fused cells were pelleted (400×g 6 minutes) and resuspended in 20 mlSelection media (for example, DMEM containing Azaserine and Hypoxanthine[HA] and other supplemental materials as necessary) per million B-cells.Cells were incubated for 20-30 minutes at 37° C. and then resuspended in200 ml selection media and cultured for three to four days in T175flasks prior to 96 well plating.

Cells were distributed into 96-well plates using standard techniques tomaximize clonality of the resulting colonies. An alternative method wasalso employed and the fused cells were directly plated clonally into384-well plates to ensure monoclonality from the start. After severaldays of culture, supernatants were collected and subjected to screeningassays as detailed in the examples below, including confirmation ofbinding to human CCR7 receptor. Positive cells were further selected andsubjected to standard cloning and subcloning techniques. Clonal lineswere expanded in vitro, and the secreted human antibodies obtained foranalysis.

In this manner, mice were immunized with cells expressing full lengthCCR7 cells with a range of 11-17 immunizations over a period ofapproximately one to two and one half months. Several hybrdidoma linessecreting CCR7-specific antibodies were obtained, and the antibodieswere further characterized.

Among the antibodies generated in this way were 6B4.1, 6B5.1, and 6E1.2.

Example 2 Selection of Binding Antibodies by FMAT

After 14 days of culture, hybridoma supernatants were screened forCCR7-specific monoclonal antibodies by Fluorometric Microvolume AssayTechnology (FMAT) by screening against either the CHO AM1/D/huCCR7 cellline or recombinant HEK293T cells that were transfected with human CCR7and counter-screening against parental CHO/AM1D or HEK293T cells.Briefly, the cells in Freestyle media (Invitrogen; Carlsbad, Calif.)were seeded into 384-well FMAT plates in a volume of 50 μL/well at adensity of 3500 cells/well for the stable transfectants, and at adensity of 8500 cells/well for the parental cells, and cells wereincubated overnight at 37° C. 20 μL/well of supernatant was then added,and the plates were incubated for approximately one hour at 4° C., afterwhich 10 μL/well of anti-human IgG-Cy5 secondary antibody was added at aconcentration of 2.8 μg/ml (400 ng/ml final concentration). Plates werethen incubated for one hour at 4° C., and fluorescence was read using anFMAT Cellular Detection System (Applied Biosystems, Grand Island, N.Y.).

In total, 81 hybridoma supernatants were identified as binding to theCCR7 receptor expressing cells but not to parental cells by the FMATmethod. These supernatants were then tested in the CCR7 functionalassays as described below.

Example 3 Preparation of Humanized Antibodies

Normal mice (i.e., mice with a murine immune system) were immunized withhuman CCR7-expressing cells. Murine anti-human CCR7 antibodies wereisolated from these mice, among them the blocking antibody MAb 22. MAb22was chimerized by replacing heavy chain constant region residues withtheir human counterparts, generating MAb22_HC_V1 and MAb22_LC_V1. Thisantibody retained its ability to bind human CCR7. The light chain ofthis antibody was further altered to generate a series of humanized MAb22 variants by altering framework regions 1, 2, 3, and 4. This producedsequences MAb22_KLC_V2, MAb22_KLC_V3, MAb22_KLC_V4, MAb22_KLC_V5,MAb22_KLC_V6, MAb22_KLC_V7, and MAb22_KLC_V8.

Example 4 Functional Screening to Identify Antibody Antagonists

Hybridoma supernatants were screened for the ability to blockCCL19-dependant or CCL21-dependant CCR7 signaling. The functional assayused was either a human or cyno CCR7 dependant aequorin-based reportersystem using engineered CHO cell lines. The assay was performed byseeding 96 well plates with 60,000 cell/well and growing them at 37° C.overnight. On day two, growth medium was removed and an assay buffercontaining 30 μM coelenterazine was added to the cells. Cells were thenincubated for 3 hours at 34° C. Hybridoma supernatants or controlsamples were then spiked into each well and incubated for an additional30 minutes at 34° C. CCL19 ligand was then added at an EC₈₀concentration (approximately 113.6 nM). Alternatively, the CCL21 ligandwas used at an EC₈₀ concentration (approximately 166.7 nM). The level ofaequorin activity is then assayed by detecting blue light emitted at awavelength of 469 nm on a mini FLASH machine. Antibodies which blockedCCL19- or CCL21-dependant CCR7 signaling were identified as thosesamples that reduced the level of activated aequorin leading to areduction in signal intensity. Data Generated on hybridoma supernatantsis shown in FIG. 2; antagonists were identified as those samples thatcause a 50% or greater reduction in signal as compared to the negativecontrol. In a similar approach, the same assay was used to determine theIC₅₀ activity of the purified antibody samples. Data are shown in FIGS.3 and 4.

Example 5 Epitope Mapping

A series of mutated variants of human CCR7 was made. Each variantcontained changes to its extracellular domain (ECD), extracellular loop(ECL) 1, ECL2, or ECL3 that converted hCCR7 amino acid residues intotheir corresponding murine CCR7 residues. In the ECD, mutations wereintroduced at positions D35E, F44Y, L47V and S49F. In ECL1, mutationswere made in the A118E, V123I, H127Y and F128L positions. In ECL2,mutations were made in the D198G, R201K, S202N, S204G, Q206D, A207T,M208L, I213V, T214S, E215A and H216Q positions. For ECL3, mutations weremade at positions S295N, T297S and L300T.

Mutations were made using the following oligos:

D35E sense: GAC GAT TAC ATC GGA GAG AAC ACC ACA GTG GAC TAD35E antisense: TAG TCC ACT GTG GTG TTC TCT CCG ATG TAA TCG TCF44Y sense: CAC AGT GGA CTA CAC TTT GTA TGA GTC TTT GTG CTC CAA GAAF44Y antisense: TTC TTG GAG CAC AAA GAC TCA TAC AAA GTG TAG TCC ACT GTGL47V sense: TGG ACT ACA CTT TGT TCG AGT CTG TGT GCT CCA AGAL47V antisense: TCT TGG AGC ACA CAG ACT CGA ACA AAG TGT AGT CCAS49F sense: TTC GAG TCT TTG TGC TTC AAG AAG GAC GTG CGG S49F antisense:CCG CAC GTC CTT CTT GAA GCA CAA AGA CTC GAA A118E sense:GGGCCT ACA GCG AGG CCA AGT CCT G A118 antisense:CAG GAC TTG GCC TCG CTG TAG GCC C V123I sense:CGG CCA AGT CCT GGA TCT TCG GTG TCC AC V123I antisense:GTG GAC ACC GAA GAT CCA GGA CTT GGC CG H127Y sense:GTC CTG GGT CTT CGG TGT CTA TTT TTG CAA GCT CAT CTT TG H127Y antisense:CAA AGA TGA GCT TGC AAA AAT AGA CAC CGA AGA CCC AGG AC F128L sense:GGG TCT TCG GTG TCC ACT TAT GCA AGC TCA TCT T F128L antisense:AAG ATG AGC TTG CAT AAG TGG ACA CCG AAG ACC C D198G sense:GCT CCT GTA CAG TGG CCT CCA GAG GAG CA D198G antisense:TGC TCC TCT GGA GGC CAC TGT ACA GGA GC R201K sense:CAG TGA CCT CCA GAA GAG CAG CAG TGA GC R201K antisense:GCT CAC TGC TGC TCT TCT GGA GGT CAC TG S202N sense:GTG ACC TCC AGA GGA ACA GCA GTG AGC AAG C S202N antisense:GCT TGC TCA CTG CTG TTC CTC TGG AGG TCA C S204G sense:TCC AGA GGA GCA GCG GTG AGC AAG CGA TG S204G antisense:CAT CGC TTG CTC ACC GCT GCT CCT CTG GA Q206D sense:GGA GCA GCA GTG AGG ATG CGA TGC GAT GCT C Q206D antisense:GAG CAT CGC ATC GCA TCC TCA CTG CTG CTC C A207T sense:AGG AGC AGC AGT GAG CAA ACG ATG CGA TCG A207T antisense:GCA TCG CAT CGT TTG CTC ACT GCT GCT CCT M208L sense:GCA GTG AGC AAG CGT TGC GAT GCT CTC TC M208L antisense:GAG AGA GCA TCG CAA CGC TTG CTC ACT GC I213V sense:GAT GCG ATG CTC TCT CGT CAC AGA GCA TGT GGA I213V antisense:TCC ACA TGC TCT GTG ACG AGA GAG CAT CGC ATC T214S sense:CGA TGC TCT CTC ATC TCA GAG CAT GTG GAG G T214S antisense:CCT CCA CAT GCT CTG AGA TGA GAG AGC ATC G E215A sense:GCT CTC TCA TCA CAG CGC ATG TGG AGG CCT T E215A antisense:AAG GCC TCC ACA TGC GCT GTG ATG AGA GAG C H216Q sense:TCT CTC ATC ACA GAG CAG GTG GAG GCC TTT ATC AC H216Q antisense:GTG ATA AAG GCC TCC ACC TGC TCT GTG ATG AGA GA S295N sense:CAA CTT CAA CAT CAC CAA TAG CAC CTG TGA GCT CA S295 antisense:TGA GCT CAC AGG TGC TAT TGG TGA TGT TGA AGT TG T297S sense:CAA CAT CAC CAG TAG CAG CTG TGA GCT CAG TAA GC T297S antisense:GCT TAC TGA GCT CAC AGC TGC TAC TGG TGA TGT TG L300T sense:CAC CAG TAG CAC CTG TGA GAC CAG TAA GCA ACT CAA CAT C L300T antisense:GAT GTT GAG TTG CTT ACT GGT CTC ACA GGT GCT ACT GGT G

The oligos were diluted to 50 ng/μl concentration. PCR reactions wereset up using 100 ng template DNA pcDNA3.1 Neo-hCCR7 (20100121357):

ATGGACCTGGGGAAACCAATGAAAAGCGTGCTGGTGGTGGCTCTCCTTGTCATTTTCCAGGTATGCCTGTGTCAAGATGAGGTCACGGACGATTACATCGGAGACAACACCACAGTGGACTACACTTTGTTCGAGTCTTTGTGCTCCAAGAAGGACGTGCGGAACTTTAAAGCCTGGTTCCTCCCTATCATGTACTCCATCATTTGTTTCGTGGGCCTACTGGGCAATGGGCTGGTCGTGTTGACCTATATCTATTTCAAGAGGCTCAAGACCATGACCGATACCTACCTGCTCAACCTGGCGGTGGCAGACATCCTCTTCCTCCTGACCCTTCCCTTCTGGGCCTACAGCGCGGCCAAGTCCTGGGTCTTCGGTGTCCACTTTTGCAAGCTCATCTTTGCCATCTACAAGATGAGCTTCTTCAGTGGCATGCTCCTACTTCTTTGCATCAGCATTGACCGCTACGTGGCCATCGTCCAGGCTGTCTCAGCTCACCGCCACCGTGCCCGCGTCCTTCTCATCAGCAAGCTGTCCTGTGTGGGCATCTGGATACTAGCCACAGTGCTCTCCATCCCAGAGCTCCTGTACAGTGACCTCCAGAGGAGCAGCAGTGAGCAAGCGATGCGATGCTCTCTCATCACAGAGCATGTGGAGGCCTTTATCACCATCCAGGTGGCCCAGATGGTGATCGGCTTTCTGGTCCCCCTGCTGGCCATGAGCTTCTGTTACCTTGTCATCATCCGCACCCTGCTCCAGGCACGCAACTTTGAGCGCAACAAGGCCATCAAGGTGATCATCGCTGTGGTCGTGGTCTTCATAGTCTTCCAGCTGCCCTACAATGGGGTGGTCCTGGCCCAGACGGTGGCCAACTTCAACATCACCAGTAGCACCTGTGAGCTCAGTAAGCAACTCAACATCGCCTACGACGTCACCTACAGCCTGGCCTGCGTCCGCTGCTGCGTCAACCCTTTCTTGTACGCCTTCATCGGCGTCAAGTTCCGCAACGATCTCTTCAAGCTCTTCAAGGACCTGGGCTGCCTCAGCCAGGAGCAGCTCCGGCAGTGGTCTTCCTGTCGGCACATCCGGCGCTCCTCCATGAGTGTGGAGGCCGAGACCACCACCACCTTCTCCCCATAGMDLGKPMKSVLVVALLVIFQVCLCQDEVTDDYIGDNTTVDYTLFESLCSKKDVRNFKAWFLPIMYSIICFVGLLGNGLVVLTYIYFKRLKTMTDTYLLNLAVADILFLLTLPFWAYSAAKSWVFGVHFCKLIFAIYKMSFFSGMLLLLCISIDRYVAIVQAVSAHRHRARVLLISKLSCVGIWILATVLSIPELLYSDLQRSSSEQAMRCSLITEHVEAFITIQVAQMVIGFLVPLLAMSFCYLVIIRTLLQARNFERNKAIKVIIAVVVVFIVFQLPYNGVVLAQTVANFNITSSTCELSKQLNIAYDVTYSLACVRCCVNPFLYAFIGVKFRNDLFKLFKDLGCLSQEQLRQWSSCRHIRRSSMSVEAETTTTFSP*

For each individual mutation, a PCR product was generated using aQuikChange Multi Site-Site Directed Mutagenesis Kit (Cat#200531)(Stratagene, La Jolla, Calif.) according to manufacturer's instructions.The resulting PCR products were DpnI digested and then transformed intoTop 10 chemically competent cells (Invitrogen, Grand Island, N.Y.).Individual colonies were picked for each construct and sequenced. Cloneswith the correct sequences were scaled up and re-sequenced. The finalclone DNA sequences and translated protein sequences follow:

D35E 20100122625 ATGGACCTGGGGAAACCAATGAAAAGCGTGCTGGTGGTGGCTCTCCTTGTCATTTTCCAGGTATGCCTGTGTCAAGATGAGGTCACGGACGATTACATCGGAGAGAACACCACAGTGGACTACACTTTGTTCGAGTCTTTGTGCTCCAAGAAGGACGTGCGGAACTTTAAAGCCTGGTTCCTCCCTATCATGTACTCCATCATTTGTTTCGTGGGCCTACTGGGCAATGGGCTGGTCGTGTTGACCTATATCTATTTCAAGAGGCTCAAGACCATGACCGATACCTACCTGCTCAACCTGGCGGTGGCAGACATCCTCTTCCTCCTGACCCTTCCCTTCTGGGCCTACAGCGCGGCCAAGTCCTGGGTCTTCGGTGTCCACTTTTGCAAGCTCATCTTTGCCATCTACAAGATGAGCTTCTTCAGTGGCATGCTCCTACTTCTTTGCATCAGCATTGACCGCTACGTGGCCATCGTCCAGGCTGTCTCAGCTCACCGCCACCGTGCCCGCGTCCTTCTCATCAGCAAGCTGTCCTGTGTGGGCATCTGGATACTAGCCACAGTGCTCTCCATCCCAGAGCTCCTGTACAGTGACCTCCAGAGGAGCAGCAGTGAGCAAGCGATGCGATGCTCTCTCATCACAGAGCATGTGGAGGCCTTTATCACCATCCAGGTGGCCCAGATGGTGATCGGCTTTCTGGTCCCCCTGCTGGCCATGAGCTTCTGTTACCTTGTCATCATCCGCACCCTGCTCCAGGCACGCAACTTTGAGCGCAACAAGGCCATCAAGGTGATCATCGCTGTGGTCGTGGTCTTCATAGTCTTCCAGCTGCCCTACAATGGGGTGGTCCTGGCCCAGACGGTGGCCAACTTCAACATCACCAGTAGCACCTGTGAGCTCAGTAAGCAACTCAACATCGCCTACGACGTCACCTACAGCCTGGCCTGCGTCCGCTGCTGCGTCAACCCTTTCTTGTACGCCTTCATCGGCGTCAAGTTCCGCAACGATCTCTTCAAGCTCTTCAAGGACCTGGGCTGCCTCAGCCAGGAGCAGCTCCGGCAGTGGTCTTCCTGTCGGCACATCCGGCGCTCCTCCATGAGTGTGGAGGCCGAGACCACCACCACCTTCTCCCCATAG MDLGKPMKSVLVVALLVIFQVCLCQDEVTDDYIGE NTTVDYTLFESLCSK KDVRNFKAWFLPIMYSIICFVGLLGNGLVVLTYIYFKRLKTMTDTYLLNLAVADILFLLTLPFWAYSAAKSWVFGVHFCKLIFAIYKMSFFSGMLLLLCISIDRYVAIVQAVSAHRHRARVLLISKLSCVGIWILATVLSIPELLYSDLQRSSSEQAMRCSLITEHVEAFITIQVAQMVIGFLVPLLAMSFCYLVIIRTLLQARNFERNKAIKVIIAVVVVFIVFQLPYNGVVLAQTVANFNITSSTCELSKQLNIAYDVTYSLACVRCCVNPFLYAFIGVKFRNDLFKLFKDLGCLSQEQLRQWSSCRHIRRSSMSVEAETTTTFSP F44Y 20100128285ATGGACCTGGGGAAACCAATGAAAAGCGTGCTGGTGGTGGCTCTCCTTGTCATTTTCCAGGTATGCCTGTGTCAAGATGAGGTCACGGACGATTACATCGGAGACAACACCACAGTGGACTACACTTTGTATGAGTCTTTGTGCTCCAAGAAGGACGTGCGGAACTTTAAAGCCTGGTTCCTCCCTATCATGTACTCCATCATTTGTTTCGTGGGCCTACTGGGCAATGGGCTGGTCGTGTTGACCTATATCTATTTCAAGAGGCTCAAGACCATGACCGATACCTACCTGCTCAACCTGGCGGTGGCAGACATCCTCTTCCTCCTGACCCTTCCCTTCTGGGCCTACAGCGCGGCCAAGTCCTGGGTCTTCGGTGTCCACTTTTGCAAGCTCATCTTTGCCATCTACAAGATGAGCTTCTTCAGTGGCATGCTCCTACTTCTTTGCATCAGCATTGACCGCTACGTGGCCATCGTCCAGGCTGTCTCAGCTCACCGCCACCGTGCCCGCGTCCTTCTCATCAGCAAGCTGTCCTGTGTGGGCATCTGGATACTAGCCACAGTGCTCTCCATCCCAGAGCTCCTGTACAGTGACCTCCAGAGGAGCAGCAGTGAGCAAGCGATGCGATGCTCTCTCATCACAGAGCATGTGGAGGCCTTTATCACCATCCAGGTGGCCCAGATGGTGATCGGCTTTCTGGTCCCCCTGCTGGCCATGAGCTTCTGTTACCTTGTCATCATCCGCACCCTGCTCCAGGCACGCAACTTTGAGCGCAACAAGGCCATCAAGGTGATCATCGCTGTGGTCGTGGTCTTCATAGTCTTCCAGCTGCCCTACAATGGGGTGGTCCTGGCCCAGACGGTGGCCAACTTCAACATCACCAGTAGCACCTGTGAGCTCAGTAAGCAACTCAACATCGCCTACGACGTCACCTACAGCCTGGCCTGCGTCCGCTGCTGCGTCAACCCTTTCTTGTACGCCTTCATCGGCGTCAAGTTCCGCAACGATCTCTTCAAGCTCTTCAAGGACCTGGGCTGCCTCAGCCAGGAGCAGCTCCGGCAGTGGTCTTCCTGTCGGCACATCCGGCGCTCCTCCATGAGTGTGGAGGCCGAGACCACCACCACCTTCTCCCCATAGMDLGKPMKSVLVVALLVIFQVCLCQDEVTDDYIGDNTTVDYTL Y ESLCSKKDVRNFKAWFLPIMYSIICFVGLLGNGLVVLTYIYFKRLKTMTDTYLLNLAVADILFLLTLPFWAYSAAKSWVFGVHFCKLIFAIYKMSFFSGMLLLLCISIDRYVAIVQAVSAHRHRARVLLISKLSCVGIWILATVLSIPELLYSDLQRSSSEQAMRCSLITEHVEAFITIQVAQMVIGFLVPLLAMSFCYLVIIRTLLQARNFERNKAIKVIIAVVVVFIVFQLPYNGVVLAQTVANFNITSSTCELSKQLNIAYDVTYSLACVRCCVNPFLYAFIGVKFRNDLFKLFKDLGCLSQEQLRQWSSCRHIRRSSMSVEAETTTTFSP L47V 20100122626ATGGACCTGGGGAAACCAATGAAAAGCGTGCTGGTGGTGGCTCTCCTTGTCATTTTCCAGGTATGCCTGTGTCAAGATGAGGTCACGGACGATTACATCGGAGACAACACCACAGTGGACTACACTTTGTTCGAGTCTGTGTGCTCCAAGAAGGACGTGCGGAACTTTAAAGCCTGGTTCCTCCCTATCATGTACTCCATCATTTGTTTCGTGGGCCTACTGGGCAATGGGCTGGTCGTGTTGACCTATATCTATTTCAAGAGGCTCAAGACCATGACCGATACCTACCTGCTCAACCTGGCGGTGGCAGACATCCTCTTCCTCCTGACCCTTCCCTTCTGGGCCTACAGCGCGGCCAAGTCCTGGGTCTTCGGTGTCCACTTTTGCAAGCTCATCTTTGCCATCTACAAGATGAGCTTCTTCAGTGGCATGCTCCTACTTCTTTGCATCAGCATTGACCGCTACGTGGCCATCGTCCAGGCTGTCTCAGCTCACCGCCACCGTGCCCGCGTCCTTCTCATCAGCAAGCTGTCCTGTGTGGGCATCTGGATACTAGCCACAGTGCTCTCCATCCCAGAGCTCCTGTACAGTGACCTCCAGAGGAGCAGCAGTGAGCAAGCGATGCGATGCTCTCTCATCACAGAGCATGTGGAGGCCTTTATCACCATCCAGGTGGCCCAGATGGTGATCGGCTTTCTGGTCCCCCTGCTGGCCATGAGCTTCTGTTACCTTGTCATCATCCGCACCCTGCTCCAGGCACGCAACTTTGAGCGCAACAAGGCCATCAAGGTGATCATCGCTGTGGTCGTGGTCTTCATAGTCTTCCAGCTGCCCTACAATGGGGTGGTCCTGGCCCAGACGGTGGCCAACTTCAACATCACCAGTAGCACCTGTGAGCTCAGTAAGCAACTCAACATCGCCTACGACGTCACCTACAGCCTGGCCTGCGTCCGCTGCTGCGTCAACCCTTTCTTGTACGCCTTCATCGGCGTCAAGTTCCGCAACGATCTCTTCAAGCTCTTCAAGGACCTGGGCTGCCTCAGCCAGGAGCAGCTCCGGCAGTGGTCTTCCTGTCGGCACATCCGGCGCTCCTCCATGAGTGTGGAGGCCGAGACCACCACCACCTTCTCCCCATAGMDLGKPMKSVLVVALLVIFQVCLCQDEVTDDYIGDNTTVDYTLFES V CSKKDVRNFKAWFLPIMYSIICFVGLLGNGLVVLTYIYFKRLKTMTDTYLLNLAVADILFLLTLPFWAYSAAKSWVFGVHFCKLIFAIYKMSFFSGMLLLLCISIDRYVAIVQAVSAHRHRARVLLISKLSCVGIWILATVLSIPELLYSDLQRSSSEQAMRCSLITEHVEAFITIQVAQMVIGFLVPLLAMSFCYLVIIRTLLQARNFERNKAIKVIIAVVVVFIVFQLPYNGVVLAQTVANFNITSSTCELSKQLNIAYDVTYSLACVRCCVNPFLYAFIGVKFRNDLFKLFKDLGCLSQEQLRQWSSCRHIRRSSMSVEAETTTTFSP S49F 20100122627ATGGACCTGGGGAAACCAATGAAAAGCGTGCTGGTGGTGGCTCTCCTTGTCATTTTCCAGGTATGCCTGTGTCAAGATGAGGTCACGGACGATTACATCGGAGACAACACCACAGTGGACTACACTTTGTTCGAGTCTTTGTGCTTCAAGAAGGACGTGCGGAACTTTAAAGCCTGGTTCCTCCCTATCATGTACTCCATCATTTGTTTCGTGGGCCTACTGGGCAATGGGCTGGTCGTGTTGACCTATATCTATTTCAAGAGGCTCAAGACCATGACCGATACCTACCTGCTCAACCTGGCGGTGGCAGACATCCTCTTCCTCCTGACCCTTCCCTTCTGGGCCTACAGCGCGGCCAAGTCCTGGGTCTTCGGTGTCCACTTTTGCAAGCTCATCTTTGCCATCTACAAGATGAGCTTCTTCAGTGGCATGCTCCTACTTCTTTGCATCAGCATTGACCGCTACGTGGCCATCGTCCAGGCTGTCTCAGCTCACCGCCACCGTGCCCGCGTCCTTCTCATCAGCAAGCTGTCCTGTGTGGGCATCTGGATACTAGCCACAGTGCTCTCCATCCCAGAGCTCCTGTACAGTGACCTCCAGAGGAGCAGCAGTGAGCAAGCGATGCGATGCTCTCTCATCACAGAGCATGTGGAGGCCTTTATCACCATCCAGGTGGCCCAGATGGTGATCGGCTTTCTGGTCCCCCTGCTGGCCATGAGCTTCTGTTACCTTGTCATCATCCGCACCCTGCTCCAGGCACGCAACTTTGAGCGCAACAAGGCCATCAAGGTGATCATCGCTGTGGTCGTGGTCTTCATAGTCTTCCAGCTGCCCTACAATGGGGTGGTCCTGGCCCAGACGGTGGCCAACTTCAACATCACCAGTAGCACCTGTGAGCTCAGTAAGCAACTCAACATCGCCTACGACGTCACCTACAGCCTGGCCTGCGTCCGCTGCTGCGTCAACCCTTTCTTGTACGCCTTCATCGGCGTCAAGTTCCGCAACGATCTCTTCAAGCTCTTCAAGGACCTGGGCTGCCTCAGCCAGGAGCAGCTCCGGCAGTGGTCTTCCTGTCGGCACATCCGGCGCTCCTCCATGAGTGTGGAGGCCGAGACCACCACCACCTTCTCCCCATAGMDLGKPMKSVLVVALLVIFQVCLCQDEVTDDYIGDNTTVDYTLFESLC F KKDVRNFKAWFLPIMYSIICFVGLLGNGLVVLTYIYFKRLKTMTDTYLLNLAVADILFLLTLPFWAYSAAKSWVFGVHFCKLIFAIYKMSFFSGMLLLLCISIDRYVAIVQAVSAHRHRARVLLISKLSCVGIWILATVLSIPELLYSDLQRSSSEQAMRCSLITEHVEAFITIQVAQMVIGFLVPLLAMSFCYLVIIRTLLQARNFERNKAIKVIIAVVVVFIVFQLPYNGVVLAQTVANFNITSSTCELSKQLNIAYDVTYSLACVRCCVNPFLYAFIGVKFRNDLFKLFKDLGCLSQEQLRQWSSCRHIRRSSMSVEAETTTTFSP A118E 20100130760ATGGACCTGGGGAAACCAATGAAAAGCGTGCTGGTGGTGGCTCTCCTTGTCATTTTCCAGGTATGCCTGTGTCAAGATGAGGTCACGGACGATTACATCGGAGACAACACCACAGTGGACTACACTTTGTTCGAGTCTTTGTGCTCCAAGAAGGACGTGCGGAACTTTAAAGCCTGGTTCCTCCCTATCATGTACTCCATCATTTGTTTCGTGGGCCTACTGGGCAATGGGCTGGTCGTGTTGACCTATATCTATTTCAAGAGGCTCAAGACCATGACCGATACCTACCTGCTCAACCTGGCGGTGGCAGACATCCTCTTCCTCCTGACCCTTCCCTTCTGGGCCTACAGCGAGGCCAAGTCCTGGGTCTTCGGTGTCCACTTTTGCAAGCTCATCTTTGCCATCTACAAGATGAGCTTCTTCAGTGGCATGCTCCTACTTCTTTGCATCAGCATTGACCGCTACGTGGCCATCGTCCAGGCTGTCTCAGCTCACCGCCACCGTGCCCGCGTCCTTCTCATCAGCAAGCTGTCCTGTGTGGGCATCTGGATACTAGCCACAGTGCTCTCCATCCCAGAGCTCCTGTACAGTGACCTCCAGAGGAGCAGCAGTGAGCAAGCGATGCGATGCTCTCTCATCACAGAGCATGTGGAGGCCTTTATCACCATCCAGGTGGCCCAGATGGTGATCGGCTTTCTGGTCCCCCTGCTGGCCATGAGCTTCTGTTACCTTGTCATCATCCGCACCCTGCTCCAGGCACGCAACTTTGAGCGCAACAAGGCCATCAAGGTGATCATCGCTGTGGTCGTGGTCTTCATAGTCTTCCAGCTGCCCTACAATGGGGTGGTCCTGGCCCAGACGGTGGCCAACTTCAACATCACCAGTAGCACCTGTGAGCTCAGTAAGCAACTCAACATCGCCTACGACGTCACCTACAGCCTGGCCTGCGTCCGCTGCTGCGTCAACCCTTTCTTGTACGCCTTCATCGGCGTCAAGTTCCGCAACGATCTCTTCAAGCTCTTCAAGGACCTGGGCTGCCTCAGCCAGGAGCAGCTCCGGCAGTGGTCTTCCTGTCGGCACATCCGGCGCTCCTCCATGAGTGTGGAGGCCGAGACCACCACCACCTTCTCCCCATAGMDLGKPMKSVLVVALLVIFQVCLCQDEVTDDYIGDNTTVDYTLFESLCSKKDVRNFKAWFLPIMYSIICFVGLLGNGLVVLTYIYFKRLKTMTDTYLLNL AVADILFLLTLPFWAYS EAKSWVFGVHFCKLIFAIYKMSFFSGMLLLLCISIDRYVAIVQAVSAHRHRARVLLISKLSCVGIWILATVLSIPELLYSDLQRSSSEQAMRCSLITEHVEAFITIQVAQMVIGFLVPLLAMSFCYLVIIRTLLQARNFERNKAIKVIIAVVVVFIVFQLPYNGVVLAQTVANFNITSSTCELSKQLNIAYDVTYSLACVRCCVNPFLYAFIGVKFRNDLFKLFKDLGCLSQEQLRQWSSCRHIRRSSMSVEAETTTTFSP V123I 20100126473ATGGACCTGGGGAAACCAATGAAAAGCGTGCTGGTGGTGGCTCTCCTTGTCATTTTCCAGGTATGCCTGTGTCAAGATGAGGTCACGGACGATTACATCGGAGACAACACCACAGTGGACTACACTTTGTTCGAGTCTTTGTGCTCCAAGAAGGACGTGCGGAACTTTAAAGCCTGGTTCCTCCCTATCATGTACTCCATCATTTGTTTCGTGGGCCTACTGGGCAATGGGCTGGTCGTGTTGACCTATATCTATTTCAAGAGGCTCAAGACCATGACCGATACCTACCTGCTCAACCTGGCGGTGGCAGACATCCTCTTCCTCCTGACCCTTCCCTTCTGGGCCTACAGCGCGGCCAAGTCCTGGATCTTCGGTGTCCACTTTTGCAAGCTCATCTTTGCCATCTACAAGATGAGCTTCTTCAGTGGCATGCTCCTACTTCTTTGCATCAGCATTGACCGCTACGTGGCCATCGTCCAGGCTGTCTCAGCTCACCGCCACCGTGCCCGCGTCCTTCTCATCAGCAAGCTGTCCTGTGTGGGCATCTGGATACTAGCCACAGTGCTCTCCATCCCAGAGCTCCTGTACAGTGACCTCCAGAGGAGCAGCAGTGAGCAAGCGATGCGATGCTCTCTCATCACAGAGCATGTGGAGGCCTTTATCACCATCCAGGTGGCCCAGATGGTGATCGGCTTTCTGGTCCCCCTGCTGGCCATGAGCTTCTGTTACCTTGTCATCATCCGCACCCTGCTCCAGGCACGCAACTTTGAGCGCAACAAGGCCATCAAGGTGATCATCGCTGTGGTCGTGGTCTTCATAGTCTTCCAGCTGCCCTACAATGGGGTGGTCCTGGCCCAGACGGTGGCCAACTTCAACATCACCAGTAGCACCTGTGAGCTCAGTAAGCAACTCAACATCGCCTACGACGTCACCTACAGCCTGGCCTGCGTCCGCTGCTGCGTCAACCCTTTCTTGTACGCCTTCATCGGCGTCAAGTTCCGCAACGATCTCTTCAAGCTCTTCAAGGACCTGGGCTGCCTCAGCCAGGAGCAGCTCCGGCAGTGGTCTTCCTGTCGGCACATCCGGCGCTCCTCCATGAGTGTGGAGGCCGAGACCACCACCACCTTCTCCCCATAGMDLGKPMKSVLVVALLVIFQVCLCQDEVTDDYIGDNTTVDYTLFESLCSKKDVRNFKAWFLPIMYSIICFVGLLGNGLVVLTYIYFKRLKTMTDTYLLNLAVADILFLLTLPFWAYSAAKSW I FGVHFCKLIFAIYKMSFFSGMLLLLCISIDRYVAIVQAVSAHRHRARVLLISKLSCVGIWILATVLSIPELLYSDLQRSSSEQAMRCSLITEHVEAFITIQVAQMVIGFLVPLLAMSFCYLVIIRTLLQARNFERNKAIKVIIAVVVVFIVFQLPYNGVVLAQTVANFNITSSTCELSKQLNIAYDVTYSLACVRCCVNPFLYAFIGVKFRNDLFKLFKDLGCLSQEQLRQWSSCRHIRRSSMSVEAETTTTFSP H127Y 20100135009ATGGACCTGGGGAAACCAATGAAAAGCGTGCTGGTGGTGGCTCTCCTTGTCATTTTCCAGGTATGCCTGTGTCAAGATGAGGTCACGGACGATTACATCGGAGACAACACCACAGTGGACTACACTTTGTTCGAGTCTTTGTGCTCCAAGAAGGACGTGCGGAACTTTAAAGCCTGGTTCCTCCCTATCATGTACTCCATCATTTGTTTCGTGGGCCTACTGGGCAATGGGCTGGTCGTGTTGACCTATATCTATTTCAAGAGGCTCAAGACCATGACCGATACCTACCTGCTCAACCTGGCGGTGGCAGACATCCTCTTCCTCCTGACCCTTCCCTTCTGGGCCTACAGCGCGGCCAAGTCCTGGGTCTTCGGTGTCTATTTTTGCAAGCTCATCTTTGCCATCTACAAGATGAGCTTCTTCAGTGGCATGCTCCTACTTCTTTGCATCAGCATTGACCGCTACGTGGCCATCGTCCAGGCTGTCTCAGCTCACCGCCACCGTGCCCGCGTCCTTCTCATCAGCAAGCTGTCCTGTGTGGGCATCTGGATACTAGCCACAGTGCTCTCCATCCCAGAGCTCCTGTACAGTGACCTCCAGAGGAGCAGCAGTGAGCAAGCGATGCGATGCTCTCTCATCACAGAGCATGTGGAGGCCTTTATCACCATCCAGGTGGCCCAGATGGTGATCGGCTTTCTGGTCCCCCTGCTGGCCATGAGCTTCTGTTACCTTGTCATCATCCGCACCCTGCTCCAGGCACGCAACTTTGAGCGCAACAAGGCCATCAAGGTGATCATCGCTGTGGTCGTGGTCTTCATAGTCTTCCAGCTGCCCTACAATGGGGTGGTCCTGGCCCAGACGGTGGCCAACTTCAACATCACCAGTAGCACCTGTGAGCTCAGTAAGCAACTCAACATCGCCTACGACGTCACCTACAGCCTGGCCTGCGTCCGCTGCTGCGTCAACCCTTTCTTGTACGCCTTCATCGGCGTCAAGTTCCGCAACGATCTCTTCAAGCTCTTCAAGGACCTGGGCTGCCTCAGCCAGGAGCAGCTCCGGCAGTGGTCTTCCTGTCGGCACATCCGGCGCTCCTCCATGAGTGTGGAGGCCGAGACCACCACCACCTTCTCCCCATAGMDLGKPMKSVLVVALLVIFQVCLCQDEVTDDYIGDNTTVDYTLFESLCSKKDVRNFKAWFLPIMYSIICFVGLLGNGLVVLTYIYFKRLKTMTDTYLLNLAVADILFLLTLPFWAYSAAKSWVFGV Y FCKLIFAIYKMSFFSGMLLLLCISIDRYVAIVQAVSAHRHRARVLLISKLSCVGIWILATVLSIPELLYSDLQRSSSEQAMRCSLITEHVEAFITIQVAQMVIGFLVPLLAMSFCYLVIIRTLLQARNFERNKAIKVIIAVVVVFIVFQLPYNGVVLAQTVANFNITSSTCELSKQLNIAYDVTYSLACVRCCVNPFLYAFIGVKFRNDLFKLFKDLGCLSQEQLRQWSSCRHIRRSSMSVEAETTTTFSP F128L 20100126472ATGGACCTGGGGAAACCAATGAAAAGCGTGCTGGTGGTGGCTCTCCTTGTCATTTTCCAGGTATGCCTGTGTCAAGATGAGGTCACGGACGATTACATCGGAGACAACACCACAGTGGACTACACTTTGTTCGAGTCTTTGTGCTCCAAGAAGGACGTGCGGAACTTTAAAGCCTGGTTCCTCCCTATCATGTACTCCATCATTTGTTTCGTGGGCCTACTGGGCAATGGGCTGGTCGTGTTGACCTATATCTATTTCAAGAGGCTCAAGACCATGACCGATACCTACCTGCTCAACCTGGCGGTGGCAGACATCCTCTTCCTCCTGACCCTTCCCTTCTGGGCCTACAGCGCGGCCAAGTCCTGGGTCTTCGGTGTCCACTTATGCAAGCTCATCTTTGCCATCTACAAGATGAGCTTCTTCAGTGGCATGCTCCTACTTCTTTGCATCAGCATTGACCGCTACGTGGCCATCGTCCAGGCTGTCTCAGCTCACCGCCACCGTGCCCGCGTCCTTCTCATCAGCAAGCTGTCCTGTGTGGGCATCTGGATACTAGCCACAGTGCTCTCCATCCCAGAGCTCCTGTACAGTGACCTCCAGAGGAGCAGCAGTGAGCAAGCGATGCGATGCTCTCTCATCACAGAGCATGTGGAGGCCTTTATCACCATCCAGGTGGCCCAGATGGTGATCGGCTTTCTGGTCCCCCTGCTGGCCATGAGCTTCTGTTACCTTGTCATCATCCGCACCCTGCTCCAGGCACGCAACTTTGAGCGCAACAAGGCCATCAAGGTGATCATCGCTGTGGTCGTGGTCTTCATAGTCTTCCAGCTGCCCTACAATGGGGTGGTCCTGGCCCAGACGGTGGCCAACTTCAACATCACCAGTAGCACCTGTGAGCTCAGTAAGCAACTCAACATCGCCTACGACGTCACCTACAGCCTGGCCTGCGTCCGCTGCTGCGTCAACCCTTTCTTGTACGCCTTCATCGGCGTCAAGTTCCGCAACGATCTCTTCAAGCTCTTCAAGGACCTGGGCTGCCTCAGCCAGGAGCAGCTCCGGCAGTGGTCTTCCTGTCGGCACATCCGGCGCTCCTCCATGAGTGTGGAGGCCGAGACCACCACCACCTTCTCCCCATAGMDLGKPMKSVLVVALLVIFQVCLCQDEVTDDYIGDNTTVDYTLFESLCSKKDVRNFKAWFLPIMYSIICFVGLLGNGLVVLTYIYFKRLKTMTDTYLLNLAVADILFLLTLPFWAYSAAKSWVFGVH L CKLIFAIYKMSFFSGMLLLLCISIDRYVAIVQAVSAHRHRARVLLISKLSCVGIWILATVLSIPELLYSDLQRSSSEQAMRCSLITEHVEAFITIQVAQMVIGFLVPLLAMSFCYLVIIRTLLQARNFERNKAIKVIIAVVVVFIVFQLPYNGVVLAQTVANFNITSSTCELSKQLNIAYDVTYSLACVRCCVNPFLYAFIGVKFRNDLFKLFKDLGCLSQEQLRQWSSCRHIRRSSMSVEAETTTTFSP D198G 20110009482ATGGACCTGGGGAAACCAATGAAAAGCGTGCTGGTGGTGGCTCTCCTTGTCATTTTCCAGGTATGCCTGTGTCAAGATGAGGTCACGGACGATTACATCGGAGACAACACCACAGTGGACTACACTTTGTTCGAGTCTTTGTGCTCCAAGAAGGACGTGCGGAACTTTAAAGCCTGGTTCCTCCCTATCATGTACTCCATCATTTGTTTCGTGGGCCTACTGGGCAATGGGCTGGTCGTGTTGACCTATATCTATTTCAAGAGGCTCAAGACCATGACCGATACCTACCTGCTCAACCTGGCGGTGGCAGACATCCTCTTCCTCCTGACCCTTCCCTTCTGGGCCTACAGCGCGGCCAAGTCCTGGGTCTTCGGTGTCCACTTTTGCAAGCTCATCTTTGCCATCTACAAGATGAGCTTCTTCAGTGGCATGCTCCTACTTCTTTGCATCAGCATTGACCGCTACGTGGCCATCGTCCAGGCTGTCTCAGCTCACCGCCACCGTGCCCGCGTCCTTCTCATCAGCAAGCTGTCCTGTGTGGGCATCTGGATACTAGCCACAGTGCTCTCCATCCCAGAGCTCCTGTACAGTGGCCTCCAGAGGAGCAGCAGTGAGCAAGCGATGCGATGCTCTCTCATCACAGAGCATGTGGAGGCCTTTATCACCATCCAGGTGGCCCAGATGGTGATCGGCTTTCTGGTCCCCCTGCTGGCCATGAGCTTCTGTTACCTTGTCATCATCCGCACCCTGCTCCAGGCACGCAACTTTGAGCGCAACAAGGCCATCAAGGTGATCATCGCTGTGGTCGTGGTCTTCATAGTCTTCCAGCTGCCCTACAATGGGGTGGTCCTGGCCCAGACGGTGGCCAACTTCAACATCACCAGTAGCACCTGTGAGCTCAGTAAGCAACTCAACATCGCCTACGACGTCACCTACAGCCTGGCCTGCGTCCGCTGCTGCGTCAACCCTTTCTTGTACGCCTTCATCGGCGTCAAGTTCCGCAACGATCTCTTCAAGCTCTTCAAGGACCTGGGCTGCCTCAGCCAGGAGCAGCTCCGGCAGTGGTCTTCCTGTCGGCACATCCGGCGCTCCTCCATGAGTGTGGAGGCCGAGACCACCACCACCTTCTCCCCATAGMDLGKPMKSVLVVALLVIFQVCLCQDEVTDDYIGDNTTVDYTLFESLCSKKDVRNFKAWFLPIMYSIICFVGLLGNGLVVLTYIYFKRLKTMTDTYLLNLAVADILFLLTLPFWAYSAAKSWVFGVHFCKLIFAIYKMSFFSGMLLLLCISIDRYVAIVQAVSAHRHRARVLLISKLSCVGIWILATVLSIPELLYS G LQRSSSEQAMRCSLITEHVEAFITIQVAQMVIGFLVPLLAMSFCYLVIIRTLLQARNFERNKAIKVIIAVVVVFIVFQLPYNGVVLAQTVANFNITSSTCELSKQLNIAYDVTYSLACVRCCVNPFLYAFIGVKFRNDLFKLFKDLGCLSQEQLRQWSSCRHIRRSSMSVEAETTTTFSP R201K 20100171268ATGGACCTGGGGAAACCAATGAAAAGCGTGCTGGTGGTGGCTCTCCTTGTCATTTTCCAGGTATGCCTGTGTCAAGATGAGGTCACGGACGATTACATCGGAGACAACACCACAGTGGACTACACTTTGTTCGAGTCTTTGTGCTCCAAGAAGGACGTGCGGAACTTTAAAGCCTGGTTCCTCCCTATCATGTACTCCATCATTTGTTTCGTGGGCCTACTGGGCAATGGGCTGGTCGTGTTGACCTATATCTATTTCAAGAGGCTCAAGACCATGACCGATACCTACCTGCTCAACCTGGCGGTGGCAGACATCCTCTTCCTCCTGACCCTTCCCTTCTGGGCCTACAGCGCGGCCAAGTCCTGGGTCTTCGGTGTCCACTTTTGCAAGCTCATCTTTGCCATCTACAAGATGAGCTTCTTCAGTGGCATGCTCCTACTTCTTTGCATCAGCATTGACCGCTACGTGGCCATCGTCCAGGCTGTCTCAGCTCACCGCCACCGTGCCCGCGTCCTTCTCATCAGCAAGCTGTCCTGTGTGGGCATCTGGATACTAGCCACAGTGCTCTCCATCCCAGAGCTCCTGTACAGTGACCTCCAGAAGAGCAGCAGTGAGCAAGCGATGCGATGCTCTCTCATCACAGAGCATGTGGAGGCCTTTATCACCATCCAGGTGGCCCAGATGGTGATCGGCTTTCTGGTCCCCCTGCTGGCCATGAGCTTCTGTTACCTTGTCATCATCCGCACCCTGCTCCAGGCACGCAACTTTGAGCGCAACAAGGCCATCAAGGTGATCATCGCTGTGGTCGTGGTCTTCATAGTCTTCCAGCTGCCCTACAATGGGGTGGTCCTGGCCCAGACGGTGGCCAACTTCAACATCACCAGTAGCACCTGTGAGCTCAGTAAGCAACTCAACATCGCCTACGACGTCACCTACAGCCTGGCCTGCGTCCGCTGCTGCGTCAACCCTTTCTTGTACGCCTTCATCGGCGTCAAGTTCCGCAACGATCTCTTCAAGCTCTTCAAGGACCTGGGCTGCCTCAGCCAGGAGCAGCTCCGGCAGTGGTCTTCCTGTCGGCACATCCGGCGCTCCTCCATGAGTGTGGAGGCCGAGACCACCACCACCTTCTCCCCATAGMDLGKPMKSVLVVALLVIFQVCLCQDEVTDDYIGDNTTVDYTLFESLCSKKDVRNFKAWFLPIMYSIICFVGLLGNGLVVLTYIYFKRLKTMTDTYLLNLAVADILFLLTLPFWAYSAAKSWVFGVHFCKLIFAIYKMSFFSGMLLLLCISIDRYVAIVQAVSAHRHRARVLLISKLSCVGIWILATVLSIPELLYSDLQ KSSSEQAMRCSLITEHVEAFITIQVAQMVIGFLVPLLAMSFCYLVIIRTLLQARNFERNKAIKVIIAVVVVFIVFQLPYNGVVLAQTVANFNITSSTCELSKQLNIAYDVTYSLACVRCCVNPFLYAFIGVKFRNDLFKLFKDLGCLSQEQLRQWSSCRHIRRSSMSVEAETTTTFSP S202N 20110009483ATGGACCTGGGGAAACCAATGAAAAGCGTGCTGGTGGTGGCTCTCCTTGTCATTTTCCAGGTATGCCTGTGTCAAGATGAGGTCACGGACGATTACATCGGAGACAACACCACAGTGGACTACACTTTGTTCGAGTCTTTGTGCTCCAAGAAGGACGTGCGGAACTTTAAAGCCTGGTTCCTCCCTATCATGTACTCCATCATTTGTTTCGTGGGCCTACTGGGCAATGGGCTGGTCGTGTTGACCTATATCTATTTCAAGAGGCTCAAGACCATGACCGATACCTACCTGCTCAACCTGGCGGTGGCAGACATCCTCTTCCTCCTGACCCTTCCCTTCTGGGCCTACAGCGCGGCCAAGTCCTGGGTCTTCGGTGTCCACTTTTGCAAGCTCATCTTTGCCATCTACAAGATGAGCTTCTTCAGTGGCATGCTCCTACTTCTTTGCATCAGCATTGACCGCTACGTGGCCATCGTCCAGGCTGTCTCAGCTCACCGCCACCGTGCCCGCGTCCTTCTCATCAGCAAGCTGTCCTGTGTGGGCATCTGGATACTAGCCACAGTGCTCTCCATCCCAGAGCTCCTGTACAGTGACCTCCAGAGGAACAGCAGTGAGCAAGCGATGCGATGCTCTCTCATCACAGAGCATGTGGAGGCCTTTATCACCATCCAGGTGGCCCAGATGGTGATCGGCTTTCTGGTCCCCCTGCTGGCCATGAGCTTCTGTTACCTTGTCATCATCCGCACCCTGCTCCAGGCACGCAACTTTGAGCGCAACAAGGCCATCAAGGTGATCATCGCTGTGGTCGTGGTCTTCATAGTCTTCCAGCTGCCCTACAATGGGGTGGTCCTGGCCCAGACGGTGGCCAACTTCAACATCACCAGTAGCACCTGTGAGCTCAGTAAGCAACTCAACATCGCCTACGACGTCACCTACAGCCTGGCCTGCGTCCGCTGCTGCGTCAACCCTTTCTTGTACGCCTTCATCGGCGTCAAGTTCCGCAACGATCTCTTCAAGCTCTTCAAGGACCTGGGCTGCCTCAGCCAGGAGCAGCTCCGGCAGTGGTCTTCCTGTCGGCACATCCGGCGCTCCTCCATGAGTGTGGAGGCCGAGACCACCACCACCTTCTCCCCATAGMDLGKPMKSVLVVALLVIFQVCLCQDEVTDDYIGDNTTVDYTLFESLCSKKDVRNFKAWFLPIMYSIICFVGLLGNGLVVLTYIYFKRLKTMTDTYLLNLAVADILFLLTLPFWAYSAAKSWVFGVHFCKLIFAIYKMSFFSGMLLLLCISIDRYVAIVQAVSAHRHRARVLLISKLSCVGIWILATVLSIPELLYSDLQ R NSSEQAMRCSLITEHVEAFITIQVAQMVIGFLVPLLAMSFCYLVIIRTLLQARNFERNKAIKVIIAVVVVFIVFQLPYNGVVLAQTVANFNITSSTCELSKQLNIAYDVTYSLACVRCCVNPFLYAFIGVKFRNDLFKLFKDLGCLSQEQLRQWSSCRHIRRSSMSVEAETTTTFSP S204G 20100171269ATGGACCTGGGGAAACCAATGAAAAGCGTGCTGGTGGTGGCTCTCCTTGTCATTTTCCAGGTATGCCTGTGTCAAGATGAGGTCACGGACGATTACATCGGAGACAACACCACAGTGGACTACACTTTGTTCGAGTCTTTGTGCTCCAAGAAGGACGTGCGGAACTTTAAAGCCTGGTTCCTCCCTATCATGTACTCCATCATTTGTTTCGTGGGCCTACTGGGCAATGGGCTGGTCGTGTTGACCTATATCTATTTCAAGAGGCTCAAGACCATGACCGATACCTACCTGCTCAACCTGGCGGTGGCAGACATCCTCTTCCTCCTGACCCTTCCCTTCTGGGCCTACAGCGCGGCCAAGTCCTGGGTCTTCGGTGTCCACTTTTGCAAGCTCATCTTTGCCATCTACAAGATGAGCTTCTTCAGTGGCATGCTCCTACTTCTTTGCATCAGCATTGACCGCTACGTGGCCATCGTCCAGGCTGTCTCAGCTCACCGCCACCGTGCCCGCGTCCTTCTCATCAGCAAGCTGTCCTGTGTGGGCATCTGGATACTAGCCACAGTGCTCTCCATCCCAGAGCTCCTGTACAGTGACCTCCAGAGGAGCAGCGGTGAGCAAGCGATGCGATGCTCTCTCATCACAGAGCATGTGGAGGCCTTTATCACCATCCAGGTGGCCCAGATGGTGATCGGCTTTCTGGTCCCCCTGCTGGCCATGAGCTTCTGTTACCTTGTCATCATCCGCACCCTGCTCCAGGCACGCAACTTTGAGCGCAACAAGGCCATCAAGGTGATCATCGCTGTGGTCGTGGTCTTCATAGTCTTCCAGCTGCCCTACAATGGGGTGGTCCTGGCCCAGACGGTGGCCAACTTCAACATCACCAGTAGCACCTGTGAGCTCAGTAAGCAACTCAACATCGCCTACGACGTCACCTACAGCCTGGCCTGCGTCCGCTGCTGCGTCAACCCTTTCTTGTACGCCTTCATCGGCGTCAAGTTCCGCAACGATCTCTTCAAGCTCTTCAAGGACCTGGGCTGCCTCAGCCAGGAGCAGCTCCGGCAGTGGTCTTCCTGTCGGCACATCCGGCGCTCCTCCATGAGTGTGGAGGCCGAGACCACCACCACCTTCTCCCCATAGMDLGKPMKSVLVVALLVIFQVCLCQDEVTDDYIGDNTTVDYTLFESLCSKKDVRNFKAWFLPIMYSIICFVGLLGNGLVVLTYIYFKRLKTMTDTYLLNLAVADILFLLTLPFWAYSAAKSWVFGVHFCKLIFAIYKMSFFSGMLLLLCISIDRYVAIVQAVSAHRHRARVLLISKLSCVGIWILATVLSIPELLYSDLQ RSS GEQAMRCSLITEHVEAFITIQVAQMVIGFLVPLLAMSFCYLVIIRTLLQARNFERNKAIKVIIAVVVVFIVFQLPYNGVVLAQTVANFNITSSTCELSKQLNIAYDVTYSLACVRCCVNPFLYAFIGVKFRNDLFKLFKDLGCLSQEQLRQWSSCRHIRRSSMSVEAETTTTFSP Q206D 20110009484ATGGACCTGGGGAAACCAATGAAAAGCGTGCTGGTGGTGGCTCTCCTTGTCATTTTCCAGGTATGCCTGTGTCAAGATGAGGTCACGGACGATTACATCGGAGACAACACCACAGTGGACTACACTTTGTTCGAGTCTTTGTGCTCCAAGAAGGACGTGCGGAACTTTAAAGCCTGGTTCCTCCCTATCATGTACTCCATCATTTGTTTCGTGGGCCTACTGGGCAATGGGCTGGTCGTGTTGACCTATATCTATTTCAAGAGGCTCAAGACCATGACCGATACCTACCTGCTCAACCTGGCGGTGGCAGACATCCTCTTCCTCCTGACCCTTCCCTTCTGGGCCTACAGCGCGGCCAAGTCCTGGGTCTTCGGTGTCCACTTTTGCAAGCTCATCTTTGCCATCTACAAGATGAGCTTCTTCAGTGGCATGCTCCTACTTCTTTGCATCAGCATTGACCGCTACGTGGCCATCGTCCAGGCTGTCTCAGCTCACCGCCACCGTGCCCGCGTCCTTCTCATCAGCAAGCTGTCCTGTGTGGGCATCTGGATACTAGCCACAGTGCTCTCCATCCCAGAGCTCCTGTACAGTGACCTCCAGAGGAGCAGCAGTGAGGATGCGATGCGATGCTCTCTCATCACAGAGCATGTGGAGGCCTTTATCACCATCCAGGTGGCCCAGATGGTGATCGGCTTTCTGGTCCCCCTGCTGGCCATGAGCTTCTGTTACCTTGTCATCATCCGCACCCTGCTCCAGGCACGCAACTTTGAGCGCAACAAGGCCATCAAGGTGATCATCGCTGTGGTCGTGGTCTTCATAGTCTTCCAGCTGCCCTACAATGGGGTGGTCCTGGCCCAGACGGTGGCCAACTTCAACATCACCAGTAGCACCTGTGAGCTCAGTAAGCAACTCAACATCGCCTACGACGTCACCTACAGCCTGGCCTGCGTCCGCTGCTGCGTCAACCCTTTCTTGTACGCCTTCATCGGCGTCAAGTTCCGCAACGATCTCTTCAAGCTCTTCAAGGACCTGGGCTGCCTCAGCCAGGAGCAGCTCCGGCAGTGGTCTTCCTGTCGGCACATCCGGCGCTCCTCCATGAGTGTGGAGGCCGAGACCACCACCACCTTCTCCCCATAGMDLGKPMKSVLVVALLVIFQVCLCQDEVTDDYIGDNTTVDYTLFESLCSKKDVRNFKAWFLPIMYSIICFVGLLGNGLVVLTYIYFKRLKTMTDTYLLNLAVADILFLLTLPFWAYSAAKSWVFGVHFCKLIFAIYKMSFFSGMLLLLCISIDRYVAIVQAVSAHRHRARVLLISKLSCVGIWILATVLSIPELLYSDLQ RSSSE DAMRCSLITEHVEAFITIQVAQMVIGFLVPLLAMSFCYLVIIRTLLQARNFERNKAIKVIIAVVVVFIVFQLPYNGVVLAQTVANFNITSSTCELSKQLNIAYDVTYSLACVRCCVNPFLYAFIGVKFRNDLFKLFKDLGCLSQEQLRQWSSCRHIRRSSMSVEAETTTTFSP A207T 20100171270ATGGACCTGGGGAAACCAATGAAAAGCGTGCTGGTGGTGGCTCTCCTTGTCATTTTCCAGGTATGCCTGTGTCAAGATGAGGTCACGGACGATTACATCGGAGACAACACCACAGTGGACTACACTTTGTTCGAGTCTTTGTGCTCCAAGAAGGACGTGCGGAACTTTAAAGCCTGGTTCCTCCCTATCATGTACTCCATCATTTGTTTCGTGGGCCTACTGGGCAATGGGCTGGTCGTGTTGACCTATATCTATTTCAAGAGGCTCAAGACCATGACCGATACCTACCTGCTCAACCTGGCGGTGGCAGACATCCTCTTCCTCCTGACCCTTCCCTTCTGGGCCTACAGCGCGGCCAAGTCCTGGGTCTTCGGTGTCCACTTTTGCAAGCTCATCTTTGCCATCTACAAGATGAGCTTCTTCAGTGGCATGCTCCTACTTCTTTGCATCAGCATTGACCGCTACGTGGCCATCGTCCAGGCTGTCTCAGCTCACCGCCACCGTGCCCGCGTCCTTCTCATCAGCAAGCTGTCCTGTGTGGGCATCTGGATACTAGCCACAGTGCTCTCCATCCCAGAGCTCCTGTACAGTGACCTCCAGAGGAGCAGCAGTGAGCAAACGATGCGATGCTCTCTCATCACAGAGCATGTGGAGGCCTTTATCACCATCCAGGTGGCCCAGATGGTGATCGGCTTTCTGGTCCCCCTGCTGGCCATGAGCTTCTGTTACCTTGTCATCATCCGCACCCTGCTCCAGGCACGCAACTTTGAGCGCAACAAGGCCATCAAGGTGATCATCGCTGTGGTCGTGGTCTTCATAGTCTTCCAGCTGCCCTACAATGGGGTGGTCCTGGCCCAGACGGTGGCCAACTTCAACATCACCAGTAGCACCTGTGAGCTCAGTAAGCAACTCAACATCGCCTACGACGTCACCTACAGCCTGGCCTGCGTCCGCTGCTGCGTCAACCCTTTCTTGTACGCCTTCATCGGCGTCAAGTTCCGCAACGATCTCTTCAAGCTCTTCAAGGACCTGGGCTGCCTCAGCCAGGAGCAGCTCCGGCAGTGGTCTTCCTGTCGGCACATCCGGCGCTCCTCCATGAGTGTGGAGGCCGAGACCACCACCACCTTCTCCCCATAGMDLGKPMKSVLVVALLVIFQVCLCQDEVTDDYIGDNTTVDYTLFESLCSKKDVRNFKAWFLPIMYSIICFVGLLGNGLVVLTYIYFKRLKTMTDTYLLNLAVADILFLLTLPFWAYSAAKSWVFGVHFCKLIFAIYKMSFFSGMLLLLCISIDRYVAIVQAVSAHRHRARVLLISKLSCVGIWILATVLSIPELLYSDLQ RSSSEQ TMRCSLITEHVEAFITIQVAQMVIGFLVPLLAMSFCYLVIIRTLLQARNFERNKAIKVIIAVVVVFIVFQLPYNGVVLAQTVANFNITSSTCELSKQLNIAYDVTYSLACVRCCVNPFLYAFIGVKFRNDLFKLFKDLGCLSQEQLRQWSSCRHIRRSSMSVEAETTTTFSP M208L 20100171271ATGGACCTGGGGAAACCAATGAAAAGCGTGCTGGTGGTGGCTCTCCTTGTCATTTTCCAGGTATGCCTGTGTCAAGATGAGGTCACGGACGATTACATCGGAGACAACACCACAGTGGACTACACTTTGTTCGAGTCTTTGTGCTCCAAGAAGGACGTGCGGAACTTTAAAGCCTGGTTCCTCCCTATCATGTACTCCATCATTTGTTTCGTGGGCCTACTGGGCAATGGGCTGGTCGTGTTGACCTATATCTATTTCAAGAGGCTCAAGACCATGACCGATACCTACCTGCTCAACCTGGCGGTGGCAGACATCCTCTTCCTCCTGACCCTTCCCTTCTGGGCCTACAGCGCGGCCAAGTCCTGGGTCTTCGGTGTCCACTTTTGCAAGCTCATCTTTGCCATCTACAAGATGAGCTTCTTCAGTGGCATGCTCCTACTTCTTTGCATCAGCATTGACCGCTACGTGGCCATCGTCCAGGCTGTCTCAGCTCACCGCCACCGTGCCCGCGTCCTTCTCATCAGCAAGCTGTCCTGTGTGGGCATCTGGATACTAGCCACAGTGCTCTCCATCCCAGAGCTCCTGTACAGTGACCTCCAGAGGAGCAGCAGTGAGCAAGCGTTGCGATGCTCTCTCATCACAGAGCATGTGGAGGCCTTTATCACCATCCAGGTGGCCCAGATGGTGATCGGCTTTCTGGTCCCCCTGCTGGCCATGAGCTTCTGTTACCTTGTCATCATCCGCACCCTGCTCCAGGCACGCAACTTTGAGCGCAACAAGGCCATCAAGGTGATCATCGCTGTGGTCGTGGTCTTCATAGTCTTCCAGCTGCCCTACAATGGGGTGGTCCTGGCCCAGACGGTGGCCAACTTCAACATCACCAGTAGCACCTGTGAGCTCAGTAAGCAACTCAACATCGCCTACGACGTCACCTACAGCCTGGCCTGCGTCCGCTGCTGCGTCAACCCTTTCTTGTACGCCTTCATCGGCGTCAAGTTCCGCAACGATCTCTTCAAGCTCTTCAAGGACCTGGGCTGCCTCAGCCAGGAGCAGCTCCGGCAGTGGTCTTCCTGTCGGCACATCCGGCGCTCCTCCATGAGTGTGGAGGCCGAGACCACCACCACCTTCTCCCCATAGMDLGKPMKSVLVVALLVIFQVCLCQDEVTDDYIGDNTTVDYTLFESLCSKKDVRNFKAWFLPIMYSIICFVGLLGNGLVVLTYIYFKRLKTMTDTYLLNLAVADILFLLTLPFWAYSAAKSWVFGVHFCKLIFAIYKMSFFSGMLLLLCISIDRYVAIVQAVSAHRHRARVLLISKLSCVGIWILATVLSIPELLYSDLQ RSSSEQA LRCSLITEHVEAFITIQVAQMVIGFLVPLLAMSFCYLVIIRTLLQARNFERNKAIKVIIAVVVVFIVFQLPYNGVVLAQTVANFNITSSTCELSKQLNIAYDVTYSLACVRCCVNPFLYAFIGVKFRNDLFKLFKDLGCLSQEQLRQWSSCRHIRRSSMSVEAETTTTFSP I213V 20100168569ATGGACCTGGGGAAACCAATGAAAAGCGTGCTGGTGGTGGCTCTCCTTGTCATTTTCCAGGTATGCCTGTGTCAAGATGAGGTCACGGACGATTACATCGGAGACAACACCACAGTGGACTACACTTTGTTCGAGTCTTTGTGCTCCAAGAAGGACGTGCGGAACTTTAAAGCCTGGTTCCTCCCTATCATGTACTCCATCATTTGTTTCGTGGGCCTACTGGGCAATGGGCTGGTCGTGTTGACCTATATCTATTTCAAGAGGCTCAAGACCATGACCGATACCTACCTGCTCAACCTGGCGGTGGCAGACATCCTCTTCCTCCTGACCCTTCCCTTCTGGGCCTACAGCGCGGCCAAGTCCTGGGTCTTCGGTGTCCACTTTTGCAAGCTCATCTTTGCCATCTACAAGATGAGCTTCTTCAGTGGCATGCTCCTACTTCTTTGCATCAGCATTGACCGCTACGTGGCCATCGTCCAGGCTGTCTCAGCTCACCGCCACCGTGCCCGCGTCCTTCTCATCAGCAAGCTGTCCTGTGTGGGCATCTGGATACTAGCCACAGTGCTCTCCATCCCAGAGCTCCTGTACAGTGACCTCCAGAGGAGCAGCAGTGAGCAAGCGATGCGATGCTCTCTCGTCACAGAGCATGTGGAGGCCTTTATCACCATCCAGGTGGCCCAGATGGTGATCGGCTTTCTGGTCCCCCTGCTGGCCATGAGCTTCTGTTACCTTGTCATCATCCGCACCCTGCTCCAGGCACGCAACTTTGAGCGCAACAAGGCCATCAAGGTGATCATCGCTGTGGTCGTGGTCTTCATAGTCTTCCAGCTGCCCTACAATGGGGTGGTCCTGGCCCAGACGGTGGCCAACTTCAACATCACCAGTAGCACCTGTGAGCTCAGTAAGCAACTCAACATCGCCTACGACGTCACCTACAGCCTGGCCTGCGTCCGCTGCTGCGTCAACCCTTTCTTGTACGCCTTCATCGGCGTCAAGTTCCGCAACGATCTCTTCAAGCTCTTCAAGGACCTGGGCTGCCTCAGCCAGGAGCAGCTCCGGCAGTGGTCTTCCTGTCGGCACATCCGGCGCTCCTCCATGAGTGTGGAGGCCGAGACCACCACCACCTTCTCCCCATAGMDLGKPMKSVLVVALLVIFQVCLCQDEVTDDYIGDNTTVDYTLFESLCSKKDVRNFKAWFLPIMYSIICFVGLLGNGLVVLTYIYFKRLKTMTDTYLLNLAVADILFLLTLPFWAYSAAKSWVFGVHFCKLIFAIYKMSFFSGMLLLLCISIDRYVAIVQAVSAHRHRARVLLISKLSCVGIWILATVLSIPELLYSDLQ RSSSEQAMRCSL VTEHVEAFITIQVAQMVIGFLVPLLAMSFCYLVIIRTLLQARNFERNKAIKVIIAVVVVFIVFQLPYNGVVLAQTVANFNITSSTCELSKQLNIAYDVTYSLACVRCCVNPFLYAFIGVKFRNDLFKLFKDLGCLSQEQLRQWSSCRHIRRSSMSVEAETTTTFSP T214S 20100168568ATGGACCTGGGGAAACCAATGAAAAGCGTGCTGGTGGTGGCTCTCCTTGTCATTTTCCAGGTATGCCTGTGTCAAGATGAGGTCACGGACGATTACATCGGAGACAACACCACAGTGGACTACACTTTGTTCGAGTCTTTGTGCTCCAAGAAGGACGTGCGGAACTTTAAAGCCTGGTTCCTCCCTATCATGTACTCCATCATTTGTTTCGTGGGCCTACTGGGCAATGGGCTGGTCGTGTTGACCTATATCTATTTCAAGAGGCTCAAGACCATGACCGATACCTACCTGCTCAACCTGGCGGTGGCAGACATCCTCTTCCTCCTGACCCTTCCCTTCTGGGCCTACAGCGCGGCCAAGTCCTGGGTCTTCGGTGTCCACTTTTGCAAGCTCATCTTTGCCATCTACAAGATGAGCTTCTTCAGTGGCATGCTCCTACTTCTTTGCATCAGCATTGACCGCTACGTGGCCATCGTCCAGGCTGTCTCAGCTCACCGCCACCGTGCCCGCGTCCTTCTCATCAGCAAGCTGTCCTGTGTGGGCATCTGGATACTAGCCACAGTGCTCTCCATCCCAGAGCTCCTGTACAGTGACCTCCAGAGGAGCAGCAGTGAGCAAGCGATGCGATGCTCTCTCATCTCAGAGCATGTGGAGGCCTTTATCACCATCCAGGTGGCCCAGATGGTGATCGGCTTTCTGGTCCCCCTGCTGGCCATGAGCTTCTGTTACCTTGTCATCATCCGCACCCTGCTCCAGGCACGCAACTTTGAGCGCAACAAGGCCATCAAGGTGATCATCGCTGTGGTCGTGGTCTTCATAGTCTTCCAGCTGCCCTACAATGGGGTGGTCCTGGCCCAGACGGTGGCCAACTTCAACATCACCAGTAGCACCTGTGAGCTCAGTAAGCAACTCAACATCGCCTACGACGTCACCTACAGCCTGGCCTGCGTCCGCTGCTGCGTCAACCCTTTCTTGTACGCCTTCATCGGCGTCAAGTTCCGCAACGATCTCTTCAAGCTCTTCAAGGACCTGGGCTGCCTCAGCCAGGAGCAGCTCCGGCAGTGGTCTTCCTGTCGGCACATCCGGCGCTCCTCCATGAGTGTGGAGGCCGAGACCACCACCACCTTCTCCCCATAGMDLGKPMKSVLVVALLVIFQVCLCQDEVTDDYIGDNTTVDYTLFESLCSKKDVRNFKAWFLPIMYSIICFVGLLGNGLVVLTYIYFKRLKTMTDTYLLNLAVADILFLLTLPFWAYSAAKSWVFGVHFCKLIFAIYKMSFFSGMLLLLCISIDRYVAIVQAVSAHRHRARVLLISKLSCVGIWILATVLSIPELLYSDLQ RSSSEQAMRCSLI SEHVEAFITIQVAQMVIGFLVPLLAMSFCYLVIIRTLLQARNFERNKAIKVIIAVVVVFIVFQLPYNGVVLAQTVANFNITSSTCELSKQLNIAYDVTYSLACVRCCVNPFLYAFIGVKFRNDLFKLFKDLGCLSQEQLRQWSSCRHIRRSSMSVEAETTTTFSP E215A 20100168567ATGGACCTGGGGAAACCAATGAAAAGCGTGCTGGTGGTGGCTCTCCTTGTCATTTTCCAGGTATGCCTGTGTCAAGATGAGGTCACGGACGATTACATCGGAGACAACACCACAGTGGACTACACTTTGTTCGAGTCTTTGTGCTCCAAGAAGGACGTGCGGAACTTTAAAGCCTGGTTCCTCCCTATCATGTACTCCATCATTTGTTTCGTGGGCCTACTGGGCAATGGGCTGGTCGTGTTGACCTATATCTATTTCAAGAGGCTCAAGACCATGACCGATACCTACCTGCTCAACCTGGCGGTGGCAGACATCCTCTTCCTCCTGACCCTTCCCTTCTGGGCCTACAGCGCGGCCAAGTCCTGGGTCTTCGGTGTCCACTTTTGCAAGCTCATCTTTGCCATCTACAAGATGAGCTTCTTCAGTGGCATGCTCCTACTTCTTTGCATCAGCATTGACCGCTACGTGGCCATCGTCCAGGCTGTCTCAGCTCACCGCCACCGTGCCCGCGTCCTTCTCATCAGCAAGCTGTCCTGTGTGGGCATCTGGATACTAGCCACAGTGCTCTCCATCCCAGAGCTCCTGTACAGTGACCTCCAGAGGAGCAGCAGTGAGCAAGCGATGCGATGCTCTCTCATCACAGCGCATGTGGAGGCCTTTATCACCATCCAGGTGGCCCAGATGGTGATCGGCTTTCTGGTCCCCCTGCTGGCCATGAGCTTCTGTTACCTTGTCATCATCCGCACCCTGCTCCAGGCACGCAACTTTGAGCGCAACAAGGCCATCAAGGTGATCATCGCTGTGGTCGTGGTCTTCATAGTCTTCCAGCTGCCCTACAATGGGGTGGTCCTGGCCCAGACGGTGGCCAACTTCAACATCACCAGTAGCACCTGTGAGCTCAGTAAGCAACTCAACATCGCCTACGACGTCACCTACAGCCTGGCCTGCGTCCGCTGCTGCGTCAACCCTTTCTTGTACGCCTTCATCGGCGTCAAGTTCCGCAACGATCTCTTCAAGCTCTTCAAGGACCTGGGCTGCCTCAGCCAGGAGCAGCTCCGGCAGTGGTCTTCCTGTCGGCACATCCGGCGCTCCTCCATGAGTGTGGAGGCCGAGACCACCACCACCTTCTCCCCATAGMDLGKPMKSVLVVALLVIFQVCLCQDEVTDDYIGDNTTVDYTLFESLCSKKDVRNFKAWFLPIMYSIICFVGLLGNGLVVLTYIYFKRLKTMTDTYLLNLAVADILFLLTLPFWAYSAAKSWVFGVHFCKLIFAIYKMSFFSGMLLLLCISIDRYVAIVQAVSAHRHRARVLLISKLSCVGIWILATVLSIPELLYSDLQ RSSSEQAMRCSLIT AHVEAFITIQVAQMVIGFLVPLLAMSFCYLVIIRTLLQARNFERNKAIKVIIAVVVVFIVFQLPYNGVVLAQTVANFNITSSTCELSKQLNIAYDVTYSLACVRCCVNPFLYAFIGVKFRNDLFKLFKDLGCLSQEQLRQWSSCRHIRRSSMSVEAETTTTFSP H216Q 20110009485ATGGACCTGGGGAAACCAATGAAAAGCGTGCTGGTGGTGGCTCTCCTTGTCATTTTCCAGGTATGCCTGTGTCAAGATGAGGTCACGGACGATTACATCGGAGACAACACCACAGTGGACTACACTTTGTTCGAGTCTTTGTGCTCCAAGAAGGACGTGCGGAACTTTAAAGCCTGGTTCCTCCCTATCATGTACTCCATCATTTGTTTCGTGGGCCTACTGGGCAATGGGCTGGTCGTGTTGACCTATATCTATTTCAAGAGGCTCAAGACCATGACCGATACCTACCTGCTCAACCTGGCGGTGGCAGACATCCTCTTCCTCCTGACCCTTCCCTTCTGGGCCTACAGCGCGGCCAAGTCCTGGGTCTTCGGTGTCCACTTTTGCAAGCTCATCTTTGCCATCTACAAGATGAGCTTCTTCAGTGGCATGCTCCTACTTCTTTGCATCAGCATTGACCGCTACGTGGCCATCGTCCAGGCTGTCTCAGCTCACCGCCACCGTGCCCGCGTCCTTCTCATCAGCAAGCTGTCCTGTGTGGGCATCTGGATACTAGCCACAGTGCTCTCCATCCCAGAGCTCCTGTACAGTGACCTCCAGAGGAGCAGCAGTGAGCAAGCGATGCGATGCTCTCTCATCACAGAGCAGGTGGAGGCCTTTATCACCATCCAGGTGGCCCAGATGGTGATCGGCTTTCTGGTCCCCCTGCTGGCCATGAGCTTCTGTTACCTTGTCATCATCCGCACCCTGCTCCAGGCACGCAACTTTGAGCGCAACAAGGCCATCAAGGTGATCATCGCTGTGGTCGTGGTCTTCATAGTCTTCCAGCTGCCCTACAATGGGGTGGTCCTGGCCCAGACGGTGGCCAACTTCAACATCACCAGTAGCACCTGTGAGCTCAGTAAGCAACTCAACATCGCCTACGACGTCACCTACAGCCTGGCCTGCGTCCGCTGCTGCGTCAACCCTTTCTTGTACGCCTTCATCGGCGTCAAGTTCCGCAACGATCTCTTCAAGCTCTTCAAGGACCTGGGCTGCCTCAGCCAGGAGCAGCTCCGGCAGTGGTCTTCCTGTCGGCACATCCGGCGCTCCTCCATGAGTGTGGAGGCCGAGACCACCACCACCTTCTCCCCATAGMDLGKPMKSVLVVALLVIFQVCLCQDEVTDDYIGDNTTVDYTLFESLCSKKDVRNFKAWFLPIMYSIICFVGLLGNGLVVLTYIYFKRLKTMTDTYLLNLAVADILFLLTLPFWAYSAAKSWVFGVHFCKLIFAIYKMSFFSGMLLLLCISIDRYVAIVQAVSAHRHRARVLLISKLSCVGIWILATVLSIPELLYSDLQ RSSSEQAMRCSLITE QVEAFITIQVAQMVIGFLVPLLAMSFCYLVIIRTLLQARNFERNKAIKVIIAVVVVFIVFQLPYNGVVLAQTVANFNITSSTCELSKQLNIAYDVTYSLACVRCCVNPFLYAFIGVKFRNDLFKLFKDLGCLSQEQLRQWSSCRHIRRSSMSVEAETTTTFSP S295N 20110018205ATGGACCTGGGGAAACCAATGAAAAGCGTGCTGGTGGTGGCTCTCCTTGTCATTTTCCAGGTATGCCTGTGTCAAGATGAGGTCACGGACGATTACATCGGAGACAACACCACAGTGGACTACACTTTGTTCGAGTCTTTGTGCTCCAAGAAGGACGTGCGGAACTTTAAAGCCTGGTTCCTCCCTATCATGTACTCCATCATTTGTTTCGTGGGCCTACTGGGCAATGGGCTGGTCGTGTTGACCTATATCTATTTCAAGAGGCTCAAGACCATGACCGATACCTACCTGCTCAACCTGGCGGTGGCAGACATCCTCTTCCTCCTGACCCTTCCCTTCTGGGCCTACAGCGCGGCCAAGTCCTGGGTCTTCGGTGTCCACTTTTGCAAGCTCATCTTTGCCATCTACAAGATGAGCTTCTTCAGTGGCATGCTCCTACTTCTTTGCATCAGCATTGACCGCTACGTGGCCATCGTCCAGGCTGTCTCAGCTCACCGCCACCGTGCCCGCGTCCTTCTCATCAGCAAGCTGTCCTGTGTGGGCATCTGGATACTAGCCACAGTGCTCTCCATCCCAGAGCTCCTGTACAGTGACCTCCAGAGGAGCAGCAGTGAGCAAGCGATGCGATGCTCTCTCATCACAGAGCATGTGGAGGCCTTTATCACCATCCAGGTGGCCCAGATGGTGATCGGCTTTCTGGTCCCCCTGCTGGCCATGAGCTTCTGTTACCTTGTCATCATCCGCACCCTGCTCCAGGCACGCAACTTTGAGCGCAACAAGGCCATCAAGGTGATCATCGCTGTGGTCGTGGTCTTCATAGTCTTCCAGCTGCCCTACAATGGGGTGGTCCTGGCCCAGACGGTGGCCAACTTCAACATCACCAATAGCACCTGTGAGCTCAGTAAGCAACTCAACATCGCCTACGACGTCACCTACAGCCTGGCCTGCGTCCGCTGCTGCGTCAACCCTTTCTTGTACGCCTTCATCGGCGTCAAGTTCCGCAACGATCTCTTCAAGCTCTTCAAGGACCTGGGCTGCCTCAGCCAGGAGCAGCTCCGGCAGTGGTCTTCCTGTCGGCACATCCGGCGCTCCTCCATGAGTGTGGAGGCCGAGACCACCACCACCTTCTCCCCATAGMDLGKPMKSVLVVALLVIFQVCLCQDEVTDDYIGDNTTVDYTLFESLCSKYKDVRNFKAWFLPIMSIICFVGLLGNGLVVLTYIYFKRLKTMTDTYLLNLAVADILFLLTLPFWAYSAAKSWVFGVHFCKLIFAIYKMSFFSGMLLLLCISIDRYVAIVQAVSAHRHRARVLLISKLSCVGIWILATVLSIPELLYSDLQRSSSEQAMRCSLITEHVEAFITIQVAQMVIGFLVPLLAMSFCYLVIIRTLLQARNFERNKAIKVIIAVVVVFIVFQLPYNGVVLAQTVANFNIT N STCELSKQLNIAYDVTYSLACVRCCVNPFLYAFIGVKFRNDLFKLFKDLGCLSQEQLRQWSSCRHIRRSSMSVEAETTTTFSP T297S 20110018203ATGGACCTGGGGAAACCAATGAAAAGCGTGCTGGTGGTGGCTCTCCTTGTCATTTTCCAGGTATGCCTGTGTCAAGATGAGGTCACGGACGATTACATCGGAGACAACACCACAGTGGACTACACTTTGTTCGAGTCTTTGTGCTCCAAGAAGGACGTGCGGAACTTTAAAGCCTGGTTCCTCCCTATCATGTACTCCATCATTTGTTTCGTGGGCCTACTGGGCAATGGGCTGGTCGTGTTGACCTATATCTATTTCAAGAGGCTCAAGACCATGACCGATACCTACCTGCTCAACCTGGCGGTGGCAGACATCCTCTTCCTCCTGACCCTTCCCTTCTGGGCCTACAGCGCGGCCAAGTCCTGGGTCTTCGGTGTCCACTTTTGCAAGCTCATCTTTGCCATCTACAAGATGAGCTTCTTCAGTGGCATGCTCCTACTTCTTTGCATCAGCATTGACCGCTACGTGGCCATCGTCCAGGCTGTCTCAGCTCACCGCCACCGTGCCCGCGTCCTTCTCATCAGCAAGCTGTCCTGTGTGGGCATCTGGATACTAGCCACAGTGCTCTCCATCCCAGAGCTCCTGTACAGTGACCTCCAGAGGAGCAGCAGTGAGCAAGCGATGCGATGCTCTCTCATCACAGAGCATGTGGAGGCCTTTATCACCATCCAGGTGGCCCAGATGGTGATCGGCTTTCTGGTCCCCCTGCTGGCCATGAGCTTCTGTTACCTTGTCATCATCCGCACCCTGCTCCAGGCACGCAACTTTGAGCGCAACAAGGCCATCAAGGTGATCATCGCTGTGGTCGTGGTCTTCATAGTCTTCCAGCTGCCCTACAATGGGGTGGTCCTGGCCCAGACGGTGGCCAACTTCAACATCACCAGTAGCAGCTGTGAGCTCAGTAAGCAACTCAACATCGCCTACGACGTCACCTACAGCCTGGCCTGCGTCCGCTGCTGCGTCAACCCTTTCTTGTACGCCTTCATCGGCGTCAAGTTCCGCAACGATCTCTTCAAGCTCTTCAAGGACCTGGGCTGCCTCAGCCAGGAGCAGCTCCGGCAGTGGTCTTCCTGTCGGCACATCCGGCGCTCCTCCATGAGTGTGGAGGCCGAGACCACCACCACCTTCTCCCCATAGMDLGKPMKSVLVVALLVIFQVCLCQDEVTDDYIGDNTTVDYTLFESLCSKKDVRNFKAWFLPIMYSIICFVGLLGNGLVVLTYIYFKRLKTMTDTYLLNLAVADILFLLTLPFWAYSAAKSWVFGVHFCKLIFAIYKMSFFSGMLLLLCISIDRYVAIVQAVSAHRHRARVLLISKLSCVGIWILATVLSIPELLYSDLQRSSSEQAMRCSLITEHVEAFITIQVAQMVIGFLVPLLAMSFCYLVIIRTLLQARNFERNKAIKVIIAVVVVFIVFQLPYNGVVLAQTVANFNITSS S CELSKQLNIAYDVTYSLACVRCCVNPFLYAFIGVKFRNDLFKLFKDLGCLSQEQLRQWSSCRHIRRSSMSVEAETTTTFSP L300T 20110018204ATGGACCTGGGGAAACCAATGAAAAGCGTGCTGGTGGTGGCTCTCCTTGTCATTTTCCAGGTATGCCTGTGTCAAGATGAGGTCACGGACGATTACATCGGAGACAACACCACAGTGGACTACACTTTGTTCGAGTCTTTGTGCTCCAAGAAGGACGTGCGGAACTTTAAAGCCTGGTTCCTCCCTATCATGTACTCCATCATTTGTTTCGTGGGCCTACTGGGCAATGGGCTGGTCGTGTTGACCTATATCTATTTCAAGAGGCTCAAGACCATGACCGATACCTACCTGCTCAACCTGGCGGTGGCAGACATCCTCTTCCTCCTGACCCTTCCCTTCTGGGCCTACAGCGCGGCCAAGTCCTGGGTCTTCGGTGTCCACTTTTGCAAGCTCATCTTTGCCATCTACAAGATGAGCTTCTTCAGTGGCATGCTCCTACTTCTTTGCATCAGCATTGACCGCTACGTGGCCATCGTCCAGGCTGTCTCAGCTCACCGCCACCGTGCCCGCGTCCTTCTCATCAGCAAGCTGTCCTGTGTGGGCATCTGGATACTAGCCACAGTGCTCTCCATCCCAGAGCTCCTGTACAGTGACCTCCAGAGGAGCAGCAGTGAGCAAGCGATGCGATGCTCTCTCATCACAGAGCATGTGGAGGCCTTTATCACCATCCAGGTGGCCCAGATGGTGATCGGCTTTCTGGTCCCCCTGCTGGCCATGAGCTTCTGTTACCTTGTCATCATCCGCACCCTGCTCCAGGCACGCAACTTTGAGCGCAACAAGGCCATCAAGGTGATCATCGCTGTGGTCGTGGTCTTCATAGTCTTCCAGCTGCCCTACAATGGGGTGGTCCTGGCCCAGACGGTGGCCAACTTCAACATCACCAGTAGCACCTGTGAGACCAGTAAGCAACTCAACATCGCCTACGACGTCACCTACAGCCTGGCCTGCGTCCGCTGCTGCGTCAACCCTTTCTTGTACGCCTTCATCGGCGTCAAGTTCCGCAACGATCTCTTCAAGCTCTTCAAGGACCTGGGCTGCCTCAGCCAGGAGCAGCTCCGGCAGTGGTCTTCCTGTCGGCACATCCGGCGCTCCTCCATGAGTGTGGAGGCCGAGACCACCACCACCTTCTCCCCATAGMDLGKPMKSVLVVALLVIFQVCLCQDEVTDDYIGDNTTVDYTLFESLCSKKDVRNFKAWFLPIMYSIICFVGLLGNGLVVLTYIYFKRLKTMTDTYLLNLAVADILFLLTLPFWAYSAAKSWVFGVHFCKLIFAIYKMSFFSGMLLLLCISIDRYVAIVQAVSAHRHRARVLLISKLSCVGIWILATVLSIPELLYSDLQRSSSEQAMRCSLITEHVEAFITIQVAQMVIGFLVPLLAMSFCYLVIIRTLLQARNFERNKAIKVIIAVVVVFIVFQLPYNGVVLAQTVANFNITSSTCE TSKQLNIAYDVTYSLACVRCCVNPFLYAFIGVKFRNDLFKLFKDLGCLSQEQLRQWSSCRHIRRSSMSVEAETTTTFSP*293T cells were transfected with each of the 22 constructs using FugeneHD Transfection Reagent (Cat#: 04709705001) (Roche Applied Sciences,Indianapolis, Ind.), according to manufacturer's protocol. DNA to FugeneHD ratio used was 1:3. Controls for the transfection were pcDNA3.1Neo-hCCR7 (20100121357) listed above, and pcDNA3.1 Neo-mouseCCR7(20060298628):

ATGGACCCAGGGAAACCCAGGAAAAACGTGCTGGTGGTGGCTCTCCTTGTCATTTTCCAGGTGTGCTTCTGCCAAGATGAGGTCACCGATGACTACATCGGCGAGAATACCACGGTGGACTACACCCTGTACGAGTCGGTGTGCTTCAAGAAGGATGTGCGGAACTTTAAGGCCTGGTTCCTGCCTCTCATGTATTCTGTCATCTGCTTCGTGGGCCTGCTCGGCAACGGGCTGGTGATACTGACGTACATCTATTTCAAGAGGCTCAAGACCATGACGGATACCTACCTGCTCAACCTGGCCGTGGCAGACATCCTTTTCCTCCTAATTCTTCCCTTCTGGGCCTACAGCGAAGCCAAGTCCTGGATCTTTGGCGTCTACCTGTGTAAGGGCATCTTTGGCATCTATAAGTTAAGCTTCTTCAGCGGGATGCTGCTGCTCCTATGCATCAGCATTGACCGCTACGTAGCCATCGTCCAGGCCGTGTCGGCTCATCGCCACCGCGCCCGCGTGCTTCTCATCAGCAAGCTGTCCTGTGTGGGCATCTGGATGCTGGCCCTCTTCCTCTCCATCCCGGAGCTGCTCTACAGCGGCCTCCAGAAGAACAGCGGCGAGGACACGCTGAGATGCTCACTGGTCAGTGCCCAAGTGGAGGCCTTGATCACCATCCAAGTGGCCCAGATGGTTTTTGGGTTCCTAGTGCCTATGCTGGCTATGAGTTTCTGCTACCTCATTATCATCCGTACCTTGCTCCAGGCACGCAACTTTGAGCGGAACAAGGCCATCAAGGTGATCATTGCCGTGGTGGTAGTCTTCATAGTCTTCCAGCTGCCCTACAATGGGGTGGTCCTGGCTCAGACGGTGGCCAACTTCAACATCACCAATAGCAGCTGCGAAACCAGCAAGCAGCTCAACATTGCCTATGACGTCACCTACAGCCTGGCCTCCGTCCGCTGCTGCGTCAACCCTTTCTTGTATGCCTTCATCGGCGTCAAGTTCCGCAGCGACCTCTTCAAGCTCTTCAAGGACTTGGGCTGCCTCAGCCAGGAACGGCTCCGGCACTGGTCTTCCTGCCGGCATGTACGGAACGCGTCGGTGAGCATGGAGGCGGAGACCACCACAACCTTCTCCCCGTAGMDPGKPRKNVLVVALLVIFQVCFCQDEVTDDYIGENTTVDYTLYESVCFKKDVRNFKAWFLPLMYSVICFVGLLGNGLVILTYIYFKRLKTMTDTYLLNLAVADILFLLILPFWAYSEAKSWIFGVYLCKGIFGIYKLSFFSGMLLLLCISIDRYVAIVQAVSAHRHRARVLLISKLSCVGIWMLALFLSIPELLYSGLQKNSGEDTLRCSLVSAQVEALITIQVAQMVFGFLVPMLAMSFCYLIIIRTLLQARNFERNKAIKVIIAVVVVFIVFQLPYNGVVLAQTVANFNITNSSCETSKQLNIAYDVTYSLASVRCCVNPFLYAFIGVKFRSDLFKLFKDLGCLSQERLRHWSSCRHVRNASVSMEAETTTTFSP

After 48 hours, transfected cells were harvested and washed with PBS+5%FBS two times. Cells were counted using the Nexcelom Cell Counter(Nexcelom Bioscience, Lawrence, Mass.), and 250,000 cells per well wereplated in a 96 well round bottom plate. Cells transfected with eachconstruct were stained in duplicate as follows: unstained control, 6B4.1primary Ab followed by Goat anti-human-PE secondary Ab, 6B5.1 primary Abfollowed by Goat anti-human-PE secondary Ab, mAb197 primary Ab (R&DSystems, Minneapolis, Minn.) followed by Goat anti-mouse-PE secondaryAb, and the controls of secondary Ab Goat anti-mouse-PE only and Goatanti-human-PE only. The cells were visualized by flow cytometry and geomeans were generated and analyzed.

FIG. 5 shows that mAb197 showed lower binding, as compared to 6B4.1 and6B5.1, to the CDR construct having the F44Y mutation, demonstrating thatantibodies 6B4.1 and 6B5.1 each bound to an epitope different than thatof mAb197. All three antibodies bound to the D35 variant about as wellas each bound to wild-type human CCR7, less well to the L47V variant,and better to the S49F variant. Of these antibodies, only mAb197 boundto wild-type murine CCR7.

FIG. 6 shows that no obvious differences occurred in binding to variantswithin ECL1. Each of the three antibodies bound roughly as well to eachmutant as it bound to wild-type human CCR7.

FIG. 7 shows that mAb197 showed less of a reduction in binding to theS202N, S204G, and A207T variants of ECL2 (as compared to its binding towild-type human CCR7) than the reduction showed by either 6B.4 or 6B.5,although all three antibodies bound less well to these variants, and tothe R201K and M208L variants, than they bound to wild-type human CCR7.

FIG. 8 shows that all three antibodies bound about as well to each ofthe tested ECL3 variants as it bound to wild-type human CCR7. Again,only mAb197 bound to the wild-type murine CCR7 receptor.

Reciprocal constructs were made in which a wild-type murine CCR7sequence was mutated to replace certain of its amino acid residues withthe residue found at the homologous position in wild-type human CCR7.

The following mutations were made: Y44F, V47L, K201R, N202S, G204S,T207A, L208M. These amino acid changes were used in the followingcombinations as individual constructs:

1) Y44F and V47L mutations

2) K201R/N202S/G204S/T207A/L208M

3) All of the above: Y44F/V47L/K201R/N202S/G204S/T207A/L208M

The following oligos were made:

Y44F_V47L sense:  ACGGTGGACTACACCCTGTTCGAGTCGTTGTGCTTCAAY44F_V47L_antisense:  TTGAAGCACAACGACTCGAACAGGGTGTAGTCCACCGTK201R_N202S_G204S_T207A_L208M sense:CAGCGGCCTCCAGAGGAGCAGCAGCGAGGACGCGATGAGATGCTCK201R_N202S_G204S_T207A_L208M antisense:GAGCATCTCATCGCGTCCTCGCTGCTGCTCCTCTGGAGGCCGCTG

The oligos were diluted to 50 ng/l concentration. PCR reactions were setup using 100 ng template DNA pcDNA3.1 Neo-mCCR7 (20060298628). For eachindividual mutation, a PCR product was generated using a QuikChangeMulti Site-Site Directed Mutagenesis Kit (Cat#200531) (Stratagene, LaJolla, Calif.) according to manufacturer's instructions. The resultingPCR products were DpnI digested and then transformed into Top 10chemically competent cells (Invitrogen, Grand Island, N.Y.). Individualcolonies were picked for each construct and sequenced. Clones with thecorrect sequences were scaled up and re-sequenced. The final clone DNAsequences and translated protein sequences follow:

Y44F and V47L construct 20110094675 (“YV”):ATGGACCCAGGGAAACCCAGGAAAAACGTGCTGGTGGTGGCTCTCCTTGTCATTTTCCAGGTGTGCTTCTGCCAAGATGAGGTCACCGATGACTACATCGGCGAGAATACCACGGTGGACTACACCCTGTTCGAGTCGTTGTGCTTCAAGAAGGATGTGCGGAACTTTAAGGCCTGGTTCCTGCCTCTCATGTATTCTGTCATCTGCTTCGTGGGCCTGCTCGGCAACGGGCTGGTGATACTGACGTACATCTATTTCAAGAGGCTCAAGACCATGACGGATACCTACCTGCTCAACCTGGCCGTGGCAGACATCCTTTTCCTCCTAATTCTTCCCTTCTGGGCCTACAGCGAAGCCAAGTCCTGGATCTTTGGCGTCTACCTGTGTAAGGGCATCTTTGGCATCTATAAGTTAAGCTTCTTCAGCGGGATGCTGCTGCTCCTATGCATCAGCATTGACCGCTACGTAGCCATCGTCCAGGCCGTGTCGGCTCATCGCCACCGCGCCCGCGTGCTTCTCATCAGCAAGCTGTCCTGTGTGGGCATCTGGATGCTGGCCCTCTTCCTCTCCATCCCGGAGCTGCTCTACAGCGGCCTCCAGAAGAACAGCGGCGAGGACACGCTGAGATGCTCACTGGTCAGTGCCCAAGTGGAGGCCTTGATCACCATCCAAGTGGCCCAGATGGTTTTTGGGTTCCTAGTGCCTATGCTGGCTATGAGTTTCTGCTACCTCATTATCATCCGTACCTTGCTCCAGGCACGCAACTTTGAGCGGAACAAGGCCATCAAGGTGATCATTGCCGTGGTGGTAGTCTTCATAGTCTTCCAGCTGCCCTACAATGGGGTGGTCCTGGCTCAGACGGTGGCCAACTTCAACATCACCAATAGCAGCTGCGAAACCAGCAAGCAGCTCAACATTGCCTATGACGTCACCTACAGCCTGGCCTCCGTCCGCTGCTGCGTCAACCCTTTCTTGTATGCCTTCATCGGCGTCAAGTTCCGCAGCGACCTCTTCAAGCTCTTCAAGGACTTGGGCTGCCTCAGCCAGGAACGGCTCCGGCACTGGTCTTCCTGCCGGCATGTACGGAACGCGTCGGTGAGCATGGAGGCGGAGACCACCACAACCTT CTCCCCGTAGMDPGKPRKNVLVVALLVIFQVCFCQDEVTDDYIGENTTVDYTLFESLCFKKDVRNFKAWFLPLMYSVICFVGLLGNGLVILTYIYFKRLKTMTDTYLLNLAVADILFLLILPFWAYSEAKSWIFGVYLCKGIFGIYKLSFFSGMLLLLCISIDRYVAIVQAVSAHRHRARVLLISKLSCVGIWMLALFLSIPELLYSGLQKNSGEDTLRCSLVSAQVEALITIQVAQMVFGFLVPMLAMSFCYLIIIRTLLQARNFERNKAIKVIIAVVVVFIVFQLPYNGVVLAQTVANFNITNSSCETSKQLNIAYDVTYSLASVRCCVNPFLYAFIGVKFRSDLFKLFKDLGCLSQERLRHWSSCRHVRNASVSMEAETTTTFSPK201R/N202S/G204S/T207A/L208M construct  20110094673 (“KNGTL”):ATGGACCCAGGGAAACCCAGGAAAAACGTGCTGGTGGTGGCTCTCCTTGTCATTTTCCAGGTGTGCTTCTGCCAAGATGAGGTCACCGATGACTACATCGGCGAGAATACCACGGTGGACTACACCCTGTACGAGTCGGTGTGCTTCAAGAAGGATGTGCGGAACTTTAAGGCCTGGTTCCTGCCTCTCATGTATTCTGTCATCTGCTTCGTGGGCCTGCTCGGCAACGGGCTGGTGATACTGACGTACATCTATTTCAAGAGGCTCAAGACCATGACGGATACCTACCTGCTCAACCTGGCCGTGGCAGACATCCTTTTCCTCCTAATTCTTCCCTTCTGGGCCTACAGCGAAGCCAAGTCCTGGATCTTTGGCGTCTACCTGTGTAAGGGCATCTTTGGCATCTATAAGTTAAGCTTCTTCAGCGGGATGCTGCTGCTCCTATGCATCAGCATTGACCGCTACGTAGCCATCGTCCAGGCCGTGTCGGCTCATCGCCACCGCGCCCGCGTGCTTCTCATCAGCAAGCTGTCCTGTGTGGGCATCTGGATGCTGGCCCTCTTCCTCTCCATCCCGGAGCTGCTCTACAGCGGCCTCCAGAGGAGCAGCAGCGAGGACGCGATGAGATGCTCACTGGTCAGTGCCCAAGTGGAGGCCTTGATCACCATCCAAGTGGCCCAGATGGTTTTTGGGTTCCTAGTGCCTATGCTGGCTATGAGTTTCTGCTACCTCATTATCATCCGTACCTTGCTCCAGGCACGCAACTTTGAGCGGAACAAGGCCATCAAGGTGATCATTGCCGTGGTGGTAGTCTTCATAGTCTTCCAGCTGCCCTACAATGGGGTGGTCCTGGCTCAGACGGTGGCCAACTTCAACATCACCAATAGCAGCTGCGAAACCAGCAAGCAGCTCAACATTGCCTATGACGTCACCTACAGCCTGGCCTCCGTCCGCTGCTGCGTCAACCCTTTCTTGTATGCCTTCATCGGCGTCAAGTTCCGCAGCGACCTCTTCAAGCTCTTCAAGGACTTGGGCTGCCTCAGCCAGGAACGGCTCCGGCACTGGTCTTCCTGCCGGCATGTACGGAACGCGTCGGTGAGCATGGAGGCGGAGACCACCACAACCTT CTCCCCGTAGMDPGKPRKNVLVVALLVIFQVCFCQDEVTDDYIGENTTVDYTLYESVCFKKDVRNFKAWFLPLMYSVICFVGLLGNGLVILTYIYFKRLKTMTDTYLLNLAVADILFLLILPFWAYSEAKSWIFGVYLCKGIFGIYKLSFFSGMLLLLCISIDRYVAIVQAVSAHRHRARVLLISKLSCVGIWMLALFLSIPELLYSGLQRSSSEDAMRCSLVSAQVEALITIQVAQMVFGFLVPMLAMSFCYLIIIRTLLQARNFERNKAIKVIIAVVVVFIVFQLPYNGVVLAQTVANFNITNSSCETSKQLNIAYDVTYSLASVRCCVNPFLYAFIGVKFRSDLFKLFKDLGCLSQERLRHWSSCRHVRNASVSMEAETTTTFSP

Using construct 20110094673, another round of QuikChange Site directedmutagenesis was run using the following oligos in order to get all 7mutations in one construct:

Y44F_V47L sense: ACGGTGGACTACACCCTGTTCGAGTCGTTGTGCTTCAAY44F_V47L_antisense: TTGAAGCACAACGACTCGAACAGGGTGTAGTCCACCGT

Y44F/V47L/K201R/N202S/G204S/T207A/L208M construct 20110105423 (“YVKNGTL”):ATGGACCCAGGGAAACCCAGGAAAAACGTGCTGGTGGTGGCTCTCCTTGTCATTTTCCAGGTGTGCTTCTGCCAAGATGAGGTCACCGATGACTACATCGGCGAGAATACCACGGTGGACTACACCCTGTTCGAGTCGTTGTGCTTCAAGAAGGATGTGCGGAACTTTAAGGCCTGGTTCCTGCCTCTCATGTATTCTGTCATCTGCTTCGTGGGCCTGCTCGGCAACGGGCTGGTGATACTGACGTACATCTATTTCAAGAGGCTCAAGACCATGACGGATACCTACCTGCTCAACCTGGCCGTGGCAGACATCCTTTTCCTCCTAATTCTTCCCTTCTGGGCCTACAGCGAAGCCAAGTCCTGGATCTTTGGCGTCTACCTGTGTAAGGGCATCTTTGGCATCTATAAGTTAAGCTTCTTCAGCGGGATGCTGCTGCTCCTATGCATCAGCATTGACCGCTACGTAGCCATCGTCCAGGCCGTGTCGGCTCATCGCCACCGCGCCCGCGTGCTTCTCATCAGCAAGCTGTCCTGTGTGGGCATCTGGATGCTGGCCCTCTTCCTCTCCATCCCGGAGCTGCTCTACAGCGGCCTCCAGAGGAGCAGCAGCGAGGACGCGATGAGATGCTCACTGGTCAGTGCCCAAGTGGAGGCCTTGATCACCATCCAAGTGGCCCAGATGGTTTTTGGGTTCCTAGTGCCTATGCTGGCTATGAGTTTCTGCTACCTCATTATCATCCGTACCTTGCTCCAGGCACGCAACTTTGAGCGGAACAAGGCCATCAAGGTGATCATTGCCGTGGTGGTAGTCTTCATAGTCTTCCAGCTGCCCTACAATGGGGTGGTCCTGGCTCAGACGGTGGCCAACTTCAACATCACCAATAGCAGCTGCGAAACCAGCAAGCAGCTCAACATTGCCTATGACGTCACCTACAGCCTGGCCTCCGTCCGCTGCTGCGTCAACCCTTTCTTGTATGCCTTCATCGGCGTCAAGTTCCGCAGCGACCTCTTCAAGCTCTTCAAGGACTTGGGCTGCCTCAGCCAGGAACGGCTCCGGCACTGGTCTTCCTGCCGGCATGTACGGAACGCGTCGGTGAGCATGGAGGCGGAGACCACCACAACCTTCTCCCCGTAGMDPGKPRKNVLVVALLVIFQVCFCQDEVTDDYIGENTTVDYTLFESLCFKKDVRNFKAWFLPLMYSVICFVGLLGNGLVILTYIYFKRLKTMTDTYLLNLAVADILFLLILPFWAYSEAKSWIFGVYLCKGIFGIYKLSFFSGMLLLLCISIDRYVAIVQAVSAHRHRARVLLISKLSCVGIWMLALFLSIPELLYSGLQRSSSEDAMRCSLVSAQVEALITIQVAQMVFGFLVPMLAMSFCYLIIIRTLLQARNFERNKAIKVIIAVVVVFIVFQLPYNGVVLAQTVANFNITNSSCETSKQLNIAYDVTYSLASVRCCVNPFLYAFIGVKFRSDLFKLFKDLGCLSQERLRHWSSCRHVRNASVSMEAETTTTFSP

293T cells were transfected with each of the 22 constructs using FugeneHD Transfection Reagent (Cat#: 04709705001) (Roche Applied Sciences,Indianapolis, Ind.) according to manufacturer's protocol. DNA to FugeneHD ratio used was 1:3. Controls for the transfection were wild typepcDNA3.1 Neo-hCCR7 (20100121357) listed above, and wild type pcDNA3.1Neo-mouseCCR7 (20060298628). After 48 hours, transfected cells wereharvested and washed with PBS+5% FBS two times. Cells were counted usingthe Nexcelom Cell Counter (Nexcelom Bioscience, Lawrence, Mass.), and250,000 cells per well were plated in a 96 well round bottom plate.Cells transfected with each construct were stained in duplicate asfollows: unstained control, 6B4.1 primary Ab followed by Goatanti-human-PE secondary Ab, 6B5.1 primary Ab followed by Goatanti-human-PE secondary Ab, mAb197 primary Ab followed by Goatanti-mouse-PE secondary Ab, and the controls of secondary Ab Goatanti-mouse-PE only and Goat anti-human-PE only. The cells werevisualized by flow cytometry and geo means were generated and analyzed.

As previously determined, of the three tested antibodies, only mAb197bound to wild-type murine CCR7, while all three bound to wild-type humanCCR7. mAb197 was the only tested antibody to bind the YV construct. Both6B.4 and 6B.5 bound to the KNGTL construct, and in fact bound to itbetter than mAb197. All three antibodies also bound to constructYVKNGTL, but mAb197 bound better than either 6B.4 or 6B.5.

What is claimed is:
 1. An isolated CCR7 antigen binding protein, whereinsaid antigen binding protein comprises either: a. the light chainvariable domain sequence of antibody 6B4.1 LC, 6B5.1 LC, 6E1.2 LC, 6B4.1LC desS, 6E1.2 LC H36Q, MAB22_KLC-V1, MAB22_KLC_V2, MAB22_KLC_V3,MAB22_KLC_V4, MAB22_KLC_V5, MAB22_KLC_V6, MAB22_KLC_V7, or MAB22_KLC_V8;or b. the heavy chain variable domain sequence of 6B4.1 HC, 6B5.1 HC,6E1.2 HC, 6E1.2 HC G2V, 6E1.2 HC F80Y, 6E1.2 HC G2V F80Y or MAB22_HC_V1;or c. a light chain variable domain sequence that is at least 90%, 95%,97%, or 99% identical to the light chain variable domain sequence of6B4.1 LC, 6B5.1 LC, 6E1.2 LC, 6B4.1 LC desS, 6E1.2 LC H36Q,MAB22_KLC-V1, MAB22_KLC_V2, MAB22_KLC_V3, MAB22_KLC_V4, MAB22_KLC_V5,MAB22_KLC_V6, MAB22_KLC_V7, or MAB22_KLC_V8; or d. a heavy chainvariable domain sequence that is at least 90%, 95%, 97%, or 99%identical to the heavy chain variable domain sequence of 6B4.1 HC, 6B5.1HC, 6E1.2 HC, or MAB22_HC_V1; or e. a light chain variable domainsequence that differs at no more than 15, 12, 10, 8, 5, or 3 amino acidpositions from the light chain variable domain sequence of 6B4.1 LC,6B5.1 LC, 6E1.2 LC, 6B4.1 LC desS, 6E1.2 LC H36Q, MAB22_KLC-V1,MAB22_KLC_V2, MAB22_KLC_V3, MAB22_KLC_V4, MAB22_KLC_V5, MAB22_KLC_V6,MAB22_KLC_V7, or MAB22_KLC_V8; or f. a heavy chain variable domainsequence that differs at no more than 15, 12, 10, 8, 5, or 3 amino acidpositions from the heavy chain variable domain sequence of 6B4.1 HC,6B5.1 HC, 6E1.2 HC, or MAB22_HC_V1; or g. a light chain variable domainsequence that is encoded by a nucleic acid sequence that is at least90%, 95%, 97%, or 99% identical to the nucleic acid sequence encodingthe light chain variable domain sequence of 6B4.1 LC, 6B5.1 LC, 6E1.2LC, 6B4.1 LC desS, 6E1.2 LC H36Q, MAB22_KLC-V1, MAB22_KLC_V2,MAB22_KLC_V3, MAB22_KLC_V4, MAB22_KLC_V5, MAB22_KLC_V6, MAB22_KLC_V7, orMAB22_KLC_V8 as provided in FIG. 1; or h. a heavy chain variable domainsequence that is encoded by a nucleic acid sequence that is at least90%, 95%, 97%, or 99% identical to the nucleic acid sequence encodingthe heavy chain variable domain sequence of 6B4.1 HC, 6B5.1 HC, 6E1.2HC, 6E1.2 HC G2V, 6E1.2 HC F80Y, 6E1.2 HC G2V F80Y or MAB22_HC_V1, asprovided in FIG. 1; or i. a light chain variable domain sequence that isencoded by a nucleic acid sequence that hybridizes under moderatelystringent, stringent, or highly stringent conditions to the nucleic acidsequence encoding the light chain variable domain sequence of 6B4.1 LC,6B5.1 LC, 6E1.2 LC, 6B4.1 LC desS, 6E1.2 LC H36Q, MAB22_KLC-V1,MAB22_KLC_V2, MAB22_KLC_V3, MAB22_KLC_V4, MAB22_KLC_V5, MAB22_KLC_V6,MAB22_KLC_V7, or MAB22_KLC_V8 as provided in FIG. 1; or j. a heavy chainvariable domain sequence that is encoded by a nucleic acid sequence thathybridizes under moderately stringent, stringent, or highly stringentconditions to the nucleic acid sequence encoding the heavy chainvariable domain sequence of 6B4.1 HC, 6B5.1 HC, 6E1.2 HC, 6E1.2 HC G2V,6E1.2 HC F80Y, 6E1.2 HC G2V F80Y or MAB22_HC_V1, as provided in FIG. 1;or k. CDR1, CDR2, and CDR3 of the light chain variable domain sequenceof 6B4.1 LC, 6B5.1 LC, 6E1.2 LC, 6B4.1 LC desS, 6E1.2 LC H36Q, orMAB22_KLC_V1; or l. CDR1, CDR2, and CDR3 of the heavy chain variabledomain sequence of 6B4.1 HC, 6B5.1 HC, 6E1.2 HC, 6E1.2 HC G2V, 6E1.2 HCF80Y, 6E1.2 HC G2V F80Y, or MAB22_HC_V1; or m. light chain variabledomain CDR1, CDR2, and CDR3 sequences that each differs at no more than3, 2, or 1 amino acid positions from the light chain variable domainCDR1, CDR2, and CDR3 sequences, respectively, of the light chainvariable domain sequence of 6B4.1 LC, 6B5.1 LC, 6E1.2 LC, 6B4.1 LC desS,6E1.2 LC H36Q, or MAB22_KLC_V1; or n. heavy chain variable domain CDR1,CDR2, and CDR3 sequences that each differs at no more than 3, 2, or 1amino acid positions from the heavy chain variable domain CDR1, CDR2,and CDR3 sequences, respectively, of the heavy chain variable domainsequence of 6B4.1 HC, 6B5.1 HC, 6E1.2 HC, 6E1.2 HC G2V, 6E1.2 HC F80Y,6E1.2 HC G2V F80Y, or MAB22_HC_V1.
 2. The isolated CCR7 antigen bindingprotein of claim 1, comprising: a. the light chain variable domainsequence of 6B4.1 LC or of 6B4.1 LC desS, as shown in FIG. 1, and theheavy chain variable domain sequence of 6B4.1 HC, as shown in FIG. 1; orb. the light chain variable domain sequence of 6B5.1 LC, as shown inFIG. 1, and the heavy chain variable domain sequence of 6B5.1 HC, asshown in FIG. 1; or c. the light chain variable domain sequence of 6E1.2LC or of 6E1.2 LC H36Q, as shown in FIG. 1, and the heavy chain variabledomain sequence of 6E1.2, 6E1.2 HC G2V, 6E1.2 HC F80Y, or 6E1.2 HC G2VF80Y, as shown in FIG. 1; or d. the light chain variable domain sequenceof MAB22_KLC-V1, MAB22_KLC_V2, MAB22_KLC_V3, MAB22_KLC_V4, MAB22_KLC_V5,MAB22_KLC_V6, MAB22_KLC_V7, or MAB22_KLC_V1, as shown in FIG. 1, and theheavy chain variable domain sequence of MAB22_HC_V1, as shown in FIG. 2;or e. the light chain CDR 1, 2, and 3 sequences of 6B4.1 LC or of 6B4.1LC desS, as shown in FIG. 1, and the heavy chain CDR 1, 2, and 3sequences of 6B4.1 HC, as shown in FIG. 1; or f. the light chain CDR 1,2, and 3 sequences of 6B5.1 LC, as shown in FIG. 1, and the heavy chainCDR 1, 2, and 3 sequences of 6B5.1 HC, as shown in FIG. 1; or g. thelight chain CDR 1, 2, and 3 sequences of 6E1.2 LC or of 6E1.2 LC H36Q,as shown in FIG. 1, and the heavy chain CDR 1, 2, and 3 sequences of6E1.2, 6E1.2 HC G2V, 6E1.2 HC F80Y, or 6E1.2 HC G2V F80Y, as shown inFIG. 1; or h. the light chain CDR 1, 2, and 3 sequences of MAB22_KLC-V1,as shown in FIG. 1, and the heavy chain CDR 1, 2, and 3 sequences ofMAB22_HC_V1, as shown in FIG. 1; or i. a light chain variable domainsequence that is at least 90%, 95%, 97%, or 99% identical to the lightchain variable domain sequence of 6B4.1 LC or of 6B4.1 LC desS, as shownin FIG. 1, and a heavy chain variable domain sequence that is at least90%, 95%, 97%, or 99% identical to the heavy chain variable domainsequence of 6B4.1 HC, as shown in FIG. 1; or j. a light chain variabledomain sequence that is at least 90%, 95%, 97%, or 99% identical to thelight chain variable domain sequence of 6B5.1 LC, as shown in FIG. 1,and a heavy chain variable domain sequence that is at least 90%, 95%,97%, or 99% identical to the heavy chain variable domain sequence of6B5.1 HC, as shown in FIG. 1; or k. a light chain variable domainsequence that is at least 90%, 95%, 97%, or 99% identical to the lightchain variable domain sequence of 6E1.2 LC or of 6E1.2 LC H36Q, as shownin FIG. 1, and a heavy chain variable domain sequence that is at least90%, 95%, 97%, or 99% identical to the heavy chain variable domainsequence of 6E1.2, 6E1.2 HC G2V, 6E1.2 HC F80Y, or 6E1.2 HC G2V F80Y, asshown in FIG. 1; or l. a light chain variable domain sequence that is atleast 90%, 95%, 97%, or 99% identical to the light chain variable domainsequence of MAB22_KLC-V1, MAB22_KLC_V2, MAB22_KLC_V3, MAB22_KLC_V4,MAB22_KLC_V5, MAB22_KLC_V6, MAB22_KLC_V7, or MAB22_KLC_V8, as shown inFIG. 1, and a heavy chain variable domain sequence that is at least 90%,95%, 97%, or 99% identical to the heavy chain variable domain sequenceof MAB22_HC_V1, as shown in FIG. 1; or m. the light chain sequence of6B4.1 LC or of 6B4.1 LC desS, as shown in FIG. 1, and the heavy chainsequence of 6B4.1 HC, as shown in FIG. 1; or n. the light chain sequenceof 6B5.1 LC, as shown in FIG. 1, and the heavy chain sequence of 6B5.1HC, as shown in FIG. 1; or o. the light chain sequence of 6E1.2 LC or of6E1.2 LC H36Q, as shown in FIG. 1, and the heavy chain sequence of6E1.2, 6E1.2 HC G2V, 6E1.2 HC F80Y, or 6E1.2 HC G2V F80Y, as shown inFIG. 1; or p. the light chain sequence of MAB22_KLC-V1, MAB22_KLC_V2,MAB22_KLC_V3, MAB22_KLC_V4, MAB22_KLC_V5, MAB22_KLC_V6, MAB22_KLC_V7, orMAB22_KLC_V8, as shown in FIG. 1, and the heavy chain sequence ofMAB22_HC_V1, as shown in FIG.
 1. 3. The isolated CCR7 antigen bindingprotein of claim 1, wherein said CCR7 antigen binding protein is ananti-CCR7 antibody, and wherein said antibody comprises the sequences:a. 6B4.1 LC and 6B4. HC; b. 6B5.1 LC and 6B5.1 HC; or c. MAB22_KLC_V1and MAB22_HC_V1.
 4. The isolated CCR7 antigen binding protein of claim1, wherein said antigen binding protein competes for binding to a humanCCR7 with antibody 6B4.1, 6B5.1, or 6E1.2.
 5. The isolated CCR7 antigenbinding protein of claim 1, wherein said antigen binding proteincomprises either: a. a light chain variable domain that differs from thelight chain variable domain of antibody 6B4.1, 6B5.1, or 6E1.2 only inthat one or more non-germline amino acid residues are replaced with thecorresponding germline residues; b. a heavy chain variable domain thatdiffers from the heavy chain variable domain of antibody 6B4.1, 6B5.1,or 6E1.2 only in that one or more non-germline amino acid residues arereplaced with the corresponding germline residues; or c. a light chainvariable domain that differs from the light chain variable domain ofantibody 6B4.1, 6B5.1, or 6E1.2 only in that one or more non-germlineamino acid residues are replaced with the corresponding germlineresidues, and a heavy chain variable domain that differs from the heavychain variable domain of the same antibody 6B4.1, 6B5.1, or 6E1.2 onlyin that one or more non-germline amino acid residues are replaced withthe corresponding germline residues.
 6. The isolated CCR7 antigenbinding protein of claim 1 wherein said antigen binding proteincomprises: a. a human antibody; b. a humanized antibody; c. a chimericantibody; d. a monoclonal antibody; e. a polyclonal antibody; f. arecombinant antibody; g. an antigen-binding antibody fragment; h. asingle chain antibody; i. a diabody; j. a triabody; k. a tetrabody; l. aFab fragment; m. a F(ab′)2 fragment; n. a domain antibody; o. an IgDantibody; p. an IgE antibody; q. an IgM antibody; r. an IgG1 antibody;s. an IgG2 antibody; t. an IgG3 antibody; u. an IgG4 antibody; or v. anIgG4 antibody having at least one mutation in a hinge region thatalleviates a tendency to form intra-H chain disulfide bond.
 7. Theisolated CCR7 antigen binding protein of claim 1 wherein said antigenbinding protein inhibits binding of CCL19 or CCL21 to CCR7.
 8. Anisolated anti-CCR7 antibody, wherein said antibody binds to wild-typehuman CCR7, but does not bind to wild-type murine CCR7.
 9. The isolatedanti-CCR7 antibody of claim 8, wherein said antibody also binds to amutated human CCR7 polypeptide, wherein said mutated human CCR7polypeptide differs from wild-type human CCR7 only by the mutation F44Y.10. The isolated anti-CCR7 antibody of claim 9, wherein said antibodybinds to said mutated human CCR7 polypeptide at least as well as eitherantibody 6B4.1 or antibody 6B5.1.
 11. The isolated anti-CCR7 antibody ofclaim 8, wherein said antibody does not bind to a mutated murine CCR7,wherein said mutated murine CCR7 differs from wild-type murine CCR7 onlyby the mutations Y44F and V47L.
 12. The isolated anti-CCR7 antibody ofclaim 8, wherein said antibody binds better than antibody mAb197 to amutated murine CCR7, wherein said mutated murine CCR7 differs fromwild-type murine CCR7 only by the mutations K201R, N202S, G204S, T207A,and L208M.
 13. An isolated polynucleotide comprising a sequence thatencodes the light chain, the heavy chain, or both of said isolated CCR7antigen binding protein of claim 1 or of the isolated anti-CCR7 antibodyof claim
 8. 14. The isolated polynucleotide of claim 13, wherein saidisolated polynucleotide comprises a light chain variable domain nucleicacid sequence and/or a heavy chain variable domain nucleic acid sequenceof FIG.
 1. 15. A plasmid comprising said isolated polynucleotide ofclaim
 13. 16. The plasmid of claim 15, wherein said plasmid is anexpression vector.
 17. An isolated cell comprising said isolatedpolynucleotide of claim
 13. 18. The isolated cell of claim 17, wherein achromosome of said cell comprises said polynucleotide.
 19. The isolatedcell of claim 17, wherein said cell is a hybridoma.
 20. The isolatedcell of claim 17, wherein an expression vector comprises saidpolynucleotide.
 21. The isolated cell of claim 17, wherein said cell isa CHO cell.
 22. The isolated cell of claim 17, wherein said cell is abacterial cell.
 23. The isolated cell of claim 17, wherein said cell isan E. coli cell.
 24. The isolated cell of claim 17, wherein said cell isa yeast cell.
 25. The isolated cell of claim 17, wherein said cell is ananimal cell.
 26. The isolated cell of claim 17, wherein said cell is ahuman cell.
 27. A method of making a CCR7 antigen binding protein,comprising incubating said isolated cell of claim 17 under conditionsthat allow it to express said antigen binding protein.
 28. Apharmaceutical composition comprising the CCR7 antigen binding proteinof claim 1 or the anti-CCR7 antibody of claim 8.